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Abstract 
The evolutionarily conserved signalling intermediate in the toll pathway (ECSIT) is a 50 
kDa protein involved in the function of many pathways and implicated in a variety of 
phenotypes. It functions as part of the toll pathway by integrating the signal from several 
toll receptors and facilitating the activation of downstream proteins NFКB, JNK and P38 
MAPK. It functions as part of the bone morphogenetic protein pathway through 
interaction with SMAD4 allowing for normal embryonic development. It also functions 
as a mitochondrial complex I assembly factor and loss of function leads to a reduction in 
fully assembled complex I.  
As part of a large scale ENU mutagenesis screen, The Harwell Ageing Screen, a novel 
missense mutation (N209I) was identified in ECSIT which resulted in a hypertrophic 
cardiomyopathy phenotype in homozygous mutant animals.  
Further investigation revealed this phenotype to be a result of a loss of function in 
ECSIT’s role as a complex I assembly factor. Mitochondria from EcsitN209I/N209I hearts 
showed a reduction in total complex I protein as well as a loss of enzymatic activity and 
fully assembled complex I.  Interestingly, this mitochondrial dysfunction was limited to 
the heart with other tissues maintaining protein levels and complex I function at or close 
to wild type levels, suggesting that there may be tissue specific differences in the 
complex I assembly pathway.  Investigation of the assembly pathway using first and 
second dimensional blue native PAGE suggests that this tissue specific pathway may 
involve the formation of a previously undescribed fragment of ECSIT that is present in 
heart tissue but absent from other tissues tested, is associated with fully assembled 
complex I in wild type mitochondria but absent in EcsitN209I/N209I hearts. 
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Chapter 1: Introduction 
2 
 
1.1. Mitochondria 
Mitochondria are present in almost all eukaryotic cells where their primary role is the 
production of ATP (adenosine triphosphate) as an energy source for other cellular 
processes. Mitochondria themselves are double membrane bound organelles that are 
believed to have evolved from gram-negative bacteria roughly 2 billion years ago. 
Through an endosymbiotic relationship with a eukaryotic ancestor, they have gradually 
lost the majority of their genome and transformed into the organelle that we study 
today [1].   
In the human heart, mitochondria occupy as much as 30% of the myocardial volume [1] 
and are responsible for producing energy in the form of around 300mg of ATP for every 
beat [2].  
1.1.1. Structure and function 
Mitochondria are tubular structures, typically about 0.1-0.5µm across, consisting of an 
outer and inner membrane each with their own unique properties [3]. The outer 
membrane is typically smooth in appearance and is permeable to molecules up to 
approximately 5kDa in size allowing for the natural diffusion of many molecules such as 
ADP, ATP, ions and small proteins [4]. Whilst the outer membrane is composed mainly 
of a phospholipid bilayer, the inner membrane has a higher proportion of proteins and 
in addition to phospholipids contains the mitochondrial specific lipid, cardiolipin [5-7]. It 
is the specific properties of cardiolipin that allows the inner membrane to fold and form 
invaginations known as cristae. These are the main sites of the oxidative 
phosphorylation (OXPHOS) machinery [7, 8]. 
The arrangement of the two membranes results in the formation of two spaces within 
the mitochondria. The first, between the two membranes, is the inter membrane space 
(IMS) and is essential for the mitochondria to perform OXPHOS as it forms a 
compartment into which protons are pumped, allowing for the establishment of a 
proton gradient. The other is the space enclosed by the inner membrane, referred to as 
the mitochondrial matrix which houses the mitochondrial DNA, and is the site of the 
tricarboxylic acid (TCA) cycle [8].  
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Despite their similarities in membrane structure, mitochondria are capable of taking on 
a variety of appearances, from small filamentous or punctate units, to large networks 
spanning a cell. There are also a variety of mitochondrial subpopulations that may take 
on different metabolic profiles or roles within a cell. In both skeletal and cardiac muscle 
these are grouped into subsarcolemmal (SS), intermyofibrillar (IMF) and perinuclear 
(PN) populations (Figure 1.1) [9-11].  
As the name would suggest, perinuclear mitochondria cluster around the nucleus and 
are thought to be involved in transcription and translation. Intermyofibrillar 
mitochondria have a small and compact structure and are organised in rows between 
muscle fibres in order to provide energy to the contractile machinery [12, 13]. Finally, 
subsarcolemmal mitochondria are slightly larger in appearance and sit immediately 
adjacent to the sarcolemma. They are slightly larger in size and demonstrate less 
organisation [9, 13]. There is evidence to suggest that there are considerable differences 
in SS and IMF mitochondrial metabolism, but that this is dependent on the muscle fibre 
type and health of the tissue in question [9]. 
 
Figure 1.1. A transmission electron micrograph of adult mouse cardiac tissue showing three distinct 
subpopulations of mitochondria: Subsarcolemmal (SM), intermyofibrillar (IM) and perinuclear (PN) with 
myofibrils (m) and nucleus (n) for reference points. Adapted from Piquereau et al. (2013) [13]. 
4 
 
1.1.2. Biogenesis 
The generation of new mitochondria in response to exercise or disease requires a 
complex system of regulatory control necessitated by the two genome nature of the 
mitochondria, especially of the complexes that drive oxidative phosphorylation. In total, 
mitochondrial biogenesis requires the expression and import of over 1000 proteins 
encoded by nuclear DNA [14]. Biogenesis is triggered by the action of a number of 
proteins and compounds (Figure 1.2) that sense a variety of situations throughout the 
cells and tissues of the body. Chief among these is AMPK, which is tasked with 
monitoring cellular energy levels and responding when the ATP/AMP ratio falls [15]. 
Some further key pathways involved are the generation of nitric oxide (NO) [16], 
increased expression of sirtuin 1 (SIRT1) [17], and through the action of TORC (target of 
rapamycin complex) [18], amongst others.  
The expression of the various genes required for mitochondrial biogenesis is under the 
control of a dedicated set of transcription factors (Figure 1.2). Amongst these are those 
responsible for direct regulatory control of the OXPHOS chain: nuclear respiratory 
factors 1 and 2 (NRF1 and NRF2) [19, 20], estrogen related receptor (ERRα) [21], and YY1 
[22]. In addition, ERRα and peroxisome proliferator activated receptor α (PPARα) assist 
in mitochondrial biogenesis through the regulation of the oxidation of fatty acids [23, 
24]. 
In common control over all of these transcription factors is the master regulator of 
mitochondrial biogenesis, PGC1α (peroxisome proliferator-activated receptor gamma 
coactivator 1α) (Figure 1.2). PGC1α was first identified as being key to mitochondrial 
biogenesis in brown adipose tissue where its expression is elevated in response to cold, 
leading to increased expression of respiratory chain proteins and mitochondrial DNA 
[25]. It is known to interact with the transcription factors mentioned above, enabling 
the expression of nuclear genes key for mitochondrial construction. Over expression of 
PGC1α leads to elevated mitochondrial content in both cultured cells and mouse tissues 
whilst knockdown animals show a mild OXPHOS defect phenotype under stable 
conditions but demonstrate severe phenotypes when exposed to challenges such as 
cold or exercise [26].  
5 
 
 
Figure 1.2. Network of key interactions showing how PGC1α acts as a master regulator over mitochondrial 
biogenesis and how control is maintained over it by proteins such as AMPK and SIRT1.  
1.1.3. The Electron Transport Chain 
The primary source of ATP production is oxidative phosphorylation (OXPHOS), which 
takes place on the mitochondrial inner membrane. OXPHOS links oxygen consumption 
with the transfer of electrons from NADH (Nicotinamide adenine dinucleotide) to O2 
through the mitochondrial electron transport chain (ETC) (Figure 1.3), a set of 5 protein 
complexes encoded by both nuclear and mitochondrial DNA (mtDNA), that allow for the 
establishment and utilisation of a H+ ion gradient across the mitochondrial inner 
membrane [27].  
The degree to which each complex is encoded by mitochondrial or nuclear DNA varies. 
Complex I (NADH:ubiquinone oxidoreductase) has 44 subunits of which 7 are encoded 
by mitochondrial DNA (mtDNA)[28]. Complex II (succinate dehydrogenase), III (ubiquinol 
cytochrome c reductase) and IV (cytochrome c oxidase) are smaller in size and comprise 
of 5, 11 and 13 subunits each, with only complexes III and IV having mtDNA encoded 
subunits (1 and 3 respectively) [29]. Complex V (F1F0 ATP Synthase) is a complex 
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molecular motor comprising of 16 subunits of which 2 are mitochondrially encoded [30, 
31]. The detail of the origin of each complex and their role in the electron transport 
chain is explored in more detail below.  
Figure 1.3. A schematic of the mitochondrial electron transport chain demonstrating proton movement 
and the subunits and structure of the individual transport chain complexes [32]. 
1.1.3.1. Complex I (NADH:Ubiquinone Oxidoreductase) 
Mammalian Complex I utilises a flavin mononucleotide (FMN) and its hydrophobic 
domain to oxidise NADH (Nicotinamide adenine dinucleotide). NADH in its reduced form 
is produced by the citric acid cycle and β-oxidation, and its oxidation to NAD+ allows 
these other processes to continue to function normally. As a result of the oxidation of 
NADH, complex I is left with two electrons which it passes through a series of eight iron-
sulphur (Fe-S) centres, acting as a series of electron acceptors and donors, ultimately 
donating the electrons to ubiquinone, reducing it to ubiquinol. The process of oxidising 
NADH to NAD+ and reducing ubiquinone is coupled to the translocation of four H+ ions 
across the mitochondrial inner membrane, beginning the establishment of a proton 
gradient [33, 34]. 
As mentioned earlier complex I is roughly 1mDa in size and consists of 44 proteins. 14 of 
these proteins are the ‘core’ subunits and form the overall ‘L’ shaped structure 
consisting of two roughly equal in size arms, one extending into the mitochondrial matrix 
and the other contained within the inner mitochondrial membrane. Of these 14 
proteins, 7 (ND1, ND2, ND3, ND4, ND4L, ND5 and ND6) are mitochondrially encoded, 
and 7 (NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7 and NDUFS8) are nuclear 
encoded [35, 36].  
7 
 
The remaining 30 proteins are known as the accessory subunits and are thought to 
contribute to the stabilisation and regulation of the complex [37, 38]. It is the matrix arm 
that contains the 9 co-factors (FMN and 8Fe-S) that are responsible for the electron 
transport from NADH to ubiquinone. The FMN sits at the tip of the matrix arm whilst the 
Q domain resides at the apex of the ‘L’ shape. The 7 subunits of the membrane arm are 
then responsible for the transport of the 4 protons across the membrane. This is thanks 
to the formation of four proton transfer routes, one in each of ND2, ND4 and ND5 and 
a fourth through the interaction of ND1, ND4L and ND6[39].  
1.1.3.2. Complex II (Succinate Dehydrogenase) 
The oxidation of succinate to fumarate is performed by complex II as part of the citric 
acid cycle. This reaction occurs on the mitochondrial inner membrane and allows for 
electrons to be passed to ubiquinone via the flavin-adenine dinucleotide (FAD), three 
Fe-S centres ([2Fe-2S], [4Fe-4S] and [3Fe-4S]) and heme. However, complex II does not 
contribute to the establishment of the H+ ion gradient [40, 41]. Structurally, complex II 
is homologous to a protein that performs the reverse role in bacteria during anaerobic 
respiration, fumarate reductase [40] and in fact the two are interchangeable.  Complex 
II contains 4 subunits, 2 of which are hydrophobic and act as membrane anchors, with 
the remaining 2 being hydrophilic and act as a binding site for the cofactor FAD and the 
catalytic centre for the reduction of succinate [42, 43].  
1.1.3.3. Complex III (CoQH2-Cytochrome C Reductase) 
Ubiquinone, having been reduced by complexes I and II to ubiquinol, now undergoes 
oxidation by complex III in a process known as the ‘Q’ cycle, which passes the liberated 
electrons from ubiquinol to cytochrome C [44]. The ‘Q’ cycle consists of two reactions, 
the first involves the oxidation of ubiquinol to a semi-quinone, the second oxidises the 
newly formed semi-quinone to ubiquinone. The 2-step process results in the reduction 
of cytochrome C and the release of 4 H+ ions into the inter membrane space, further 
contributing to the established H+ ion gradient [45, 46]. Structurally, complex III contains 
11 subunits and spans the inner mitochondrial membrane, with the membrane portion 
consisting of 4 subunits, the transmembrane of 4 and the intermembrane portion of the 
remaining 3[44].   
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1.1.3.4. Complex IV (Cytochrome C Oxidase) 
The final step in the electron transport chain is the oxidation of cytochrome C and the 
passing of the electrons to oxygen to allow its reduction to water [47].  The process 
begins with the acceptance of 2 electrons from cytochrome C and the breaking of the 
O2 molecule’s bond; this, when coupled with the uptake of 2 H+ ions from the 
mitochondrial matrix, forms the first water molecule. The second is formed in a similar 
fashion, with the process also being linked to the translocation of 4 further H+ ions across 
the inner membrane [48]. Structurally, complex IV is a large integral membrane protein 
consisting of 13 subunits with 2 heme sites and 2 copper sites that are active in the 
transfer of electrons from cytochrome C to oxygen [49]. 
1.1.3.5. Complex V (ATP Synthase)  
The first 4 complexes of the electron transport chain allow for the establishment of the 
H+ ion gradient across the mitochondrial inner membrane. ATP synthase, or complex V, 
uses this electrochemical gradient to convert ADP into ATP [50, 51]. ATP synthase is 
comprised of an F1 and an F0 subunit. The F1 subunit is entirely nuclear encoded and 
comprises of 9 subunits (α3β3γδε) which sit in the mitochondrial matrix and catalyse the 
conversion of ADP to ATP via a rotary mechanism powered by the F0 subunit [52-55]. 
The F0 subunit is made up of: a main ‘C’ ring comprised of 8 identical protein subunits; a 
peripheral stalk of subunits b, d, F6 and OSCP; and a number of membrane associated 
proteins, e, f, g and A6L [53]. It is the main C ring that acts as a rotational motor powering 
the synthesis of ATP through the F1 subunit. Protons pass through the C ring at a rate of 
8 protons per cycle causing a rotational force to be exerted through the central stalk 
(γδε) of the F1 subunit. This rotational motion powers the catalytic activity of the β3  
subunits, producing 3 ATP molecules per cycle, a rate of 2.7 protons per ATP [56].  
1.1.3.6. Super-complexes 
Relatively small proportions of mitochondrial OXPHOS complexes actually exist as 
isolated complexes in the inner membrane. Most form large super molecules known as 
‘super-complexes’ or ‘respirasomes’, binding together with other respiratory complexes 
to improve efficiency of the OXPHOS machinery and improve complex stability [57]. This 
improved efficiency is thought to come from the ability of the super-complexes to 
perform substrate channelling, the passing of a reduced substrate directly from one 
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catalytic site to the next where it is immediately re-oxidised, thereby removing the delay 
associated with diffusion of the substrate [58].   
In mammalian systems these super-complexes are formed by the interactions between 
complexes I, III and IV in various stoichiometry. Complex II is rarely seen interacting with 
the other complexes in this manner whilst complex V is known to form homodimers that 
may closely interact with other super-complexes without acting as a constitutive 
component [57].  
The most common arrangements found in mammalian systems are; a single complex I 
associated with a complex III dimer (I + III2), a complex III dimer associated with 1 or 2 
complex IV units (III2 + IV1-2), and a single complex I associated with both a complex III 
dimer and a variable number of complex IV units (I + III2 + IV1-4) [59]. Super-complex 
formation may also include the integration of accessory subunits such as ubiquinone 
and cytochrome C, which are essential partners in the substrate channelling process. 
Evidence suggests that ubiquinone is an essential component of I + III2 + IV1-4, resulting 
in 2 pools of ubiquinone in the mitochondria; that which is bound in super-complexes 
and undergoes rapid reduction and oxidation, and that which is free and seemingly plays 
little role in the OXPHOS process. In contrast, cytochrome C may or may not be 
incorporated into the super-complex and as a result, fast or slow interactions may occur 
between complexes III and IV and bound or unbound cytochrome C (Figure 1.4) [60].  
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Figure 1.4. The 3 main super-complex formations identified in mammalian mitochondria, demonstrating 
the primary substrates and the fast and slow interactions with cytochrome C. A – supercomplex of I, III 
and IV with or without cytochrome C, and electrons being passed between various supercomplex 
formations. B - supercomplex of I and III, passing electrons to individual complex IV units. C – Electrons 
entering through complex II passed to various complex III and IV supercomplex arrangements [60]. 
The formation of the I + III2 + IV1-4 super-complex confers a significant advantage over 
the free complexes in that it not only allows for substrate channelling but the interaction 
of the complexes also appears to induce conformational changes that improve the 
efficiency of the individual complexes. In fact, super-complex formation may be an 
essential aspect of the OXPHOS machinery, as there is evidence to suggest that it is 
required for the stabilisation of complex I. Studies have shown that patients with 
mutations in complex III subunits also exhibit complex I deficiency. These studies 
demonstrated that in these patients, complex I was formed normally but demonstrated 
a reduced stability and ultimately a loss of function [61, 62]. It was also demonstrated 
that whilst complex III was essential for complex I stability, the reverse was not true [61]. 
Complex IV and cytochrome C were also revealed to be required for complex I stability, 
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indicating that it is the formation of a complete respirasome that confers complex I 
stability, and not the interaction with any one other complex [63, 64]. 
As with the individual complexes, assembly of super-complexes requires the assistance 
of assembly factors. As the field is fairly nascent, most of what is known comes from 
work on yeast species, with two assembly factors, RCF1 (respiratory complex factor 1) 
and RCF2 (respiratory complex factor 2), being identified. A study conducted by Chen et 
al. (2012) [65], compared the role of RCF1 to its human homologue HIG2A (HIG1 domain 
family member 2A), by knocking down the latter using siRNA in mammalian cells. This 
work  showed that loss of HIG2A protein resulted in a failure to assemble all super-
complexes[65]. Additionally, work by Jian et al. [66] has implicated the mitochondrial 
scaffold proteins PHB1 and PHB2 as super-complex assembly factors. By knocking down 
either of these proteins in HeLA cells using siRNA a reduction in super-complex 
formation was observed, coupled with elevated ROS production [66].  
Whist the role of super-complexes is still poorly understood it is becoming clear that 
their formation is an essential step in the establishment of a functional OXPHOS system 
and not just a convenient means to improve catalytic efficiencies.  
1.1.3.7. Complex I Assembly Factors 
As is detailed further in section 1.1.3.8, complex I assembly is an intricate process that 
requires the assistance of a large number of assembly factors that are not themselves 
incorporated into the final functional complex. To date at least 13 complex I assembly 
factors have been identified in mammalian systems. However, the actual function of 
these assembly factors is still unknown, it is hypothesised that they may act as 
chaperones, stabilising the intermediate assembly steps to allow the process to continue 
unhindered [67, 68]. 
The mitochondrial complex I assembly (MCIA) complex is formed from 5 of these 
assembly factors and is involved in the early assembly of the PP-b subcomplex. The 4 
core proteins in the MCIA are NDUFAF1 (NADH:ubiquinone oxidoreductase complex 
assembly factor 1), ECSIT (evolutionarily conserved signalling intermediate in toll 
pathway), ACAD9 (acyl-coA dehydrogenase  family member 9), and TMEM126B 
(transmembrane protein 126B) with possible involvement from TIMMDC1 (translocase 
of inner mitochondrial membrane domain containing 1) [69, 70]. This complex 
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assembles on the inner membrane with TMEM126B acting as the membrane anchor. 
ECSIT and NDUFAF1 bind to TMEM126B and are joined in turn by a dimer of ACAD9. It 
is then thought that this 4 protein complex interacts with TIMMDC1 prior to any complex 
I interaction [68]. The formation of this complex precedes the binding of complex I 
constituent proteins and appears to be an initiation step for the process of assembling 
membrane arm of complex I. 
Other assembly factors of the membrane arm of complex I include FOXRED1 (FAD 
dependant oxidoreductase containing 1), TMEM70 (transmembrane protein 70) and 
ATP5SL (ATP synthase subunit s-like protein) however, the function of these proteins 
remains poorly understood [71, 72].  
Evidence also suggests that the proteins COA1 (cytochrome c oxidase assembly factor 1 
homolog) and TMEM186 (transmembrane protein 186) play a role in the assembly of 
the membrane arm, however this role appears to be more transient than that of the 
proteins in the MCIA complex. These proteins were identified interacting with sub-
assemblies of the proximal portion of the membrane arm (PP-a) but were not identified 
in larger subassemblies incorporating both the membrane and matrix arms (Q/P) where 
members of the MCIA could still be seen [72, 73]. 
In addition to assembly factors of the membrane arm, there are a number of assembly 
factors associated with the matrix arm. Amongst these, NDUFAF2  (NADH:ubiquinone 
oxidoreductase complex assembly factor 2), NDUFAF3 (NADH:ubiquinone 
oxidoreductase complex assembly factor 3) and NDUFAF4 (NADH:ubiquinone 
oxidoreductase complex assembly factor 4) have been linked with mutations in patients 
resulting in deficiencies of complex I levels and activity [74-76]. NDUFAF2 has been 
shown to interact with the N module of complex I and mutations lead to an 
accumulation of the matrix arm structural subunits, indicating a role in the late stages 
of complex I assembly [77, 78]. Evidence suggests that NDUFAF3 is involved earlier in 
the assembly process as mutations do not lead to obvious accumulations of the matrix 
arm as was seen with NDUFAF2 [76]. Mutations in NDUFAF4 lead to accumulation of 
both large and small subassemblies, indicating that it may work in tandem with both 
NDUFAF2 and NDUFAF3 at both early and late stages of matrix arm formation [75] 
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Finally, there are assembly factors that appear not to be involved in the assembly of the 
structural aspect of complex I but with modifications of subunits, or in delivering the Fe-
S clusters to the complex. NUBPL is an iron-sulphur protein with an N terminal 
mitochondrial localisation signal. Through interactions with its CXXC domain, Fe-S 
clusters may be transported into the mitochondria and delivered to complex I where 
they are incorporated into key subunits. Knocking down the NUBPL protein in human 
cells results in the accumulation of matrix arm subassemblies and a reduction in the 
levels of iron incorporated into complex I [79, 80].  
Much is still to be gleaned about the mechanism of complex I assembly factors although 
there is little doubt that their role is absolutely essential. It is likely that there are more 
assembly factors yet to be discovered and there remains the possibility that there are 
tissue specific assembly factors that remain elusive. It is also probable that some 
redundancy exists in the system, given its essential nature.  
1.1.3.8. Complex I Assembly 
Given complex I’s size, complexity and two genome nature it is unsurprising that its 
assembly is an intricate process which we are only beginning to come to understand the 
detail of. As mentioned previously, complex I contains 44 subunits, 7 of which are 
encoded by the mitochondrial genome and the remaining by the nuclear genome. 
Involved in its assembly are at least 14 assembly factors which are not thought to 
comprise part of the final structure but are essential in the intervening steps between 
isolated proteins and functional complex [71, 72].  
The 14 core subunits are considered to be the main driving force behind complex I’s 
function but evidence suggests that many of the remaining 30 accessory subunits are 
also required for normal function either through stabilisation of the complex structure 
or through a contribution to the function of one of the modules [35, 81]. As a result, the 
assembly process has developed to ensure correct integration of both the core subunits 
as well as the seemingly essential accessory subunits.  
The assembly process proceeds in a step wise fashion with individual building blocks or 
sub-assemblies forming first before joining to form structural or functional portions of 
the complex and ultimately the complete complex. There are 4 main modules that must 
be assembled for full function: N, the NADH binding domain; Q, the quinone binding 
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domain; Pp, and PD, the proximal and distal portions of the membrane arm involved in 
proton pumping [82]. 
Guerrero Castillo et al. (2016) demonstrated that assembly begins within 4 hours of the 
induction of protein translation with the formation of the mitochondrial complex I 
assembly (MCIA) complex and its association with constitutive proteins of the Pp-b sub 
assembly, as can be seen in figure 1.5. Alongside the formation of the Pp-b unit, assembly 
of the Q/Pp-a unit begins, with the marrying of the fully assembled Q subunit with the 
adjacent segment of the Pp module. The assembly of the PD subunits was more difficult 
to observe and it was published that this module assembles in two sections, PD-a and 
PD-b, which begins around the same time as the Pp-b and Q/PP-a module formation but 
doesn’t finish until sometime later. Also at this time point, the N subunit has begun to 
form in two separate building blocks of 71 and 88kDa, these then join over the following 
2 hours to form the fully assembled N module.  
This 6-hour time point also sees the formation of a large 680kDa complex consisting of 
the Pp-b and PD-a modules as well as a 736kDa complex consisting of the Pp-b with the 
Q/Pp-a module. By 8 hours post translational induction, these two complexes have been 
replaced by a single large complex consisting of all three of the modules. These data 
suggest that the binding of PP-b with either PD-a or Q/PP-a is not a highly controlled 
process and which binding event occurs first is seemingly random. This single large 
complex (Q/P) now resembles completed complex I with the exception of the missing N 
module and some accessory subunits as well as the presence of a number of assembly 
factors. These remaining steps occur with an apparent lack of strict organisation or 
timing. By 24 hours post translational induction this process results in a significant 
amount of fully assembled and functional complex I. These fully assembled units are 
then stabilised by formation of respiratory chain super complexes through interaction 
with complexes III and IV [72]. 
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Figure 1.5. Assembly pathway of complex I demonstrating the assembly intermediates created during the 
course of assembly and the assembly factors associated with each sub-complex. Adapted from Guerrero-
Castillo et al. (2016) [72]. 
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1.1.4. Mitochondrial Processes 
1.1.4.1. Mitochondrial Fusion and Fission 
The classical view of the mitochondria as a small, rod shaped organelle isolated from its 
peers is an outdated one with little to no relevance in modern mitochondrial research. 
Instead mitochondria are viewed as a dynamic network in constant flux between 
individual punctate units and large branching networks.   
There exist two opposing processes that work in co-operation with mitophagy pathways 
to maintain functional mitochondria; mitochondrial fusion, and mitochondrial fission. 
Mitochondrial fusion is the process by which smaller units join to create large networks, 
allowing for the exchange of respiratory chain components, mitochondrial DNA and 
maintenance of membrane potential (Δψm). Mitochondrial fission is the reverse process, 
whereby networks are divided again allowing for the removal of dysfunctional portions 
or subunits.  
Fusion is governed by 3 GTPases, mitofusins 1 and 2 (MFN1 and MFN2) on the outer 
membrane and OPA1 on the inner membrane [83, 84]. MFN 1 and 2 form hetero and 
homodimers between adjacent mitochondrial subunits allowing for the fusion of the 
outer membrane. OPA1 performs a similar role on the inner mitochondrial membrane 
although evidence suggests that its expression is not required on both mitochondria for 
inner membrane fusion to occur [85]. To complicate matters, OPA1 is known to have as 
many as 8 protein isoforms in humans, with each seemingly playing slightly different 
roles in mitochondrial dynamics, mtDNA abundance, cristae formation and energetic 
efficiency. Longer isoforms appear to lend themselves to mitochondrial fusion whilst 
shorter isoforms focus on cristae structure and OXPHOS efficiency [86]. In mouse this 
number is reduced, with only 6 isoforms identified [87].  
Fission is a more complex process that involves a larger array of proteins. Key amongst 
these in the mammalian system is dynamin related protein 1 (DRP1). DRP1 is recruited 
to the outer mitochondrial membrane (OMM) where it oligomerizes and through the 
action of its GTPase domain contracts around the mitochondrial body, constricting it and 
creating a ‘pinch point’ [88]. However, as DRP1 lacks a transmembrane domain it is 
hypothesised that an adaptor protein must be present to recruit DRP1. A number of 
proteins have been implicated in this role including mitochondrial fission protein 1 
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(FIS1), mitochondrial fission factor (MFF) and mitochondrial dynamics proteins of 49 and 
51 kDa (MID49 and MID51)[83]. Zhang et al. (2016) [89] employed ASTC-a-1 cells 
exposed to UV light to induce mitochondrial fragmentation in order to dissect the 
function of a number of these proteins and proposed the following mechanism. The 
results suggest that DRP1 is dephosphorylated at the inhibitory site of Ser637 and 
migrates to the OMM where it is recruited by MFF1, which simultaneously stimulates 
the GTPase activity of DRP1. At the same time, the inhibitory effect of MID51 binding to 
DRP1 is ablated by the competitive binding of FIS1, thereby liberating DRP1. The model 
remains incomplete but offers a foundation on which future work can build.  
Ultimately the function of mitochondrial dynamics appears to be one of quality control. 
As mitochondria carry their own genome, without appropriate DNA repair mechanisms 
and in the presence of high levels of ROS (reactive oxygen species), mtDNA mutations 
can accumulate over the lifespan of an organism. In addition, mitochondrial OXPHOS 
units may become defective and membranes can become damaged leading to a loss of 
membrane potential. All of these issues, if left unchecked could lead to mitochondrially 
triggered apoptosis. Hence the exchange of mitochondrial components allows for the 
collection and removal of defective parts by mitophagy and ultimately promotes 
homeostasis [90].  
1.1.4.2. Reactive Oxygen Species Production 
Reactive oxygen species (ROS) such as superoxide (O2-), hydrogen peroxide (H2O2) and 
hydroxyl (•OH) are primarily produced by complexes I and III as part of normal OXPHOS 
function. As these compounds can lead to damage of mtDNA and proteins their 
production is counteracted by antioxidants that mop up ROS and ensure the health of 
the mitochondria [91, 92].  
Under normal conditions the main source of ROS is complex I, which takes electrons 
from NADH and passes them through the Fe-S centres to ubiquinone; this is assisted by 
the flavin mononucleotide (FMN) cofactor that initially accepts the electrons from 
NADH. O2- is produced by the reaction of the fully reduced FMN, the level of which is 
defined by the ratio of NADH to NAD+, with O2 [93-95]. This means that deficiencies in 
the electron transport chain lead to an increased reduction of the mitochondrial 
NADH/NAD+ pool, a shift in the amount of fully reduced FMN and an over-production of 
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ROS. In the case of reverse electron transport, where respiration is driven through 
complex II substrates, electrons are forced backwards through complex I from ubiquinol, 
reducing the NADH/NAD+ pool as well as the FMN, again leading to high ROS production 
[96, 97].  
The link between elevated ROS and cardiomyopathy has been established by a number 
of studies but the mechanism linking the two remains elusive [98, 99]. Furthermore, the 
link remains tentative as some animal models of complex I deficiency induced 
hypertrophic cardiomyopathy (HCM) demonstrate no elevation of ROS or evidence of 
oxidative stress induced damage [100]. 
1.1.4.3. Regulation of Energetic Supply and Demand 
ATP is required for the normal function of the myocyte during both contraction and 
relaxation, with levels being maintained at around 10mmol/L by alterations in pathways 
involving ATP use and synthesis. The primary source of ATP is the mitochondrial electron 
transport chain and under normal conditions this system is capable of maintaining ATP 
levels even during periods of increased demand. Typically, reactions that hydrolyse ATP 
to ADP and Pi are inhibited by the accumulation of the products in a sub cellular 
compartmental fashion [101]. The oxidation of NADH and FADH2 by the electron 
transport chain establishes the proton gradient (ΔpH) which is one of the major 
components (along with membrane potential (ΔΨm)) of the proton motive force (ΔµH) 
that drives protons through the F1F0-ATP synthase, producing ATP. In the healthy heart, 
NADH and FADH2 are produced primarily by the utilisation of two substrates; glucose, 
via glycolysis; and fatty acids, via β-oxidation [102]. The utilisation of each substrate is 
tightly controlled to meet demand and maintain cellular ATP levels. β-oxidation of fatty 
acids is inhibited by the accumulation of both acetyl-CoA and NADH, whilst glycolysis is 
inhibited by the accumulation of pyruvate dehydrogenase (PDH). In addition the 
pathways reciprocally regulate each other through the Randle cycle, with the NADH and 
acetyl-coA produced by β-oxidation inhibiting glycolysis and the acetyl-coA produced by 
glycolysis inhibiting β-oxidation [103, 104].  
Under normal physiological conditions, β-oxidation accounts for roughly 70% of utilised 
substrate. During periods of increased demand, the upregulation of substrate utilisation 
is governed by two main factors, [ADP] and [Ca2+]. Increased ATP usage leads to a drop 
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in [ATP] and triggers the F1F0-ATP synthase to increase the turnover of ADP into ATP. 
This results in a temporary loss of ΔµH which acts as a signal drawing more electrons 
through the ETC. Increased ETC activity elevates the oxidation of NADH and FADH2, and 
reduces their inhibition of glycolysis and β-oxidation. Increased flow of Ca2+ through the 
cell both from extracellular deposits and the sarcoplasmic reticulum (SR) lead to an 
increase in [Ca2+] in the mitochondrial matrix. The elevation of [Ca2+] in this fashion 
stimulates PDH as well as the TCA cycle, elevating the production of NADH and FADH2 
[104, 105].    
In addition to the electron transport chain, the creatine kinase system plays an 
important role in buffering ATP levels in order to maintain constant ATP concentrations 
during fluctuations in supply and demand. Phosphocreatine (PCr) acts by buffering the 
local [ATP] and providing an energetic reserve during times of high energy demand. 
Creatine kinase catalyses the reversible phosphorylation of creatine to produce PCr 
when [ATP] is high, then when [ATP] is low the phosphate group is released back to ADP 
to restore [ATP]. In addition to its role in buffering and reserve capacity, PCr is more 
readily diffusible than ATP and is able to act as a shuttle through facilitated diffusion, 
collecting phosphate from sites of ATP production (mitochondria) and ferrying it to sites 
of high ATP usage in the muscle fibre [101, 104, 106]. This is possible due to multiple 
isoforms of creatine kinase in the cell. The mitochondrial isoform (mtCK) which catalyzes 
the phosphorylation of creatine to phosphocreatine  and the cytosolic isoforms (CK-MM, 
MB and BB) which typically catalyse the reverse reaction, releasing the phosphate group 
from the creatine to ADP, producing ATP at sites of high demand [107].  
The concept of the failing heart having a deficiency of ATP or being ‘energy starved’ has 
existed for many years and there is a great deal of evidence in support of this concept. 
The end stage failing heart may have reduced [ATP] in myocardium by as much as 30%, 
with even greater deficits in phosphocreatine, and the ratio of [PCr]:[ATP] provides a 
predictive metric for the severity of heart failure [101, 106, 108].  
Animals with pressure overload cardiomyopathy, as induced by transverse aortic 
constriction (TAC), demonstrate a reduced [PCr]:[ATP] very early in the progression of 
left ventricular hypertrophy, and show an increased relationship between the two as LV 
remodelling progresses [109]. Furthermore, mice with an inducible deletion of the gene 
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Slc25a3, resulting in the loss of the mitochondrial phosphate carrier protein (PiC), show 
a reduction in [ATP] and a severe cardiomyopathy by 10 weeks post deletion [110]. 
These results support the idea that energy insufficiency plays a key role in the 
development of cardiac hypertrophy. In contrast to this work, knockout mice lacking 
functional guanidinoacetate N-methyltransferase (GAMT), unable to produce creatine 
and maintained on a diet free of it, show no differences in maximal exercise capacity or 
in the 48 hour survival rate post myocardial infarction [111].  
As [ADP] rises, so too does [AMP] as a result of the reaction catalysed by adenylate 
kinase (2ADP ↔ ATP + AMP). AMP-dependant protein kinase (AMPK) is a molecular 
sensor of [AMP] and as such can be thought of as a ‘fuel gauge’ for the mammalian cell. 
When [AMP] is high, AMPK is activated by the upstream AMPK kinase and begins 
remodelling cellular processes to improve ATP production. Amongst the pathways 
AMPK affects are: fatty acid synthesis (reduced), fatty acid oxidation (increased), glucose 
uptake and metabolism (increased), and mitochondrial biogenesis via PGC1α (increased) 
[112, 113]. Rats with pressure overload hypertrophy show near normal [ATP] whilst 
[PCr] is decreased resulting in an elevation of [ADP] and [AMP]. These hypertrophied 
hearts show activation of AMPK which in turn leads to elevated glucose uptake through 
GLUT1 and surprisingly a decrease in β-oxidation [114].   
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1.1.4.4. The Mitochondrial Unfolded Protein Response 
The mitochondrial unfolded protein response (UPRmt) is a mechanism for the detection 
of the accumulation of misfolded proteins within the mitochondria and the upregulation 
of factors intended to remove and counteract their formation. By necessity it differs 
from the endoplasmic reticulum unfolded protein response (UPRER) due to the double 
membrane structure of the mitochondria [115].  
The UPRmt can be activated by any one of a number of mitochondrial stresses including; 
accumulation of misfolded mitochondrial proteins, mitochondrial ribosome 
impairment, mitochondrial chaperone or protease inhibition, OXPHOS dysfunction, high 
glucose metabolism, and high ROS levels [116]. When activated, the UPRmt has three 
distinct mechanisms of action to counter any non-specific stress, these three prongs are; 
increased expression of mitochondrial chaperones, inhibition of protein production 
through translation inhibition and degradation of misfolded proteins by proteases. 
The UPRmt can be separated into two distinct sensing mechanisms and their associated 
responses. The first monitors protein folding in the mitochondrial matrix and is activated 
by JNK2 (c-JUN N-terminal kinase) and PKR (dsRNA-activated protein kinase), the second 
monitors the inter membrane space (IMS) and is activated by the phosphorylation of 
AKT (protein kinase B) [115]. 
Early work undertaken by Zhao et al. (2002) investigated the UPRmt in a model that 
introduced a mutant form of the protein ornithine transcarbamylase (OTC) into COS7 
cells. It was found that there is a distinct UPRmt that involves the upregulation of the 
mitochondrial chaperones HSP60 (heat shock 60kDa protein 1 (CPN60)), HSP10 (heat 
shock 10kDa protein (CPN10)) and MTDNAJ (mitochondrial DNAJ heat shock protein) as 
well as the protease CLPP (caseinolytic mitochondrial matrix peptidase proteolytic 
subunit), without any change in expression of factors known to be involved the UPRER. 
Central to this pathway are the transcription factors C/EBPβ (CCAAT/enhancer-binding 
protein) and CHOP (C/EBPβ homology protein). There also seems to be an inferred role 
for the mitochondrial unfolded protein response elements (Mure1 and Mure2), whose 
role is yet to be determined, but which have been found in close proximity to CHOP 
binding sites in many UPRmt genes [117, 118]. Bioinformatics tools have been used to 
identify the presence of an AP-1 binding site in the promoters of both Chop and Cebpb 
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[118]. AP-1 binding sites are the target of C-JUN, a transcription factor which is positively 
regulated by the NH2-terminal kinase, JNK2, indicating that this pathway is key for the 
activation of the matrix portion of the UPRmt (Figure 1.6) [119, 120]. 
 
Figure 1.6. Schematic representation of the matrix portion of the UPRmt. Accumulation of misfolded 
proteins triggers the response via PKR and JNK2 which activate the transcription factor c-Jun, leading to 
expression of the transcription factors CHOP and C/EBPβ which up regulate the expression of UPRmt genes 
encoding chaperones such as HSP60 and proteases such as ClpP. [115]. 
At the same time as there is upregulation of mitochondrial chaperones, there is also a 
reduction in protein translation in the cytoplasm. This is mediated by the action of 
dsRNA-activated protein kinase (PKR) which phosphorylates eukaryotic translation 
initiation factor 2α (EIF2α) and prevents protein translation to reduce the load on the 
mitochondrial chaperones [121]. It is also worth noting that the action of PKR with the 
aforementioned protease CLPP also activates the AP-1 binding transcription factor C-
JUN [121].    
In addition to this core set of proteins identified in the UPRmt, Aldridge et al. (2007) used 
bioinformatics tools to identify a further six genes under the control of CHOP, that were 
upregulated during the UPRmt response. In addition to the CHOP site in the promoter 
region of these genes, the bioinformatics analysis also identified the Mure1 and Mure2 
regions previously seen in other UPRmt genes. The six genes encode a variety of proteins; 
from mitochondrial proteases, YME1L and MPPβ; to enzymes, NDUFB2, EndoG and 
thioredoxin 2; and the import machinery component Tim17a. Whilst the role of these 
proteins in the UPRmt is not yet fully understood, mutation of the ‘Mure’ elements 
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results in a loss of upregulation during UPRmt activation indicating a putative role for 
these proteins in managing misfolded proteins in the mitochondrial matrix [118].  
Fiorese et al. (2016) set out to determine if, as in C.elegans, there is a key mammalian 
regulator of the UPRmt. In C.elegans this key regulator is ATFS-1, which is normally 
transported to the mitochondria, but under periods of stress accumulates in the cytosol 
before entering the nucleus and triggering the UPRmt. Bioinformatics analysis identified 
2 proteins with significant homology to ATFS-1, ATF4 (activating transcription factor 4) 
and ATF5 (activating transcription factor 5). Interestingly, only ATF5 had signs of a 
mitochondrial localisation signal, and only ATF5 was able to restore the UPRmt in worms 
lacking the ATFS-1 protein. Further work has confirmed that ATF5 behaves similarly to 
ATFS-1 in worms, by localising to the mitochondria under normal conditions, but 
activating the UPRmt under periods of stress. ATF5 primarily promotes the expression of 
genes with a UPRmtEs promoter, including the chaperones; HSP10, HSP60, MTHSP70 and 
the mitochondrial protease LONP1 (lon peptidase 1) [122]. 
More recent work has utilised a mutant form of the protein endonuclease G (ENDOG) 
(N174A), which accumulates in the IMS and induces mitochondrial stress [123, 124]. The 
results from this work indicate the existence of a second arm of the UPRmt which is solely 
concerned with proteins of the IMS (Figure 1.7).  
 
Figure 1.7. Schematic representation of the IMS portion of the UPRmt. In this case accumulation of 
misfolded proteins results in elevated ROS which activate AKT and lead to activation of the proteasome 
as well as upregulation of genes such as HTRA2. [115]. 
Control of the IMS UPRmt is held by protein kinase B (AKT) that becomes phosphorylated 
due to elevated ROS levels caused by accumulation of misfolded proteins in the IMS. 
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Phosphorylation of AKT leads to activation and in turn phosphorylation of estrogen 
receptor α (ERα) at serine 167 [123]. From here the response takes on a 2 step approach, 
both of which are promoted by ERα activation. The first is the activation of the 
proteasome to degrade misfolded proteins in the cytosol before they enter the IMS. The 
second is the increased expression of the protease HTRA2 (high temperature 
requirement protein A2) which degrades any misfolded proteins that have made it into 
the IMS [123, 124].  
Ultimately, any failure of the UPRmt leads to complete mitochondrial dysfunction 
without the requirement for loss of mitochondrial membrane potential (Δψm). This 
mitochondrial dysfunction can lead to accumulation of PINK1 (PTEN induced putative 
kinase 1) on the OMM via a currently unknown pathway and the activation of mitophagy 
[125]. The mechanism of mitophagy is discussed further in section 1.1.4.6.  
1.1.4.5. Mitophagy 
Mitophagy is the means by which a cell selectively disposes of defective mitochondria 
through autophagic processes. This typically follows the process of fusion/fission and is 
a significant portion of the process of mitochondrial quality control. The primary axis for 
inducing mitophagy involves the proteins PTEN-induced putative kinase 1 (PINK1) and 
parkin (PARK2) which recognise mitochondria through a drop in membrane potential, 
Δψm, and target them for digestion by autophagosomes. As mentioned in the previous 
section, there is also an unknown mechanism by which PINK1 can accumulate on the 
OMM without any change in Δψm, as may be seen during inability of the UPRmt to cope 
with mitochondrial stress [125]. 
Under conditions where Δψm is high, the serine-threonine kinase PINK1 (63kDa), 
localises to the outer mitochondrial membrane (OMM) where it is transported to the 
inner mitochondrial membrane (IMM) by the TOM (translocation of outer mitochondrial 
membrane) and TIM23 (translocation of inner mitochondrial membrane) complexes. 
Following insertion into the IMM, PINK1 is cleaved at residue A103 by the presenilin-
associated rhomboid-like protein (PARL) to form ΔN-PINK1 (52kDa). This process leads 
to degradation of PINK1 by the proteasome rendering it inert and allowing for 
mitochondria with high Δψm to be maintained in the cell [126-128]. When Δψm is low, 
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PINK1 remains in the OMM and is unable to be cleaved and targeted for degradation by 
PARL, leading to its accumulation on defective mitochondria.  
When left as a full length protein, PINK1 autophosphorylates at Serine 228 and 402, 
leading to activation and recruitment of PARK2. Okatsu et al. (2012) demonstrated that 
pseudo-phosphorylated PINK1 (S228D/S402D) is capable of recruiting PARK2 whilst 
introducing mutations that inhibit phosphorylation (S228A/S402A) demonstrate the 
opposite effect [129]. In addition to autophosphorylation, PINK1 is capable of 
phosphorylating both MFN2, at residues T111 and S442, and ubiquitin, at S65, with both 
events having independently been shown to be necessary for the translocation of PARK2 
to the OMM [130, 131]. As PARK2 is recruited it ubiquitinates proteins such as BNIP3L 
[132] on the OMM, with the ubiquitination acting as a signal to autophagosomes to 
degrade the damaged mitochondria [133, 134].  
Failure to remove mitochondria by this method leads to accumulation of defective 
subunits, mtDNA mutations and inefficient OXPHOS and has been associated with 
elevated levels of systemic inflammation and cardiomyopathy [135, 136] 
1.1.5. Genetic Defects of the Mitochondrial Electron Transport Chain 
1.1.5.1. Nuclear Encoded Mutations 
Of the roughly 1500 proteins in the mitochondrial proteome, only 13 are encoded by 
the mtDNA, leaving the vast majority to be synthesised in the cytoplasm and transported 
into the mitochondria [137]. Nuclear genome mutations that lead to mitochondrial 
defects can be broadly divided into 5 categories according to which genes they effect; 
nuclear encoded ETC subunits, assembly factors, mtDNA integrity maintenance, mtDNA 
copy number maintenance and control of mitochondrial gene expression. In the interest 
of brevity, this section will only focus on those mutations that directly affect the ETC.  
Between 1990 and 2014 in the north east of England, 62 individuals were reported with 
nuclear DNA (nDNA) mutations, corresponding to a prevalence of 2.9 per 100,000 adults 
(>16 years) [138]. Of these 62, the majority had mutations in the genes SPG7 (spastic 
paraplegia 7) (17), PEO1 (progressive external ophthalmoplegia) (15), OPA1 (optic 
atrophy 1) (8), POLG (polymerase gamma) (6) and RRM2B (ribonucleotide reductase M2 
B) (5) [138]. None of these proteins are constitutive elements of the electron transport 
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chain, indicating that even amongst mitochondrial disease, ETC mutations are rare, likely 
due to the essential nature of many components of the ETC. 
As complex I is the largest complex of the electron transport chain it is unsurprising that 
it is the site of most of the identified nuclear mutations causing ETC deficiency. Of 
complex I’s 37 nuclear encoded proteins, pathogenic mutations have been identified in 
at least 17, including all seven of the nuclear encoded ‘core’ subunits and 10 of the 
remaining subunits [28, 139, 140]. The patients identified so far represent a roughly 
60:40 split of those carrying core gene mutations to those with non-core gene mutations 
[139]. Table 1.1 shows all of the identified mutations in nuclear encoded complex I 
subunits. 
Mutations affecting the core subunit proteins of NDUFV1, NDUFV2, NDUFS1, NDUFS2, 
NDUFS3 NDUFS7 and NDUFS8, which comprise the main functional portions of the N 
and Q domains, account for the majority of known mutations [140]. Below I will give a 
brief overview of mutations identified in these 7 core subunits.  
Mutations in NDUFV1 were first identified in 3 children with symptoms including 
myoclonic epilepsy, muscular hypotonia and elevated lactate levels. The first 2 patients 
were found to be compound heterozygotes for 2 mutations (R59X and T423M), with the 
first mutation leading to a truncated protein, and the second lying in a well conserved 
region of the protein. The third patient was shown to be homozygous for an A341V 
mutation, leading to isolated complex I deficiency [141].  
An NDUFV2 mutation was identified in 3 members of a single family whom all suffered 
from a fatal HCM within the first 12 months of life. The causative mutation was found 
to be a 4bp deletion in the consensus splice-donor site of intron 2 resulting in the loss 
of the 66bp exon 2 and a reduction in the amount of NDUFV2 protein produced [142]. 
3 patients with NDUFS1 mutations were identified through a screening process looking 
for the disease causing alleles in a group of patients with complex I deficiency. This study 
identified 3 patients from 3 families, 2 of which had siblings with mitochondrial disease. 
The first presented with optical atrophy, leukodystrophy and lactic acidosis, with the 
causative mutation being identified as a deletion resulting in an aspartic acid being 
substituted for a glycine at residue 252 (D252G). The second patient demonstrated axial 
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hypotonia, hepatomegaly and hyperlactatemia and carried 2 mutations as a compound 
heterozygote (R412W and R557X). The final patient had similar symptoms of 
hyperlactatemia and hypotonia with the addition of microcephalia and pyramidal 
syndrome. This patient was found to be a heterozygote for a methionine to valine 
substitution at position 707 (M707V) with the addition of a de novo deletion in the 
paternal allele [143].  
NDUFS2 mutations were identified in members of 3 families with symptoms of complex 
I deficiency including nystagmus, acidosis, muscle hypotonia, cognitive development 
and HCM. Further study found 3 mutations within the NDUFS2 gene, (Arg228Gln, 
Pro229Gln, and Ser413Pro) all of which resulted in a complex I deficiency as measured 
by enzymatic assay [144].  
A patient with Leigh syndrome was identified with a mutation in NDUFS3. Briefly, Leigh 
syndrome is typically associated with neurological symptoms including epilepsy, 
nystagmus, ataxia and optic artrophy. A limited number of cases have also been 
described with cardiac involvement although this is variable [145]. The patient was 
found to be a compound heterozygote. The first mutation resulted in a well conserved 
Threonine at position 145 being changed to an Isoleucine (T145I) and the second 
changed an arginine into a tryptophan at position 199 (R199W). The R199W mutation 
was found to be paternally inherited and was also found in a healthy brother, with no 
signs of mitochondrial disease [146].   
Patients with mutations in NDUFS7 and NDUFS8 have mostly been identified as sufferers 
of Leigh syndrome. The first nuclear encoded mutations linked to Leigh syndrome were 
found in NDUFS8, the first being a proline to leucine change at position 79 (P79L) and 
the second an arginine to histidine at residue 102 (R102H). NDUFS7 was subsequently 
also found to be causative of Leigh syndrome with the mutation causing residue 122 to 
swap from a valine to a methionine (V122M) [147, 148].  
Complex II mutations are most commonly found in the gene for the subunit SDHA. An 
arginine to tryptophan change at reside 554 (R554W) resulted in Leigh syndrome in 2 
siblings [149]. Whilst a later study identified a third patient with Leigh syndrome as a 
result of a paternally inherited W119X mutation and a maternally inherited A83V 
mutation which resulted in a significant loss of functional complex II [150]. Mutations in 
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many of the other units of complex II are associated with various cancers. Mutations in 
SDHB, SDHC and SDHD are associated with paraganglioma and phaeochromocytoma 
whilst mutations in other TCA cycle enzymes such as fumarate hydratase (FH) can lead 
to leiomyoma, leiomyosarcoma or renal cell carcinoma. Possibly as a result of blocked 
metabolism of succinate or fumarate in the mitochondria which then trigger other 
cellular processes in pre-cancerous cells [151].  
Of the 10 nuclear encoded subunits of complex III, only UQCRB, UQCRQ, UQCRC2 and 
CYC1 have been found to contain mutations resulting in any form of complex III 
deficiency [152]. The UQCRB mutation was discovered in a single patient with a 4bp 
deletion in exon 4; this resulted in a reduction in complex III levels and symptoms 
including acute gastroenteritis and lactic acidosis [153].  
A change at residue 45 from serine to phenylalanine (S45F) in UQCRQ was identified in 
25 members of an Israeli Bedouin family, all of whom developed Leigh syndrome [154]. 
A mutation in UQCRC2 was discovered in a family in Mexico, the patients presented with 
similar symptoms to the UQCRB patient mentioned previously. The arginine to 
tryptophan (R183W) change caused a ~80% reduction in complex III levels and 
enzymatic activity levels reduced by half [155]. Finally, 2 unrelated mutations have been 
found in CYC1 (W96C and L215F). Yeast studies demonstrated an almost total absence 
of complex III for both mutations. Symptomatically, both patients demonstrated hyper-
glycaemia without any developmental delay [156]. The lack of known mutations in 
complex III probably stems from its essential role in the ETC. Damage to complex III 
structure or function results in lack of super-complex formation, which is required for 
complex I stability (see section 1.1.3.6) and it forms the funnel for electrons entering the 
chain from both complex I and complex II. As a result, mutations in complex III are likely 
to be too severe to be viable and unlikely to be found in patient populations.  
Mutations in complex IV structural subunits are rare, with the majority of complex IV 
deficiencies being caused by mutations in assembly factors such as SURF1, COX10, 
COX15, SCO1 and SCO2 [157]. To date, only 3 genes have been found with mutations in 
complex IV subunits that lead to complex IV deficiency. Of these genes, COX4I2, COX7B 
and COX6B1, only COX6B1 has been found to carry a mutation leading to 
cardiomyopathy. The mutation caused an arginine to cysteine change at position 20 
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(R20C) of the protein and resulted in an 89% reduction in protein levels and an 83% drop 
in complex IV enzymatic activity [158].  
Disorders of complex V or ATP synthase are also rare, the majority have been traced to 
mutations in mtDNA, over 30 have been linked to the mtDNA genes MTATP6 and 
MTATP8 [159]. Of those that have been traced to nuclear mutations, most are 
associated with assembly factors which will be covered in more detail in section ‘1.1.5.3. 
Assembly factor mutations’, only the genes ATP5A1 and ATP5E have been implicated in 
human disease with a total of three patients being known. A mutation (R329C) in 
ATP5A1 of 2 patients led to severe neonatal encephalopathy and was shown to cause 
an ATP synthase deficiency in both patients [160]. A less severe phenotype was also 
found in a patient harbouring a homozygous Y12C mutation in ATP5E. This mutation also 
led to an ATP synthase deficiency as confirmed by a 70% reduction in ATP synthase 
content when compared to controls [161]. 
Overall, of the roughly 75 nuclear encoded subunits of the mitochondrial electron 
transport chain, at least 27 have been implicated in causing conditions associated with 
mitochondrial deficiency. This is likely an underrepresentation of the real rate of 
causative mutations in the general population as many mutations are likely to result in 
phenotypes too severe to be viable. Furthermore, the lack of identified mutations in 
supernumerary subunits may indicate that these are better tolerated and less likely to 
be pathogenic.   
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Subunit Location Known Mutations Clinical Phenotype Reference 
NDUFV1 N R59X-T423M Progressive unspecified encephalomyopathy  [141] 
  
 
A341V Leukoencephalopathy with macrocephaly  [143] 
  
 
E214K-IVS8+4A>C (Skip exon 8) Leigh syndrome  [143] 
  
 
A432P-c.989-990del (C332X) Leigh-like syndrome  [145] 
  
 
Y204C-C206G Leigh-like syndrome  [145] 
  
 
A4341V Leukoencephalopathy with macrocephaly  [162] 
  
 
R386C Leukoencephalopathy  [163] 
  
 
R257Q-A211V Leukoencephalopathy  [164] 
  
 
E377K Lethal infantile mitochondrial disease  [74] 
NDUFV2 N IVS2+5_+8delGTAA (Skip exon 2) Cardiomyopathy and encephalopathy  [142] 
  
 
IVS2+5_+8delGTAA (Skip exon 2) Cardiomyopathy and encephalopathy  [165] 
NDUFS1 N del222leu-D252G Leukoencephalopathy  [145] 
  
 
R421W-R557X Unspecified Encephalopathy  [145] 
  
 
M707V-LS deletion Leigh-like syndrome  [145] 
  
 
Q552K Leukoencephalopathy  [163] 
  
 
L231V Leigh syndrome  [166] 
  
 
D619N-R557X Leukoencephalopathy  [167] 
  
 
R408C Leukoencephalopathy  [168] 
  
 
R408C Leigh syndrome  [168] 
  
 
del211Glu-V228A Leukoencephalopathy  [169] 
  
 
V228A-D252G Leukoencephalopathy  [169] 
  
 
T595A Progressive cavitating leukoencephalopathy  [170] 
NDUFS2 Q R228Q Hypertrophic cardiomyopathy/encephalomyopathy  [144] 
  
 
P229Q Hypertrophic cardiomyopathy/encephalomyopathy  [146] 
  
 
S413P Encephalomyopathy  [146] 
  
 
M292T-R118Q Leigh syndrome  [169] 
  
 
M292T-M443K Leigh syndrome  [169] 
  
 
M292T-E148K Leigh syndrome  [169] 
  
 
R138Q-R333Q Leigh-like syndrome  [169] 
  
 
M292T-c.866+4A>G ‡ Leigh-like syndrome  [169] 
NDUFS3 Q T145I-R199W Leigh syndrome  [146] 
NDUFS7 Q V122M Leigh syndrome  [147] 
  
 
R145H Leigh-like syndrome  [171] 
  
 
c.17-1167C>G (Cryptic exon and fs) Leigh-like syndrome  [172] 
NDUFS8 Q P79L-R102H Leigh syndrome  [148] 
  
 
P85L-R138H Leigh syndrome  [173] 
  
 
P79L  Leigh-like syndrome  [169] 
  
 
G154S Leukoencephalopathy  [74] 
NDUFV3 N None     
NDUFS4 N K158fs Unspecificed encephalomyopathy  [174] 
  
 
W97X Leigh-like syndrome  [175] 
  
 
R106X Leigh-like syndrome  [176] 
  
 
R106X Leigh-like syndrome  [176] 
  
 
W14X Leigh-like syndrome  [177] 
  
 
IVS1-1G>A Leigh-like syndrome  [178] 
  
 
K154fs Leigh-like syndrome  [179] 
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D119H-K154fs Leigh-like syndrome  [180] 
  
 
c.99-1G>A-K154fs Leigh syndrome  [74] 
  
 
c.99-1G>A-c.351-2A>G Leigh syndrome  [74] 
NDUFS6 N Exon 3/4 deletion Lethal infantile mitochondrial disease  [181] 
  
 
c.186+2T>A Lethal infantile mitochondrial disease  [182] 
  
 
C115Y Severe neonatal lactic acidosis  [182] 
NDUFA12 N R60X Leigh syndrome  [183] 
NDUFA13 Pp R57H Leigh-like syndrome  [184] 
NDUFA11 Pp IVS1+5G>A ‡ Lethal infantile mitochondrial disease  [185] 
  
 
IVS1+5G>A ‡ Encephalocardiomyopathy  [185] 
NDUFA7 Q None     
NDUFA5 Q None     
NDUFA2 N IVS2+5G>A Leigh-like syndrome  [186] 
NDUFA10 Pp c.1A>G-c.425A>G Leigh syndrome  [187] 
NDUFA9 Q R360C Myopathy  [188] 
  
 
R321P Leigh-like syndrome  [189] 
NDUFS5 Pp None     
NDUFA1 Pp G8R Leigh-like syndrome  [189] 
  
 
R37S Encephalomyopathy  [188] 
  
 
G32R Progressive neurodegeneration  [190] 
NDUFA8 Pp None     
NDUFA6 Q None     
NDUFA3 Pp None     
NDUFC1 Pp None     
NDUFA4 * C.42+1G>C ‡ Leigh syndrome (COX deficient only)  [191] 
NDUFAB1 Q/ PD None     
NDUFB4 PD None     
NDUFB2 PD None     
NDUFB8 PD None     
NDUFB11 PD R88X MLS syndrome  [192] 
  
 
c.402delG MLS syndrome  [193] 
NDUFB1 PD None     
NDUFB10 PD E70X-C107S Lactic acidosis and cardiomyopathy  [193] 
NDUFB5 PD None     
NDUFB9 PD None     
NDUFB7 PD None     
NDUFB6 PD None     
NDUFC2 Pp None     
NDUFB3 PD None     
Table 1.1. Mutations of nuclear encoded complex I subunits and associated clinical phenotypes. Adapted 
and updated from Pagniez-Mammeri et al. (2012) [140]. Locations of proteins in modules according to 
Guerrero-Castillo et al. (2016) [72]. *NDUFA4 does not have a recognized position within complex I. ‡ 
Mutation results in splicing abnormality.  
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1.1.5.2. Mitochondrial DNA Mutations 
Human mitochondrial DNA is 16.5 kb in length and codes for 37 genes, 22 of which are 
tRNAs and 2 are rRNAs, the remaining genes are all constituent proteins of the 
mitochondrial electron transport chain [145]. Due to the large copy number of 
mitochondrial DNA, mutations may often not lead  to symptoms until mutated DNA 
reaches a threshold level of heteroplasmy in a given tissue, this threshold level may 
differ from tissue to tissue and can depend on the type of causative mutation [194]. 
Mitochondrial mutations take on 2 forms, those affecting mitochondrial protein 
synthesis, and those affecting mitochondrial protein coding genes. 
Mutations that affect mitochondrial tRNA, lead to a defect in protein synthesis and an 
overall reduction in the assembly of mitochondrial proteins, this type accounts for 
almost 60% of mutations whilst tRNA genes only account for 10% of the mitochondrial 
genome [194]. Perhaps the most well characterised mitochondrial mutation, an A to G 
at nucleotide 3423 in tRNALEU, is widely associated with MELAS syndrome. However, 
evidence has also linked it to a maternally inherited cardiomyopathy without any other 
signs or symptoms of MELAS [195, 196]. Other tRNAs have also been implicated in 
mitochondrial disorders, with mutations in the genes MTTL1 (tRNALeu(UUR)), MMTI 
(tRNAIle), MTTK (tRNALys), MTTL2 (tRNALeu(CUN)) and MTTT (tRNAThr) all being linked 
to conditions involving cardiomyopathy [145].  Large scale deletions can also lead to the 
loss of tRNA genes, these mutations are suspected to occur in the germ line rather than 
be maternally inherited as it is uncommon to find parents or siblings sharing mutations. 
These mutations can occur anywhere in the mitochondrial genome and typically result 
in one of three syndromes; Kearns-Sayre, progressive external ophthalmoplegia (PEO), 
or Pearson’s. The threshold level for deletion mutations tends to be lower than that for 
point mutations with a requirement for roughly 80% of damaged DNA before symptoms 
become apparent [194].  
Mutations in mitochondrial protein coding genes are less common than those in tRNA, 
accounting for roughly 40% of mutations in the 13 protein coding genes that account for 
70% of the genome [194].  Complexes I, III, and IV as well as ATP synthase may be 
affected by mutations in any of their mitochondria encoded subunits, but complex II is 
unaffected as it is entirely nuclear encoded [197]. Symptoms are typically noticed in 
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infants and vary from cardiomyopathy to myopathy, deafness, mental retardation, 
cataracts, retinitis pigmentosa, epilepsy, encephalopathy and neuropathy. Govindaraj 
et al. (2013) identified 28 novel mutations in mtDNA from 114 HCM patients. Of these, 
10 were non-synonymous and lay in genes encoding electron transport chain proteins 
including MTND1, MTCOI, MTATPase8 and MTATPase6 [198].   
Finally, rRNA mutations are comparatively rare, accounting for about 2% of mutations, 
and may occur in either the 12 or 16kDa ribosomal subunits. These conditions may be 
mild, resulting in hearing loss,  or more severe, resembling MELAS [197].  
1.1.5.3. Assembly Factor Mutations 
The complexity and two genome nature of most of the mitochondrial electron transport 
chain complexes necessitates the involvement of a variety of chaperone and assembly 
factor proteins which allow for the correct and efficient assembly of the complexes 
within the mitochondria. Mutations in these assembly factors account for the majority 
of mitochondrial deficiencies and the resultant diseases [29].  
All five of the mitochondrial electron transport chain complexes have a unique set of 
assembly factors that are required for functional assembly. Despite the identification of 
many of these assembly factors there is still an incomplete picture and more work is 
required. This section will primarily focus on complex I assembly factors, although the 
remaining complexes will be summarised.  
In mammals complex I is known to have at least 13 assembly factors involved directly 
with structural assembly (NDUFAF1, NDUFAF2, NDUFAF3, NDUFAF4, ACAD9, ECSIT, 
TIMMDC1, TMEM186, TMEM126B, COA1, TMEM70, FOXRED1 and ATP5SL) as well as a 
number of other chaperones or assembly factors involved in other aspects of forming 
functional complex I or whose role is not yet fully understood (NDUFAF5, NDUFAF6, 
NDUFAF7, IND1, DNAJC11, and AIF). Of these 19 proteins, at least 11 (Table 1.2) have 
been identified in human patients with mitochondrial disease and it is noteworthy that 
roughly 40% of all patients suffering from mitochondrial disease have no mutations in 
structural genes [74, 199-202]. Mutations in complex I assembly factors lead to a loss of 
fully assembled complex I, an accumulation of complex I assembly intermediates and a 
reduction in enzymatic activity [29, 75, 203].  
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Subunit Known Mutations Clinical Phenotype Reference 
NDUFAF1 (CIA30) T207P-K253R Cardioencephalopmyopathy [204] 
  R211C-G245R Fatal infantile hypertrophic cardiomyopathy [205] 
NDUFAF2 (NDUFA12L/B17.2L) R45X-LS deletion Progressive encephalopathy [78] 
  M1L Progressive encephalopathy [206] 
  Y38X Leigh syndrome [77] 
  LS deletion Encephalomyopathy [207] 
  W3X Leigh syndrome [208] 
  W74X Leigh syndrome [74] 
  I35SfsX17 Leigh syndrome [74] 
  A73GfsX5 Leigh syndrome [74] 
NDUFAF3 (C3ORF60) G77R Lactic acidosis [76] 
  R122P Encephalomyopathy with macrocephaly [76] 
  M1T-R122P leukoencephalopathy [76] 
NDUFAF4 (C6ORF66) L65P Encephalomyopathy [75] 
  L65P Encephalomyopathy and Cardiomyopathy [75] 
NDUFAF5 (C20ORF7) L229P Dysmorphism and lactic acidosis [209, 210] 
  L159F Leigh-like syndrome [211] 
  G250V Leigh syndrome [212] 
NDUFAF6 (C8ORF38) Q99R Leigh-like syndrome [213] 
NDUFAF7 (MIDA) None     
ACAD9 R518H Exercise intolerance, hypertrophic cardiomyopathy [214] 
  E63X-E413K Encephalopathy, hypertrophic cardiomyopathy [216] 
  V546L Hypertrophic cardiomyopathy [215] 
  A170V-H563D Hypertrophic cardiomyopathy [217] 
  R414S-c.1650_1672dup Fatal infantile hypertrophic cardiomyopathy [217] 
ECSIT None     
TMEM186 None     
TMEM126B G212V Exercise intolerance [201] 
  c.401delA-G212V Exercise intolerance [203] 
TMEM70 * c.317-2A>G 
Hypotonia, lactic acidosis, hypertrophic 
cardiomyopathy [202] 
  c.317-2A>G;c.A628C 
Hypotonia, lactic acidosis, hypertrophic 
cardiomyopathy [204] 
  c.701A>C 
Leukoencephalopathy, hypertrophic 
cardiomyopathy [204] 
COA1 None     
TIMMDC1 (C3ORF1) None     
FOXRED1 Q232X-N430S Leigh syndrome [74] 
IND1 (NUBPL) G56R-D273QfsX31 - del. Dup. Encephalomyopathy [74] 
ATP5SL None     
DNAJC11 None     
AIF None     
Table 1.2. Mutations of complex I assembly factors and associated clinical phenotypes. Adapted and 
updated from Pagniez-Mammeri et al. (2012) [200]. *Mutations result in complex V deficiency, not 
complex I. 
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In the interests of brevity, this report will focus only on those assembly factors identified 
as part of complex I assembly by Guerrero-Castillo et al. (2016) [72]. 
Of the 5 assembly factors that form the MCIA complex [69, 70] 3 have been identified 
with pathogenic mutations, NDUFAF1, ACAD9 and TMEM126B (Table 1.2). In addition 
to the 2 unrelated patients identified by Nouws et al. (2010), Dewulf et al. (2016) 
identified a further 9 patients from 3 families who all suffered from hypertrophic 
cardiomyopathy and due to mutations in ACAD9. Loss of full ACAD9 function led to 
decreased levels of the associated proteins NDUFAF1 and ECSIT as well as a reduction in 
the levels of complex I [214, 215].  The two patients identified with NDUFAF1 mutations 
also demonstrate a loss of complex I, 30%[204] and ~40%[205] of healthy controls, 
however, ACAD9 levels were not measured to confirm the reciprocal relationship. In 
contrast to the other patients with MCIA complex protein mutations, TMEM126B 
patients display a milder phenotype with a later onset. Most of these patients were 
identified over the age of 8 years with an exercise intolerance phenotype due to reduced 
complex I protein levels (10-48% of healthy control) and elevated complex II, III, IV and 
V levels, possibly as a compensatory mechanism. Of most interest is that these patients 
all show decreased levels of all of the other MCIA components, raising the question of 
why these patients display a comparatively mild phenotype [201]. Furthermore, in 2 of 
these patients it was seen that both ECSIT and ACAD9 were present in super-complexes 
containing complexes I, III and IV. 
Of the remaining characterised membrane arm assembly factors only 2, TMEM70 and 
FOXRED1, contain known pathogenic mutations. TMEM70 mutations result in a severe 
phenotype including hypertrophic cardiomyopathy, however these mutations all result 
in complex V deficiency with no reports of effects on complex I [202]. Only a single 
patient with Leigh syndrome has been identified with a FOXRED1 mutation [74]. 
The three known matrix arm assembly factors all have greater numbers of known 
patients with pathogenic mutations. The NDUFAF2 mutations described in table 1.2 all 
result in a truncation or complete loss of the protein leading to a significant loss of 
complex I protein in all cases. The NDUFAF3 mutations were found in 5 patients from 3 
families all of whom died before 6 months of age. In contrast to the NDUFAF2 patients, 
these mutations did allow for the formation of NDUFAF3 protein, although the levels of 
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complex I in those tested was severely reduced [76]. Finally, NDUFAF4 is the only 
remaining assembly factor from this list whose place in the assembly pathway was 
characterised by Guerrero-Castillo et al. (2016) [72]. Six patients from 2 families were 
identified carrying the same leucine to proline change (Table 1.2), which resulted in a 
loss of complex I activity which caused encephalopathy in all of the patients and 
hypertrophic cardiomyopathy in one [75].  
It is interesting to note that certain phenotypes appear to be common to different arms 
of complex I and the associated assembly factors. Assembly factors of the matrix arm 
appear to have an anecdotal link with Leigh syndrome and encephalopathy whilst those 
of the membrane arm are more often than not found with a cardiomyopathy in addition 
to other phenotypes.  
In humans, complex II has only two known assembly factors, SDHAF1 (succinate 
dehydrogenase assembly factor 1) and SDHAF2 (succinate dehydrogenase assembly 
factor 2), though there are expected to be further undiscovered proteins with an 
important role as there are at least four assembly factors in yeast [29]. SDHAF1 was the 
first to be implicated in disease with a study finding 2 families with children exhibiting 
leukoencephalopathy caused by loss of complex II activity [216]. SDHAF2 mutations 
have been identified in families with history of certain types of cancer (paraganglioma 
and phaeochromocytoma), but there remains to be a case of SDHAF2 mutation linked 
to any classical mitochondrial disease [217].  
Complex III again only has two known assembly factors, BCS1L and TTC19, but with 
complex III deficiencies being rare, possibly due to the catastrophic effect of reduced 
complex III on super-complex formation, little is known about the involvement of any 
other assembly factors [29]. A large number of patients with mutations throughout the 
BCS1L gene have been identified with a variety of phenotypes [29]. The BCS1L protein is 
known to contain 4 domains; a transmembrane domain (TMD), a mitochondrial 
targeting sequence (MTS), an import auxiliary sequence (IAS) and an ATPase domain 
[218]; with mutations identified in at least 3, although there appears to be no correlation 
between the disease caused and the domain affected. The mildest form of disease is 
Björnstad syndrome which results in sensorineural hearing loss and twisted brittle hair 
cells (pili torti), mutations that lead to this condition have been identified throughout 
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the BCS1L gene [219]. At the other end of the scale is GRACILE (growth retardation, 
aminoaciduria, cholestasis, iron overload, lactacidosis, and early death) syndrome, 
which results in neonatal lethality and may again be caused by mutations anywhere in 
the BCS1L gene [219, 220]. In between these two extremes a number of patients have 
been identified with phenotypes ranging from encephalomyopathy, lactic acidosis, liver 
failure and muscle weakness [218, 221-223]. Mutations in the other known assembly 
factor, TTC19, typically result in neurological impairment although the age of onset is 
highly variable. The first patients identified with neurological conditions varied in onset 
from late infancy to 42 years of age [224]. A later study identified another patient with 
a TTC19 mutation that resulted in Leigh syndrome with early onset at about 13 months 
of age [225].      
Studies in yeast have shown that Complex IV assembly is highly regulated and may 
involve as many as 40 assembly factors though only a fraction have been identified as 
causative of human disease [226], however, these will not be covered in detail in this 
section. The mutations identified in complex IV assembly factors are associated with a 
wide range of clinical phenotypes ranging from Leigh syndrome and leukodystrophy, to 
myopathy, cardiomyopathy and lactic acidosis as well as others.   
Finally, ATP synthase has a similar situation to that of complex III. Several factors 
required for assembly have been identified in yeast but of these only two have been 
found in humans (ATP12 and ATP11), both of which prevent the formation of aggregates 
of the incomplete F1 portion of the complex by binding the α and β subunits 
respectively[227]. A single patient with a tryptophan to arginine mutation (W94R) was 
described as having a condition resembling COFS (cerebro-oculofacioskeletal) syndrome 
[228]. 
It can be seen as a common feature that the majority of assembly factor mutations result 
in multi-system disorders that invariably prove fatal. Only those mutations affecting the 
membrane arm of complex I appear to cause milder or mono-systemic disorders. This 
may be due to a greater degree of toleration for these mutations in the complex I 
assembly process, it may be due to complex I’s earlier point in the ETC meaning a loss of 
function is less devastating to the overall function of the chain, or it may reflect some 
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degree of redundancy either across tissue types (different assembly factors in different 
tissues) or within tissues (other assembly factors can take up the slack). 
1.2. ECSIT 
In humans, evolutionarily conserved signalling intermediate in toll pathway (ECSIT) is a 
431 amino acid adapter protein with 2 identifiable isoforms (50/33kDa) and a third 
potential isoform based on splice prediction (24kDa) [229, 230]. In the mouse ECSIT 
contains 435 amino acids and maintains almost 75% sequence homology with the 
human protein (Figure 1.8), however there is only experimental evidence of a single 
protein isoform existing in mouse tissues (50kDa).  
ECSIT was first identified from a yeast 2 hybrid screen as a signalling intermediate in the 
toll/IL-1 pathway, where it was shown to regulate MAP3K1 (MEKK-1) [229]. Later work 
in a mouse knock-out line implicated ECSIT in the bone morphogenetic protein (BMP) 
pathway. As part of this pathway, ECSIT interacts with SMAD1 and SMAD4 and is 
involved in mesoderm formation of the early embryo [230]. More recently, ECSIT has 
been shown to localise to mitochondria where it binds and stabilises the complex I 
assembly factor NDUFAF1, allowing for the efficient assembly of complex I [231]. 
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Figure 1.8. Protein sequence alignment of ECSIT protein in Homo sapiens, Mus musculus, Rattus 
norvegicus, Bos taurus, Danio rerio and Drosophila melanogaster. Source: ncbi.nlm.nih.gov/homologene. 
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1.2.1. Protein Structure and Homology 
Human ECSIT protein has 3 recognisable domains in the full length protein, an N-
terminal mitochondrial targeting sequence (amino acids 1-48), a highly ordered (Figure 
1.9) pentatricopeptide repeat region (PPR) (amino acids 90-266) and a less ordered C 
terminal domain that shows some 3D resemblance to pleckstrin homology domains 
(amino acids 275-380) [68]. Mouse ECSIT protein maintains roughly 73% sequence 
homology to the human protein (Figure 1.9) and shows the presence of the same 
mitochondrial targeting sequence seen in the human protein (amino acids 1-48) (results 
according to Phyre2 web server) [232]. The PPR motif in mouse is reduced in size from 
the human protein prediction, 176 vs 129 amino acids. However, the pleckstrin 
homology domain appears to occupy roughly the same section of the protein from 278 
to 379 amino acids, only being 4 amino acids shorter in the mouse.  
The N terminal mitochondrial targeting (MTS) sequence is required for the localisation 
of the protein to the mitochondria where the MTS is cleaved, this results in 2 protein 
products from the single long ECSIT isoform, a ~50kDa cytosolic form, and a ~45kDa 
mitochondrial form [231]. Of the remaining two potential domains in the ECSIT protein, 
only the PPR domain has been shown to have any potential link to mitochondrial 
processes. These domains are thought to bind RNA in a sequence specific manner, 
although this has not been demonstrated for ECSIT, and play a role in maturing and 
stabilising RNA molecules [233]. There is some evidence to suggest that at least one 
mammalian protein containing at PPR domain, PTCD2, is involved in mitochondrial 
electron transport chain assembly, and interfering with the PPR domain results in 
defects of complex I and complex III assembly in a variety of tissues [234, 235].  
 
Figure 1.9. Protein domains of human [68] and mouse ECSIT as predicted by Phyre2 webserver [232]. 
Mitochondrial targeting sequence (MTS) shows no variation between the two models whilst the PPR 
domain is shorter in the mouse model and the PH domain differs in length by 4 amino acids.  
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1.2.2. Toll Like Response 
As mentioned above, ECSIT was first identified as interacting with the proteins TRAF6 
(tumour necrosis factor (TNF) receptor associated factor 6) and MEKK-1/MAP3K1 (ERK 
kinase kinase-1/Mitogen–activated protein kinase) in the Toll/IL-1 pathway. It was 
shown that ECSIT binds to the multi-adapter protein TRAF6 and allows for the 
phosphorylation of MEKK1 (MAP3K1) into an active state. This phosphorylation event 
leads to activation of NF-κB and promotion of the innate immune response [229]. The 
work by Kopp et al. (1999) also suggested that the ECSIT-TRAF6 complex leads to 
activation of the TAK1 protein, allowing it to interact with and phosphorylate TAB1 and 
2, offering another pathway by which ECSIT can participate in the toll pathway [229].  
Studies around the same time showed that TRAF6, and by association ECSIT, is involved 
in not only the activation of NF-κB but also in the activation of other aspects of the 
MAP3K1 signalling cascade, resulting in phosphorylation of JNK, IKK and NF-κB [236]. It 
was later revealed that the nature of the interaction between TRAF6 and ECSIT is not 
simply binding but poly-ubiquitination of ECSIT, leading to localisation to the OMM 
(outer mitochondrial membrane) and degradation [237]. Macrophages deficient in 
either TRAF6 or ECSIT exhibit reduced mitochondrial ROS and had an increased 
susceptibility to intracellular bacteria, as was demonstrated by infecting the cells with a 
strain of salmonella expressing GFP (green fluorescent protein). These infected 
macrophages showed increased levels of bacterial CFU (colony forming units) at all of 
the time points tested, indicating that ECSIT may link mROS production with the innate 
immune system [237].  
In the first of two papers, Wi et al. (2014) demonstrated that the interaction between 
TRAF6 and ECSIT occurs between residues 200 and 257 of the human ECSIT protein and 
in a second paper showed that the poly-ubiquitination of ECSIT by TRAF6 occurs at 
residue K372 of the human protein, leading to ECSIT interacting directly with the 
p65/P50 NF-κB proteins, activating them and facilitating their translocation to the 
nucleus [238]. In addition, this group confirmed the suspicions of Kopp et al. (1999) by 
demonstrating that ECSIT interacts with TAK1 in the region of residues 257-431 of the 
human protein, resulting in the formation of a TAK1-ECSIT-TRAF6 complex that is 
activated by TLR4. The formation of this complex activates TAK1, in turn activating IKK 
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complexes. IKK complexes are then activated to phosphorylate and polyubiquitinate IκB-
α which is degraded, liberating p65/P50 NF-κB [239]. 
In addition to investigating ECSIT’s part in the BMP pathway, Xiao et al. (2003) knocked 
down ECSIT in the macrophage cell line Raw 264.1 using shRNA, showing that loss of 
ECSIT protein leads to loss of NF-κB activation through the toll pathway, but not through 
the TNFα pathway, indicating that ECSIT works exclusively as an intermediary of the TLR 
pathway [230].  
The role of ECSIT in the innate immune system and in particular the Toll like receptor 
pathway is demonstrated in figure 1.10, this shows that the result of ECSIT interaction 
with TRAF6 is the activation of MEKK-1 (MAP3K1) ultimately leading to the activation of 
NF-κB, JNK and p38 MAPK resulting in stimulation of the innate immune response.  
 
Figure 1.10. Diagram of the Toll-like response and the position of ECSIT (1) in the pathway. Interaction of 
ECSIT with TRAF6 and MEKK-1 results in the activation of NF-κB (2) through the degradation of IκB-α, and 
phosphorylation of JNK (3) and p38 MAPK (4) through the activation of MEKK-1 (MAP3K1). Image courtesy 
of Cell Signaling Technology® (www.cellsignal.com). 
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1.2.3. Bone Morphogenetic Protein Pathway 
In addition to its role in toll-like receptor (TLR) signalling and complex I assembly, ECSIT 
also has an identified role in the bone morphogenetic protein (BMP) pathway and 
mouse knockouts show embryonic lethality around the point of gastrulation (E7.5). 
Mutant embryos demonstrated abnormal development with the loss of mesoderm 
development and a thickening of the epiblast as well as a loss of downstream expression 
of the BMP pathway gene, Tlx2 (T-Cell leukaemia homeobox 2).  Ultimately the role of 
ECSIT in the BMP pathway was found to be as an essential co-factor of SMAD4. Following 
BMP expression, the ECSIT-SMAD4 complex interacts with SMAD1 and allows the 
complex to bind the BMP response element of the Tlx2 promoter, enabling transcription 
[230].   
 
Figure 1.11.  Schematic of the BMP and TGF-β pathways. ECSIT interacts with SMAD4 (1) as an essential 
co-factor leading to Tlx2 expression. Image courtesy of Cell Signaling Technology® (www.cellsignal.com). 
Interestingly, ECSITs interaction with SMAD4 implicates it in the TGF-β pathway (Figure 
1.11) as SMAD4 acts as the common cofactor of all TGF-β activated SMAD complexes in 
the nucleus, possibly through its unique SAD (SMAD-activation domain) [240].  
The link between the BMP and TGF-β pathways and innate immunity is well established 
and ECSIT may function as part of the mechanism linking these essential pathways [241]. 
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1.2.4. Complex I Assembly 
The role of ECSIT in the assembly of complex I was first noted by Vogel et al. (2007), this 
work used tandem affinity purification (TAP) of mitochondrial lysates from human 
embryonic kidney (Hek293) cells containing a tagged form of the known complex I 
assembly factor NDUFAF1. Amongst the proteins identified by FT-MS (Fourier transform 
mass spectrometry) were a number of peptides specifically related to ECSIT. Prediction 
software also identified a cleavable mitochondrial targeting sequence corresponding to 
the 49 N-terminal amino acids, the presence of which was confirmed by the persistence 
of a ~45-kDa isoform upon treatment with trypsin and the loss of the non-mitochondrial 
~50-kDa isoform under the same conditions. Further work, using a GFP tagged form of 
ECSIT with and without its N-terminal targeting sequence, confirmed that the 5-kDa 
fragment is necessary for mitochondrial localisation [231].  
The interaction of ECSIT with NDUFAF1 and complex I was confirmed using two-
dimensional blue native PAGE analysis of mitochondrial lysates. ECSIT was found in large 
complexes of ~500, 600 and 850kDa, the same as that of NDUFAF1 in the cell type of 
interest. siRNA knock-down of ECSIT then showed a severe reduction in complex I levels 
and a loss of 50% of complex I enzymatic activity [231].   
In support of the work completed on the ECSIT-NDUFAF1 interaction, Nouws et al. 
(2010) demonstrated that ACAD9 is also a complex I assembly factor that interacts with 
both ECSIT and NDUFAF1 and knock down of ACAD9 leads to a decrease in NDUFAF1 
and ECSIT protein levels and a reduction in functional complex I levels [214].  
Since the initial discovery of ECSIT’s interaction with NDUFAF1 and ACAD9, work by 
Heide et al. (2012) has shown that ECSIT forms part of the MCIA complex (Figure 1.12) 
along with NDUFAF1, ACAD9, TMEM126B and TIMMDC1 [68, 69].  ACAD9 forms a 
homodimer which acts as the scaffold for the interaction of ECSIT and NDUFAF1, 
bringing the 3 proteins together. This trimer then interacts with the membrane bound 
proteins TMEM126B and TIMMDC1 before acting as part of the complex I assembly 
process [68].   
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Figure 1.12. Structure and subunits of complex I alongside the proposed formation of the MCIA complex 
containing ACAD9, NDUFAF1 and ECSIT which go on to interact with TMEM126B and TIMMDC1. [68] 
ECSIT protein contains an RNA binding domain in the form of a PPR domain. The same 
is true for NDUFAF1 which contains an RRM (RNA recognition motif) (Figure 1.13) and 
whilst no evidence yet exists, this may implicate the MCIA complex in the processing of 
RNA for complex I proteins [68].  
 
Figure 1.13. Protein domains of human ECSIT, NDUFAF1 and ACAD9 proteins showing RNA recognition 
motifs within ECSIT and NDUFAF1. ACAD9 has 3 AcylCoA domains denoted as the N, M and C domains 
with the C domain being split into the C-1 and C-2.  Adapted from Giachin et al. (2016) [68]. 
Finally, the role of ECSIT in complex I assembly was confirmed by Guerrero-Castillo et al. 
(2017) in work that dissected the full complex I assembly process and was detailed 
earlier in section ‘1.1.3.8. – Complex I Assembly’. By synchronising the complex I 
assembly process this work demonstrated that the MCIA is involved in the formation of 
the PP-b module of the membrane arm of complex I as one of the initial steps of complex 
I assembly [72]. 
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1.3. Cardiomyopathy 
1.3.1. Definition, classification and identification 
Cardiomyopathy by its broadest definition is any disease of the heart muscle, of which 
there are many types with a wide range of genetic and environmental causes (Table 1.3), 
however this report will focus on the two main kinds of hypertrophic and dilated 
cardiomyopathy (Figure 1.14).  
Disease Mutated gene Pathology 
Hypertrophic cardiomyopathy Myosin binding protein C Increased heart mass 
  β-Myosin heavy chain Left ventricular wall thickening 
  α-Myosin heavy chain Increased cardiomyocyte size 
  α-tropomyosin Myofibrillar disarray 
  Troponin T Decreased volume of left ventricular chamber 
  α-Cardiac actin Interstitial fibrosis 
  Troponin I Enlarged nuclei 
  Titin Ventricular wall stiffness 
  Myosin light chains Inflammation 
  Troponin C   
  Vinculin   
  Muscle LIM protein   
  Telothonin   
Dilated Cardiomyopathy β-Myosin heavy chain Ventricular wall thinning 
  Desmin Ventricular chamber enlargement 
  N-cadherin Cardiomyocyte apoptosis 
  α-Cardiac actin Interstitial fibrosis 
  Skeletal muscle myopathies Enlarged nuclei 
  α-Tropomyosin 1 Ventricular wall stiffness 
  Muscle LIM protein δ-sarcoglycan Inflammation 
  Lamin A/C   
  TAZ (G4.5)   
  Titin   
  Phospholamban   
  Vinculin   
  Troponin I   
  Troponin T2   
  SCN5A   
  Presenilin 1 & 2   
  Troponin C   
  α-Cardiac actinin   
  Plakoglobin   
Restrictive cardiomyopathy Troponin I Ventricular wall stiffness 
  Desmin Apoptosis 
  α-Cardiac actin Fibrosis 
  Skeletal muscle myopathies Myofibrillar disarray 
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  Troponin T   
  β-Myosin heavy chain   
Left ventricular non-compaction TAZ (G4.5) Trabeculated ventricular walls 
  α-Dystrobrevin Noncompaction of ventricular andocardium 
  FKBP12 Necrotic myocytes 
  β-Myosin heavy chain Fibrosis 
  α-Cardiac actin Myofibrillar disarray 
  Cardiac troponin   
Arrhythmogenic right ventricular Plakophilin-2 Right ventricular dilation 
cardiomyopathy Junctional plakoglobin Right ventricular fibrosis 
  Desmocollin-2 Fibrofatty infiltration 
  Desmoglein-2 Apoptosis 
  Desmoplakin   
Muscular dystrophy-associated Dystrophin Left ventricular hypertrophy or dilation 
cardiomyopathy Sarcoglycan Fibrosis 
  Dystroglycan Apoptosis 
  Dystrobrevin   
Table 1.3. Different classifications of cardiomyopathy with associated genetic causes and typical 
pathological features. Adapted from Harvey and Leinwand (2011) [242]. Bold – genetic causes common 
to more than one classification of cardiomyopathy.  
Figure 1.14. Diagrammatic representation of healthy heart (A) vs hypertrophic (B) and dilated (C) 
cardiomyopathy. Ao – Aorta, RV – right ventricle, LV – left ventricle, LA – left atrium. Hypertrophic 
cardiomyopathy shows characteristic thickening of the left ventricular (LV) free wall and intraventricular 
septum (IVS) resulting in decreased LV volume. Dilated cardiomyopathy shows an increase in LV volume 
and a thinning of the LV free wall and IVS. Taken from Harvey and Leinwand (2011) [242]. 
Hypertrophic cardiomyopathy (HCM) was first described by Donald Teare in 1957 where 
he described 8 patients between the ages of 14 and 44 all of whom died of a poorly 
understood cardiac condition which he then characterised as HCM [243]. Today HCM 
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affects approximately 1 in 500 people with annual mortality rates around 6 per 10,000 
affected individuals [244]. Classical diagnosis of HCM is performed by echocardiography 
to look for thickening of the left ventricular (LV) free wall, in humans this diagnosis is 
typically greater than 15mm, without an increase in LV chamber volume. More recently 
the use of cardiac magnetic resonance imaging (CMR) has improved understanding of 
the disease and refined risk assessment by providing more detail of the state of not only 
the LV wall, but also of the mitral valves, papillary muscles and any potential scarring 
that may have taken place [245]. The genetic causes of HCM are quite well understood 
with 60% of cases having an identified genetic cause in one of 11 genes encoding 
proteins of the sarcomere, typically with an autosomal dominant inheritance pattern 
[245, 246]. Of these 11 sarcomeric genes, 8 are considered to be the core sarcomeric 
proteins leading to inherited HCM (MYH7, MYBCP3, TNNT2, TPM1, MYL2, MYL3, TNNI3 
and ACTC1) [247]. The most common mutations are in beta-myosin heavy chain (MYH7) 
and myosin-binding protein c (MYBPC3) which account for between 60% and 70% of  
cases with an identified genetic variant [245, 247].   
Despite the predominance of sarcomeric protein mutations as the cause of HCM, there 
is also evidence linking ATP regulation to the development of HCM in some patients. 
Specifically, mutations in the γ2 subunit protein PRKAG2, have been identified in two 
families containing a total of 8 affected individuals. The two mutations (‘Exon 5:ins Leu’ 
and H142R) lead to HCM, ECG traces with pre-excitation, symptomatic wolf-parkinson-
white syndrome (WPWS) as well as a high incidence of sudden death [248].  
In addition to these common mutations there is also significant involvement from 
mitochondrial OXPHOS deficiencies with cardiomyopathy along with encephalopathy 
being among the most common manifestations of a variety of mitochondrial disorders 
(See section 1.3.2.) [27]. 
Whereas HCM is characterised by an increased thickness of the LV wall without an 
increase of the LV volume, dilated cardiomyopathy (DCM) is characterised by an 
increase in LV volume and systolic dysfunction, typically without thickening of the LV 
wall [249]. Whilst the incidence rate for DCM is not as well understood as HCM, 
conservative estimates put it in the region of 1 in 250 people, though mortality rates are 
unknown. As with HCM, most DCM is inherited in an autosomal dominant pattern with 
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a variable, age-dependant variance. However, unlike HCM, DCM has been linked to 
more than 40 genes including many which are also implicated in HCM. Pathogenic 
mutations in these 40 genes only account for roughly 30% of known cases of DCM, with 
the most common being truncation mutants of the protein TITIN. These truncation 
mutants are found in about 25% of familial cases and 18% of sporadic cases [250].  
1.3.2. Mitochondrial Conditions with Cardiac Involvement 
Given the essential nature of mitochondria it is unsurprising that defects in 
mitochondrial OXPHOS function cause a wide variety of diseases with a diverse set of 
symptoms. Tissues with increased energy demands, such as liver, kidney, brain and 
heart, are often worst affected [158], but which tissues are affected and which 
symptoms are present is often unpredictable.  
Common amongst the most well characterised mitochondrial syndromes are symptoms 
resulting from cardiac abnormalities, these can include both myocardial changes and 
cardiac conduction abnormalities which may include long QT syndromes, increased PR 
interval, atrioventricular (AV) block and cardiomyopathy (hypertrophic and dilated) 
amongst others [145]. This section details some of the conditions known to include 
cardiac abnormalities but is not meant to be exhaustive.  
Kearns-Sayre syndrome is a mitochondrial syndrome characterised by pigmentary 
retinopathy and ophthalmoparesis that affects individuals within the first 2 decades of 
life. Also present are cardiac conduction abnormalities, hearing loss, cerebellar ataxia, 
dementia [251] and the condition can ultimately lead to sudden cardiac death [252]. 
Kearns-Sayre syndrome is a result of large scale deletions of mtDNA which may affect 
multiple genes involved in the OXPHOS complexes and their assembly.  
Myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) was first 
described in 1984 where it was described as being clinically separate from both Kearns-
Sayre syndrome and myoclonus epilepsy and ragged red fibres (MERRF) [253]. The 
clinical diagnosis was later defined as requiring 3 key features; stroke before 40 years of 
age, encephalopathy, and either lactic acidosis or ragged red fibres [254]. The condition 
may also lead to a variety of other phenotypes including diabetes mellitus, small stature, 
deafness, cataracts and cardiomyopathy (38% of patients) [145]. The mitochondrial DNA 
mutation m.3243A>G in the mitochondrial encoded tRNA leucine 1 (MT-TL1) accounts 
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for roughly 80% of all known MELAS cases [255]. However, the condition has also been 
associated with as many as 30 other mtDNA mutations [255] including in the complex I 
subunits MT-ND1[256], MT-ND5[257] and MT-ND6[258].    
Leigh syndrome was first described in 1951 by Denis Leigh and is characterised by lesions 
in the brainstem, thalamus, cerebellum, spinal cord and optic nerves [259]. Clinical 
symptoms may include respiratory abnormalities, epilepsy, nystagmus, ataxia, optic 
atrophy, elevated lactate levels and some cases have presented with dilated or 
hypertrophic cardiomyopathy, although cardiac involvement appears to be dependent 
on the nature of the mutation [145]. Leigh syndrome can be caused by mutations in 
either nuclear or mitochondrial DNA and may affect any of the electron transport chain 
complexes with over 75 individual genes being linked to the condition (Table 1.4) [260].  
However the most common are mutations affecting complex I (34%) [261], with the 
most common individual mutation being m.9176T>G in the gene MT-ATP6 [145, 262]. 
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Biochemical Deficiency Genes 
Pyruvate dehydrogenase PDHA1a, PDHB, PDHX, DLAT, DLD, LIPT1, TPK1, SLC19A3, SLC25A19 
Complex I 
MTND1b, MTND2b, MTND3b, MTND4b, MTND5b, MTND6b, NDUFV1, NDUFV2, NDUFS1, 
NDUFS3, NDUFS4, NDUFS7, NDUFS8, NDUFA1a, NDUFA2, NDUFA9, NDUFA10, 
NDUFA12, NDUFAF2, NDUFAF5, NDUFAF6, FOXRED1 
Complex II SDHA, SDHAF1 
Coenzyme Q10 PDSS2 
Complex III UQCRQ, BCS1L, TTC19 
Complex IV MTCO3b, NDUFA4, SURF1, COX10, COX15, SCO2, PET100, LRPPRC, TACO1, ETHE1 
Complex V MTATP6b 
Combined OXPHOS defects - Pathway 
affected   
Mitochondrial DNA maintenance FBXL4, POLG, SUCLA2, SUCLG1 
Mitochondrial translation 
ΔmtDNAc, MTTIb, MTTKb, MTTL1b, MTTVb, MTTWb, MTFMT, GTPBP3, TRMU, EARS2, 
FARS2, IARS2, NARS2, GFM1, GFM2, TSFM, C12orf65, PNPT1  
Disease genes that cause secondary 
impairment of mitochondrial energy 
generation   
OXPHOS ± PDHc HIBCH, ECHS1, SERAC1, AIFM1a 
Biotinidase BTD 
Table 1.4. Table of human genes containing mutations known to cause Leigh syndrome. Adapted from 
Lake et al. (2016) [260]. Except where denoted, all genes show autosomal recessive inheritance pattern. 
aX-linked inheritance, bmaternal inheritance, csporadic inheritance.  
Other conditions such as Pearson syndrome, myoclonus epilepsy and ragged red fibres 
(MERRF) and neuropathy, ataxia and pigmentary retinopathy (NARP) have also been 
linked with cardiomyopathy, but this link is less robust and the number of affected 
patients is much lower, hence it has not been covered in detail here [145].  
1.3.3. Mouse models of Complex I Dysfunction Related Cardiomyopathy 
A number of techniques are available for the study of mitochondrial diseases in animal 
models; these include the production of point mutations, knockout animals, knockdown 
using siRNA and chemical inhibition amongst others. Here I will focus on the few 
knockout animal models of complex I deficiency in existence.   
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At present no technology exists to produce reliable mutations in mitochondrially 
encoded electron transport chain proteins and no mouse lineages exist with stable 
mitochondrial mutations, hence all murine models are a result of nuclear encoded 
mutations [263].  
NDUFS4 was the first protein to be globally knocked out in mice that produced a complex 
I deficiency in mice. However these animals presented with primarily neurological 
defects and died at 7 weeks of age due to encephalomyopathy and symptoms 
resembling Leigh syndrome, no cardiological manifestations were observed [264]. Later 
work involving a tissue specific knockout in cardiac tissue resulted in a ~50% loss of 
complex I activity and a profound cardiomyopathy as shown by MRI imaging. By assaying 
mitochondrial hydrogen peroxide production and investigating caspase 3 cleavage this 
work demonstrated that the cardiomyopathy was not the result of oxidative damage or 
elevated apoptosis and occurs solely because of complex I deficiency [100]. 
Another protein, NDUFS6, has also been globally knocked down in a mouse model 
resulting in a severe cardiomyopathy. Animals demonstrated a 3.2 fold increase in heart 
weight when compared with wild type mice and a ~90% reduction in complex I activity. 
This research did not investigate whether there was a relationship with ROS production 
or increased apoptosis that may ultimately be causative of the cardiomyopathy [265]. 
Interestingly, this model differs from known human mutations in its presentation, with 
humans having a system wide disease and early death, although cardiac involvement 
was not investigated and hence cannot be ruled out.  
1.4. ENU Mutagenesis 
The discovery that N-Ethyl-N-Nitrosourea (ENU) functioned as a powerful chemical 
mutagen was first described in 1979 [266] and has since become a valuable tool for the 
identification of novel genes and pathways associated with mammalian disease. ENU is 
an alkylating agent which functions by transferring an ethyl or methyl group to the 
oxygen or nitrogen of nucleotide bases resulting in a DNA adduct that if not corrected 
leads to a point mutation or small deletion in the genome. ENU typically modifies A/T 
base pairs either by transversion to T/A (44%) or transition to G/C (38%). G/C to A/T 
transitions (8%), G/C to C/G transversions (3%), A/T to C/G transitions (5%), and G/C to 
T/A transitions (2%) are less common [267]. ENU mutagenesis is typically administered 
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as a series of injections into a male mouse where sperm are mutagenised, allowing for 
the phenotyping and genetic characterisation of his offspring. Typical dosage leads to a 
mutation load in the region of one mutation for every 1-1.5Mb [268].  
Two of the key advantages of ENU mutagenesis over other systems for genetic 
modification is the ability to produce a wide range of alleles (hypo, hyper, neo, null, anti) 
and breeding schemes can be employed to screen for a variety of different mutation 
types. Single generation breeding can allow for the investigation of dominant or X-linked 
dominant traits, whilst multi generation schemes can allow for recessive screens. In 
addition, ENU mutagenesis can be employed in so called ‘sensitized strains’ which carry 
a pre-existing mutation or heritable trait to look for modifier genes or regions of the 
genome associated with a particular trait [269]. A limitation of ENU mutagenesis is the 
preference for A/T modifications, resulting in the favouring of certain areas of the 
genome or amino acid changes [268]. 
1.4.1. The Harwell Ageing Screen 
The Harwell ageing screen was a large scale recessive ENU mutagenesis screen using a 
phenotype driven approach to discover new models of diseases associated with ageing. 
C57BL/6J male mice were mutagenised with an initial ENU dose of 120mgkg-1 followed 
by two further doses of 100mgkg-1 with a week between each dose. Mutagenised mice 
were then bred with C3H.Pde6b+ females to produce a G1 cohort. G1 males were again 
crossed to C3H.Pde6b+ females to produce a G2 cohort. G2 females were genotyped for 
the presence of the hypomorphic Cdh23 allele ahl1 (Inherited from the C57BL/6J 
parent), this allele is associated with hearing loss and would confound the phenotyping 
tests planned as part of the screening process. Wild-type animals crossed back to their 
G1  fathers to produce an experimental G3 cohort of roughly 100 male and female 
carrying a wide variety of genetic modifications. Screening was primarily undertaken on 
female mice due to issues with singly housing males following long term procedures, but 
males were screened at a later time point where phenotypes were identified in females 
from any given pedigree.  
Phenotyping tests were carried out longitudinally, typically at an early (3-6 months), 
intermediate (~12 months) and late (15-18 months) time point with final terminal 
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procedures undertaken at 18 months of age (Table 1.5) and included a wide variety of 
systems [270].  
Test Phenotypic Area Group Age (weeks) 
ECG Cardiac All 12 
SHIRPA Neurological Females (males) 13, 66 
Grip strength Musculoskeletal/neurological All 13, 66 
Slit lamp/ophthalmoscope Vision All 15, 49, 65, (73) 
Optokinetic drum Vision/neurological All 15, 49, 65, (73) 
Click box Hearing Non ahl 14, 26, 39, 50 
Auditory brainstem response+click stimulus Hearing Non ahl 14, 39 
Echo-MRI Growth/body composition Males (females) 16, 27, 51, 71 
DEXA Musculoskeletal/body composition Females (males) 16, 51, 
X-ray Musculoskeletal Females (males) 16, 51, 74 
Pupillometry Vision/neurobehaviour All 18, 68 
Sleep tracking Neurobehaviour Females (males) 18, 68 
Clinical chemistry Pathology Females (males) 28, 53, 80 
Fasted bleed Diabetes/metabolism Males (females) 17, 28, 52, 80 
Fasted insulin Diabetes/metabolism Males (females) 33, 57, 72 
IPGTT Diabetes/metabolism Males (females) 33, 57, 72 
Table 1.5. Summary and timetable of phenotyping tests performed during the Harwell Ageing Screen 
showing tests used, time points performed and sex of animals used. In addition, all animals were weighed 
every 3 months up until 12 months of age and then monthly. Where a single sex is indicated the other sex 
was tested where outliers were identified. ECG – electrocardiograph, SHIRPA – Smithkline Beecham, 
Harwell, Imperial College and Royal London Hospital phenotyping assessment, DEXA – dual energy x-ray 
absorptiometry, MRI – magnetic resonance imaging, IPGTT – intraperitoneal glucose tolerance test. 
Adapted from Potter et al. (2016) [270]. 
1.4.2. ENU Screens for Models of Cardiac Disease 
ENU screens have previously been used to investigate novel mutations leading to 
cardiovascular defects in mice. These screens have focused screening both on adult mice 
[271] and on identifying defects in the embryonic mouse by using non-invasive in utero 
Doppler echocardiography [272]. Use of colour Doppler to identify defects in mouse 
embryos was successful in identifying 425 out of 10,091 screened foetuses with cardiac 
abnormalities, however only small portion of these were mapped and causative genes 
were not described [273]. It is important to note that limitations with the screening 
method result in conditions such as hypertrophic cardiomyopathy being under reported 
in the screen [272].   
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1.5. Thesis Aims and Objectives 
The aim of this project is to characterise a novel model of cardiomyopathy resulting from 
an ENU induced point mutation in the gene Ecsit and identified as part of the Harwell 
ageing screen. Ecsit, the evolutionarily conserved signalling intermediate in the toll 
pathway, encodes a 50kDa protein known to be involved in innate immunity through 
the toll pathway, embryogenesis via the bone morphogenetic pathway and in 
mitochondrial complex I assembly as a key assembly factor with a currently unknown 
mechanism.  
The study will involve the following: 
- Phenotyping analysis 
o Characterisation of the cardiomyopathy and longitudinal study to 
determine disease progression. 
o Characterisation of other body systems, liver, renal, neurological, bone, 
to determine if there are secondary effects of the mutation which are less 
prominent than the observed cardiomyopathy.  
- Gene identification 
o SNP mapping to identify region of genome carrying mutation. 
o Whole genome sequencing to identify candidate mutations. 
o Sanger sequencing and pyrosequencing, to confirm candidate mutations 
and isolate causative mutation.  
- Functional characterisation of the pathways affected 
o Ex vivo investigation of the BMP pathway. 
o In vitro investigation of the TLR pathway using bone marrow derived 
macrophages. 
o Protein expression, complex analysis, mitochondrial function analysis, 
and downstream effects of mitochondrial dysfunction to investigate the 
mechanism of ECSITs involvement in complex I assembly.  
  
56 
 
Chapter 2: Materials and Methods 
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2.1. Materials List 
Consumable Supplier Product code 
2,3-Butanedione monoxime Sigma-Aldrich B0753-100G 
20% SDS Solution National Diagnostics EC-874 
2-Mercaptoethanol Gibco 21985-023 
2-Mercaptoethanol (50mM) Gibco 31350-010 
2x Taqman Fast Universal PCR Mastermix Applied Bioystems 4352042 
3,3'-Diaminobenzidine tetrahydrochloride 
hydrate 
Sigma-Aldrich D5637-1G 
70µm cell strainer Greiner bio-one 542070 
96F Without lid Microwell plate Thermo Scientific 269620 
96-Well PCR Plate Non-Skirted 4titude 4ti-0750-25 
Accelerator TAAB Embedding Resin Premix TAAB T037 
Acetonitrile, anhydrous 99.8% Sigma-Aldrich 271004-1L 
Adhesive Film Covers Abgene AB-0558 
Adhesive Sealing Sheets Thermo Scientific AB-0558 
Alkaline Phosphatase New England Biolabs M0290S 
Amersham hyperfilm ECL GE Life Sciences 28906839 
Amersham™ Hybond™ P 0.45 PVDF GE Healthcare 10600023 
Ampicillin Sodium FORMEDIUM AMP25 
Antimycin A Sigma-Aldrich A8764 
Bovine Serum Albumin Sigma-Aldrich A7906-100G 
Bovine Serum Albumin, fatty acid free Sigma-Aldrich A8806-5G 
Carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone 
Sigma-Aldrich C2920-10MG 
CELLSTAR 10cm Cell Culture Dishes Greiner bio-one 664-160 
CELLSTAR 6 Well Cell Culture Plate, Sterile, 
With Lid 
Greiner bio-one 657-160 
CELLSTAR Cell Culture Flasks 25cm2, 50ml, 
Red filter 
Greiner bio-one 690-175 
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CELLSTAR Cell Culture Flasks 75cm2, 250ml, 
Red filter 
Greiner bio-one 658-175 
Collagen from calf skin Sigma-Aldrich C9791-
100MG 
Collagen from calf skin Sigma-Aldrich C8919-20ML 
Collagenase/Dispase Roche 10 269 638 
001 
cOmplete Tablets EDTA-free, EASYpack Roche 04 693 132 
001 
Cytochrome C from bovine heart Sigma-Aldrich C2037 
Cytosine β-D-arabinofuranoside Sigma-Aldrich C1768-
100MG 
D-Mannitol Sigma-Aldrich M9546-250G 
DMEM (1x) + GlutaMAX™-1 +4.5g/L D-
Glucose, -Pyruvate 
Gibco 61965-026 
DMEM (1x) +4.5g/L D-Glucose, +L-Glutamine, 
+Pyruvate 
Gibco 41966-029 
DPBS (1x) -CaCl2, -MgCl2 Gibco 14190-094 
Dried Skimmed Milk Marvel   
EDTA Thermo Scientific 17892 
EGTA Sigma-Aldrich E4378-25G 
Ethanol, absolute Fisher Scientific E/0650DF/17 
Foetal Bovine Serum Gibco 10500064 
Glycerol VWR 444482V 
Hardener Component TAAB Embeddding 
Resin Premix 
TAAB T035 
HBSS -Calcium Chloride, -Magesium Chloride, 
-Magnesium Sulfate 
Gibco 14175-095 
HEPES Buffer Solution (1M) Gibco 15630-056 
High Capacity cDNA Reverse Transcription Kit Applied Bioystems 4368814 
Horse Serum Gibco 16050-122 
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HotShot Mastermix   HS002 
Illustra™ DNA Esxtraction Kit BACC2 GE Healthcare RPN-8502 
Isoproterenol hydrochloride Sigma-Aldrich I-6501 
jetPRIME reagent Polyplus 114-07 
Kanamycin Sulfate from Streptomyces 
kanamyceticus 
Sigma-Aldrich K4000-1G 
L-(-)-Malic acid Sigma-Aldrich M6413-25G 
LCGreen® Plus+ BioFire BCHM-ASY-
0005 
Leibovitz's L-15 Medium (1x) +L-Glutamine 
+L-Amino Acids 
Gibco 11415-049 
L-Glutamic acid Sigma-Aldrich G8415-100G 
L-Glutamine Sigma-Aldrich G8540-25G 
Lipopolysaccharides from Escherichia coli 
O55:B5 
Sigma-Aldrich L2880-10MG 
Live/Dead Cytoxicity/Viability Kit Invitrogen L3224 
Medium 199 (1x) +Earle's Salts +L-Glutamine 
+2.2g/L Sodium Bicarbonate 
Gibco 11150-059 
MEM Non-Essential Amino Acids Solution 
(100x) 
Gibco 11140-050 
Methanol Fisher Scientific M/4000/PC1
7 
MicroAmp® Fast Optical 96-Well Reaction 
Plate w/ Barcode 0.1mL 
Applied Bioystems 4346906 
MicroAmp™ Optical Adhesive Film Applied Bioystems 4311971 
Mlu1 Promega R6381 
NADH, disodium salt Roche 10 107 735 
001 
NativePAGE™ 20x Cathode Buffer Additive Invitrogen BN2002 
NativePAGE™ 20X Running Buffer Invitrogen BN2001 
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NativePAGE™ 3-12% Bis-Tris Gel 
1.0mmx10well 
Invitrogen BN1001BOX 
NativePAGE™ 3-12% Bis-Tris Gel 
1.0mmx15well 
Invitrogen BN1003BOX 
NativePAGE™ Sample Prep Kit Invitrogen BN2008 
Nitro Blue Tetrazolium Sigma-Aldrich N5514-
10TAB 
Nonidet® P 40 Substitute Fluka 74385 
NuPAGE™ 4-12% Bis-Tris Gel 1.0mmx10well Invitrogen NP0321BOX 
NuPAGE™ 4-12% Bis-Tris Gel 1.0mmx12well Invitrogen NP0322BOX 
NuPAGE™ 4-12% Bis-Tris Gel 1.0mmx15well Invitrogen NP0323BOX 
NuPAGE™ 4-12% Bis-Tris Gel 1.0mmx2Dwell Invitrogen NP0326BOX 
NuPAGE™ Antioxidant Invitrogen NP0005 
NuPAGE™ LDS Sample Buffer Invitrogen NP0007 
NuPAGE™ MOPS SDS Running Buffer (20x) Invitrogen NP0001 
NuPAGE™ Sample Reducing Agent (10x) Invitrogen NP0004 
NuPAGE™ Transfer Buffer (20x) Invitrogen NP0006 
Oligomycin Sigma-Aldrich 75351 
Penicillin-Streptomycin (10,000U/mL) Gibco 15140-122 
Penicillin-Streptomycin (5,000U/mL) Gibco 15070-063 
Phenylephrine Sigma-Aldrich P-6126 
PhosSTOP EASYpack Roche 04 906 837 
001 
Pierce® ECL Western Blotting Substrate Thermo Scientific 32106 
Plasmid Midi Kit (25) QIAGEN 12143 
Potassium hydroxide Fisher Scientific P/5640/53 
Potassium phosphate monobasic Sigma-Aldrich P5655-100G 
Precellys Lysing Kit Tissue Grinding 
CKmix50_7mL 
Bertin Technologies KT03961-1-
306.7 
Precision Plus Protein™ Dual Color Standard Bio Rad 1610374 
Propan-2-ol Fisher Scientific P/7490/21 
61 
 
Protein G Sepharose® Fast Flow Sigma-Aldrich P3296-5ML 
Proteinase A/G Sepharose® Abcam ab193262 
Proteinase K Solution QIAGEN 19133 
Pyromark Annealing Buffer QIAGEN 979009 
Pyromark Binding Buffer QIAGEN 979006 
Pyromark Denaturation Solution QIAGEN 979007 
Pyromark Gold Q96 QIAGEN 972807 
Pyromark Q96 HS plates QIAGEN 979001 
Pyromark Q96 Vaccuum Prep Troughs QIAGEN 979011 
Pyromark Wash Buffer QIAGEN 979008 
Q5® Site-Directed Mutagenesis Kit New England Biolabs E0554S 
QIAquick Gel Extraction Kit (50) QIAGEN 28704 
QIAquick PCR Purification Kit (50) QIAGEN 28104 
QIAzol Lysis Reagent QIAGEN 79306 
Quick Start™ Bradford 1x Dye Reagent Bio Rad 500-0205 
Resin Component TAAB Embedding Resin 
Premix 
TAAB T033 
Rneasy® Micro Kit (50) QIAGEN 74004 
RNeasy® Midi Kit (50) QIAGEN 75144 
RNeasy® Plus Mini Kit (50) QIAGEN 74134 
Rotenone Sigma-Aldrich R8875-1G 
RPMI Medium 1640 (1x) +L-Glutamine Gibco 21875-034 
RT2 SYBR®Green ROX™FAST Mastermix Qiaqen 7570665 
Seahorse XF Assay Medium Modified DMEM 
(0mM glucose) 
Agilent 102365-100 
Seahorse XF-24 FluxPak Agilent 100850-001 
Sgf1 Promega R7103 
SOC Outgrowth Medium New England Biolabs #B9020S 
Sodium acetate Sigma-Aldrich S2889-250G 
Sodium carbonate decahydrate, 99+% Acros Organics 213500010 
Sodium deoxycholate Sigma-Aldrich D6750-100G 
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Sodium phosphate Sigma-Aldrich 342483-25G 
Streptavidin Sepharose™ High Performance GE Healthcare 17-5113-01 
Sucrose Fisher Scientific S/8600/60 
Syringe filter 0.2µm Fisherbrand 09-719c 
T4 DNA Ligase New England Biolabs M0202S 
TBS (10x) Cell Signaling 
Technology 
12498S 
Triton X-100 Sigma-Aldrich X100-100ML 
Trizma® base Sigma-Aldrich T6066-500G 
Trizma® hydrochloride Sigma-Aldrich T5941-500G 
Trypsin (0.25%) phenol red Gibco 25050-014 
Trypsin-EDTA (0.05%) phenol red Gibco 25300-054 
Trypsin-EDTA (0.25%) phenol red Gibco 25200-056 
Tween® 20 National Diagnostics EC-607 
Ultrapure Agarose Invitrogen 16500-500 
Western Blotting Filter Paper, 
7cmx8.4cmx0.83mm 
Thermo Scientific 84783 
XL-10 Gold ultracompetent E.coli cells Agilent 200314 
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2.2. Primers 
2.2.1. Sequencing Primers for Mutation Validation 
Primer Sequence (5’ to 3’) 
Pdgfd Forward CCTTATTGCTGGTGGCCAGA 
Pdgfd Reverse AAGGCTGGTGCTGTCAAAGT 
Trpc6 Forward ACTATGAAAATTTTCC 
Trpc6 Reverse GCACCTCCGTCACTACCAAT 
Ecsit Forward AAAGGGACGATCACGGTCAC 
Ecsit Reverse TGGATCTGCCCAAAACAGGG 
 
2.2.2. Pyrosequencing Primers 
Primer Sequence (5’ to 3’) 
9-7.16 (Dync2h1) Forward  AAAATGCCTTCACAGACAAGT 
9-7.16 (Dync2h1) Reverse Biotinylated GAGGTACCAGCATGATTCTCT 
9-7.16 (Dync2h1) Sequencing Forward TGAAAACCCACTTCCA 
9-14.36 (Endod1) Forward AGGGATCCACAGAGGACA 
9-14.36 (Endod1) Reverse Biotinylated CGTGTGGTCAGAACACAAA 
9-14.36 (Endod1) Sequencing Forward GAGGACACTGAGCAGG 
9-16.63 Forward Biotinylated AGGCCCCAGAGAGTTTAGAGG 
9-16.63 Reverse CACTCCATATTCCGTTCTCTAGC 
9-16.63 Sequencing Reverse TCCACTCTCCAATTGC 
9-20.65 (Pin1) Forward TGGTCGTGCAAACCTGTAATCT 
9-20.65 (Pin1) Reverse Biotinylated AATTCAGGCCCTTAAGTTTAGTGG 
9-20.65 (Pin1) Sequencing Forward AGTGGGCAAAGGTACT 
9-22.07 (Ecsit) Forward Biotinylated CACTGGGTAGGGGTTGAT 
9-22.07 (Ecsit) Reverse AAGTTACCCCATGCTCAAG 
9-22.07 (Ecsit) Sequencing Reverse TCACCCGATTCAAGA 
9-23.24 (Bmper) Forward Biotinylated CTCAGGGTTTTAGAAATGTGG 
9-23.24 (Bmper) Reverse CGGCCTGTCTCTAGTCAAA 
9-23.24 (Bmper) Sequencing Reverse CAGAAGATGCTGACCTC 
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9-27.22 Forward Biotinylated CACTTCCTTCGCTCAGAATGC 
9-27.22 Reverse AGCAAGGACCACACCTTCAACAT 
9-27.22 Sequencing Reverse CTTTGGAAGACATCCC 
9-32.13 (Arhgap32) Forward 
Biotinylated 
GGGGTGCAGTTTACTTGG 
9-32.13 (Arhgap32) Reverse GTGGGAGTCTCCATACCTG 
9-32.13 (Arhgap32) Sequencing Reverse ATGCTGGGCAAGTATG 
9-44.10 (Rnf26) Forward Biotinylated TTCTGTGGTTGCCTCTTG 
9-44.10 (Rnf26) Reverse TTTCCACACGCGTCATAG 
9-44.10 (Rnf26) Sequencing Reverse CGTCATAGGCACTTCTG 
 
2.2.3. Lightscanner Primers 
Primer Sequence (5’ to 3’) 
Ecsit Forward TGCTCAAGTTCCTGCGGAT 
Ecsit Reverse CTAGCTTGGCCAGGTCCAAA 
Ecsit Lunaprobe GTTCACCCGATTCAAGATTATCAACCC 
 
2.2.4. Cloning Primers 
Primer Sequence (5’ to 3’) 
Ecsit Forward Sgf1 AGGCGATCGCCATGAGCTGGGTGCAGGTCAACTT 
Ecsit Reverse Mlu1 GCGACGCGTACTTTGCCCCTGCTGCTGCTCTG 
Ndufaf1 Forward Sgf1 GAGGCGATCGCCATGTCTTCCATTCACAAATTACT 
Ndufaf1 Reverse Mlu1 GCGACGCGTTCTGAAGAGTCTTGGGTTAAGAA 
 
2.2.5. Site Directed Mutagenesis Primers 
Primer Sequence (5’ to 3’) 
Ecsit N209I Forward CGATTCAAGATTATCAACCCCTAC 
Ecsit N209I Reverse GGTGAACCACAGCTTCATC 
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2.2.6. Cloning Sequencing Primers 
Primer Sequence (5’ to 3’) 
VP1.5 Forward GGACTTTCCAAAATGTCG 
XL39 Reverse ATTAGGACAAGGCTGGTGGG 
 
2.3. Vectors and cDNA clones 
Vector Supplier Code 
pCMV6-Entry Origene PS100001 
pCMV6-AC-His Origene PS100002 
pCMV6-Entry-ACAD9 Origene MR209542 
pCMV6-Entry-SMAD4 Origene MR208755 
pCMV6-Entry-TRAF6 Origene MR208489 
MGC Mouse Ecsit cDNA Dharmacon MMM1013-202766953 
MGC Mouse Ndufaf1 cDNA Dharmacon MMM1013-202762755 
 
2.4. Primary Antibodies 
Antibody (Protein) Species 
/clonality 
Supplier Code Dilution Size 
(kDa) 
6X His Rabbit 
poly 
Origene TA150031 1:1000 N/A 
ACAD9 Rabbit 
poly 
Abcam ab99952 1:500 69 
AMPK Mouse 
mono 
CST 2793 1:1000 62 
ATP5A Mouse 
mono 
Abcam ab14748 1:1000 53 
CD5 – BV421 Rat mono BD  562739 1:800 
(FACS) 
N/A 
CD11b – PE – CF594 Rat mono BD 562317 1:200 
(FACS) 
N/A 
66 
 
CLPP Rabbit 
poly 
Abcam ab124822 1:5000 26 
COXIV Mouse 
mono 
Abcam ab14744 1:1000 17 
DRP1 Rabbit 
mono 
Abcam ab184247 1:1000 82 
ECSIT Rabbit 
poly 
Abcam ab21288 1:1000 50/45 
ECSIT Rabbit 
poly 
Abcam ab66380 1:800 50/45 
ECSIT Rabbit 
poly 
Atlas HPA042979 1:100 50/45 
EIF2α Rabbit 
mono 
CST 5324 1:1000 36 
F4/80 - PE Rat mono Thermo 
Fisher 
12-4801-80 1:200 
(FACS) 
N/A 
GRP75 Mouse 
mono 
Abcam ab2799 1:1000 74 
HSP60 Rabbit 
poly 
Abcam ab46798 1:20000 60 
JNK Rabbit 
poly 
CST 9252S 1:1000 54/46 
LONP1 Rabbit 
poly 
Abcam ab103809 1:1000 106 
LY6C – FITC Rat mono Abcam ab15686 1:200 
(FACS) 
N/A 
LY6G – BV421 Rat mono BD  562737 1:200 
(FACS) 
N/A 
MFN2 Mouse 
mono 
Abcam ab56889 1:1000 86 
MHCI Mouse 
mono 
DSHB A4.840 1:1 (ICC) N/A 
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MHCIIA Mouse 
mono 
DSHB A4.74 1:1 (ICC) N/A 
MHCIIB Mouse 
mono 
DSHB BF.F3 1:1 (ICC) N/A 
MHCIIX Mouse 
mono 
DSHB 6H1 1:1 (ICC) N/A 
MTCO1 Mouse 
mono 
Abcam ab14705 1:2000 40 
MT-ND1 Rabbit 
mono 
Abcam ab181848 1:1000 36 
Myc Mouse 
mono 
Origene TA150121 1:1000 N/A 
NDUFA10 Rabbit 
poly 
Abcam ab103026 1:500 41 
NDUFA3 Mouse 
mono 
Santa 
Cruz 
sc-365351-
S 
1:1000 9 
NDUFA8 Mouse 
mono 
Santa 
Cruz 
sc-398097-
S 
1:1000 20 
NDUFAF1 Rabbit 
mono 
Nijtmans 
Lab 
N/A 1:250 43/38 
NDUFB1 Rabbit 
poly 
Abcam ab201302 1:1000 12 
NDUFB11 Rabbit 
mono 
Abcam ab183716 1:10000 17 
NDUFB3 Mouse 
mono 
Santa 
Cruz 
sc-393351-
S 
1:1000 12 
NDUFB8 Mouse 
mono 
Abcam ab110242 1:2000 22 
NDUFC2 Rabbit 
mono 
Abcam ab192265 1:1000 14 
NDUFS2 Rabbit 
mono 
Abcam ab192022 1:1000 49 
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NDUFS3 Mouse 
mono 
Santa 
Cruz 
sc-374282-
S 
1:1000 30 
NDUFS8 Mouse 
mono 
Santa 
Cruz 
sc-515527-
S 
1:1000 23 
NDUFV2 Rabbit 
mono 
Abcam ab183715 1:1000 24 
NFκB Mouse 
mono 
CST 6956T 1:1000 65 
OPA1 Rabbit 
poly 
Abcam ab42364 1:1000 92/86 
P38 MAPK Rabbit 
poly 
CST 9212S 1:1000 43 
PARP Rabbit 
mono 
Abcam ab32138 1:1000 113 
PGC1α Rabbit 
poly 
Abcam ab54481 1:1000 105 
Phospho AMPK Rabbit 
mono 
CST 2535 1:1000 62 
Phospho DRP1 
(Ser616) 
Rabbit 
poly 
CST 3455S 1:1000 82 
Phospho DRP1 
(Ser637) 
Rabbit 
poly 
CST 4867S 1:1000 82 
Phospho EIF2S1 Rabbit 
mono 
Abcam ab32157 1:500 36 
Phospho JNK 
(T183/Y185) 
Rabbit 
poly 
CST 9251S 1:1000 46/54 
Phospho NFκB Rabbit 
mono 
CST 3033T 1:1000 65 
Phospho P38 MAPK 
(T180/Y182) 
Mouse 
mono 
CST 9216S 1:2000 43 
PINK1 Rabbit 
poly 
Abcam ab23707 1:1000 66 
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SDHA Mouse 
mono 
Abcam ab14715 1:10000 70 
TOM20 Rabbit 
poly 
Abcam ab199641 1:1000 16 
UQCRC2 Mouse 
mono 
Abcam ab14745 1:1000 49 
VDAC Rabbit 
poly 
Abcam ab15895 1:1000 31 
α-TUBULIN Rabbit 
mono 
Abcam ab176560 1:2000 50 
FACS – Fluorescence associated cell sorting, ICC – Immunocytochemistry 
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2.5. Secondary Antibodies 
Antibody Supplier Code Dilution 
IRDye® 680LT Goat 
anti-Mouse IgG (H 
+ L) 
Li-Cor 926-68020 1:15000 
IRDye® 680LT Goat 
anti-Rabbit IgG (H + 
L) 
Li-Cor 926-68021 1:15000 
IRDye® 800CW 
Goat anti-Rabbit 
IgG (H + L 
Li-Cor 926-32211 1:15000 
IRDye® 800CW 
Goat anti-Mouse 
IgG (H + L) 
Li-Cor 926-32210 1:15000 
Alexa fluor 633 
Goat anti-Mouse 
Life Technologies A20146 1:200 (ICC) 
Alexa fluor 488 
Goat anti-Mouse 
Life Technologies A11029 1:200 (ICC) 
Anti Mouse HRP Promega W402B 1:1000 
Anti Rabbit HRP Promega W401B 1:1000 
ICC – immunocytochemistry 
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2.6. Animals 
All animals were housed at the Mary Lyon Centre (Harwell, Oxfordshire) according to 
the Animals (Scientific Procedures) Act 1986 (ASPA) (amended in 2012) and according 
to MRC guidance issued in ‘Responsibility in the Use of Animals in Bioscience Research’. 
Animals were maintained under the home office project licence 30/3070 (MRC Harwell) 
– ‘New mouse models of human disease’ and according to the procedures laid out 
within. Animal husbandry work was carried out by staff in ward 3 of the Mary Lyon 
centre. 
Animals were caged in individually ventilated cages with no more than 5 animals to a 
cage, except in cages with nursing mothers. Checks were performed daily and food (RM3 
(E) – Dietex -  Special Diet Services (irradiated to 3 rads)) and water (Mains water purified 
by reverse osmosis and chlorinated to 9-13 ppm) supplied ad libitum. Standard 12:12 
(0700:1900) light dark cycle with 30 minute dawn and dusk periods was maintained 
throughout. Temperature was maintained between 19 and 22oC with 45-65% humidity. 
Health screening was performed regularly on sentinel animals to ensure a pathogen free 
environment.  
2.6.1. Original Pedigree 
The original muta-ped-c3pde-178 (MPC-178) pedigree from which all further animals 
were derived was produced from the intercrossing of C57BL/6J mutagenised males to 
C3H.Pde6b+ females to produce a G1 cohort (Figure 2.1), heterozygous for any ENU 
induced mutations. C57BL/6J (G0) animals were mutagenised using the chemical 
mutagen N-ethyl-N-nitrosourea (ENU) which induces point mutations throughout the 
mouse genome. Mice were dosed with 1x120mgkg-1 and 2x100mgkg-1 with 7 days 
between each dose. G1 males were subsequently crossed to C3H.Pde6b+ females to 
obtain a G2 cohort. G2 females were finally crossed to the G1 male parent to obtain the 
experimental G3 cohort carrying both heterozygous and homozygous ENU induced 
mutations and allowing for screening of dominant and recessive traits [270].  
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Figure 2.1. ENU mutagenesis and breeding plan for the production of the G3 experimental cohort. Male 
C57BL/6J mice are mutagenized and crossed to female C3H.Pde6b+ to produce a G1 cohort. Through 
successive rounds of breeding a G3 experimental cohort is produced that allows for the screening of 
recessive mutations. Adapted from Goldsworthy and Potter (2014) [274].  
The G3 pedigree was produced as 2 cohorts of approximately 50 animals 3 months apart. 
With the first (A) cohort undergoing primary screening and the second (B) cohort used 
to confirm the presence of phenotypes observed in the first.  
 
Figure 2.2. Graphical representation of the phenotyping tests undertaken during the Harwell Ageing 
Screen. Circles represent phenotyping tests carried out at each time point. In addition to these tests mice 
are weighed every 3 months up until 12 months of age and monthly thereafter. Adapted from Potter et 
al. [270] 
Animals were aged for 18 months and screened throughout their lifetimes (Figure 2.2) 
using a variety of techniques including, clinical chemistry, auditory brain stem response 
(ABR), optokinetic drum (OKD), ophthalmoscope, X-ray, Dual energy x-ray 
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absorptiometry (DEXA), grip strength, SHIRPA (Smithkline Beecham, Harwell, Imperial 
College, Royal London Hospital, phenotype assessment), and Echo-MRI. 
The G3 mating program typically results in one in eight mice from the G3 cohort which 
are homozygous for any given ENU induced mutation.  
2.6.2. Incipient Congenic Pedigree 
Following identification of the cardiac phenotype in the MPC-178 pedigree the line was 
re-derived from frozen sperm and subsequently backcrossed to C3H.Pde6b+ for 5 
generations before intercrossing to obtain the incipient congenic pedigree used for the 
majority of phenotyping and sample collection. All animals and samples used are from 
this backcross unless otherwise stated.  
2.6.3. Compound Heterozygote 
Heterozygous Ecsit knockout (Ecsit+/-) animals on a C57BL/6J background were obtained 
from the laboratory of Professor Sankar Ghosh at Columbia University (New York, USA) 
and imported into the Mary Lyon Centre through standardised quarantine procedure. 
Briefly, sperm is collected from Ecsit+/- males and used to fertilise eggs from 
superovulated donor females. Embryos are imported into the Mary Lyon Centre, 
implanted into pathogen free female mice and carried to term.  
Following import and confirmation of allele transfer, heterozygous Ecsit knockout 
(Ecsit+/-) males were crossed to incipient congenic heterozygous females (EcsitN209I/+) to 
produce offspring of 4 possible genotypes (Ecsit+/+, Ecsit+/-, EcsitN209I/+, EcsitN209I/-) for 
further phenotyping and sample collection.  
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2.7. Phenotyping 
2.7.1. Clinical Chemistry 
Male and female mice from both backcross one and the incipient congenic pedigree 
were terminally anaesthetised using Euthatal (pentobarbital) and blood samples 
collected using a lithium heparin coated capillary tube inserted into the retro-orbital 
sinus. Blood samples were collected in lithium heparin microvette tubes on ice.  
Following collection, plasma is separated by centrifugation at 5000xg at 4oC for 10 
minutes and is collected in a separate uncoated micro centrifuge tube. Plasma 
concentrations of relevant compounds were assessed by the clinical chemistry core at 
MRC Harwell using an Olympus U400 bio analyser.  
2.7.2. Echocardiogram 
Echocardiography was performed by the phenotyping core of the Mary Lyon centre at 
MRC Harwell. Twelve week old male and female mice were anaesthetised with 4% 
isoflurane (maintained at 1.5%) in oxygen and echo-cardiogram performed using a Vevo 
770 high-resolution in vivo micro imaging system with a Visualsonics RMV707B Probe 
(30 MHz). Body temperature was monitored using a rectal thermometer and maintained 
using a heat lamp at 36-38oC. ECG monitoring was performed using limb electrodes, to 
which the animals paws were attached using surgical tape and the heart rate maintained 
at or above 400bpm. Short axis B and M mode images were taken using the papillary 
muscles as a point of reference for positioning of the probe. Image contrast and gain 
functions were used for clarity and frame rate of 110Hz used throughout. 
Measurements were taken from M-mode images using the inbuilt Vevo software.  
2.7.3. ECG 
ECG was performed on 12 week old male and female animals using an anaesthetised 
ECG technique. Animals were anaesthetised using 4% isoflurane (maintained at 1.5%) 
and placed on a corkboard. 25G needles were passed through the skin in both armpits 
and on either flank into the cork board. ECG cables were attached to the needles and 2 
lead ECG readings recorded at 2kHz taken for 90 seconds using a  Dual Bio Amp (ML135) 
(AD Instruments, Oxford, UK)  connected to a Powerlab 4/30 (ML866) (AD Instruments, 
Oxford, UK). A spirometer pod (ML311) (AD Instruments, Oxford, UK) connected to a 
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spirometry pad placed under the animals chest was used to monitor breathing rate. 
Anaesthetic regime was monitored in order to maintain steady heart rate (350-450 bpm) 
and breathing rate (90-120 bpm). Analysis was performed on lead 1 using LabChart pro 
V.8.1.5 (AD Instruments, Oxford, UK) with ECG analysis plugin with setting for rodent T 
wave, block averaging, and default detection and analysis parameters. Where software 
was unable to determine position of ECG parameters these were manually called 
according to the guidelines set out in Boukens et al. (2014) [275]. 
2.7.4. Intra Peritoneal Glucose Tolerance Test 
Intra peritoneal glucose tolerance test (IPGTT) was performed by Mr Laurence Goosey 
at MRC Harwell. IPGTT was performed on 12 week old male and female wild type and 
incipient congenic EcsitN209I/N209I animals. Mice were fasted overnight prior to IPGTT 
assessment. The tail is anaesthetised with EMLA (Lidocaine/Prilocaine) to induce local 
anaesthesia prior to a 40µL sample of blood being collected in a lithium heparin 
microvette tube. Plasma is collected from this sample for later analysis. 2g of glucose 
per kg is then injected by intraperitoneal (IP) injection and animals returned to the home 
cage. Blood glucose levels are then measured using an Alphatrak (Abbott, UK) at 30, 60 
and 120 minutes post glucose injection.  
2.7.5. Echo-MRI 
Echo-MRI was performed on male and female wild type and incipient congenic 
homozygous animals (EcsitN209I/N209I) at 8, 10, 14 and 18 weeks of age to show the 
accumulation of fat and lean mass over time. Animals were weighed to determine true 
body weight before measurements were made on mice using an ECHO MRI-100 
(Houston, TX, USA) body composition analyser. Briefly, un-anaesthetised animals were 
placed into an acrylic tube and restrained using a second acrylic rod. The restrained 
animal was then placed inside the ECHO MRI-100 and measurements taken using the 
magnet, taking approximately 60 seconds. Animals were returned to their home cage 
immediately following measurements. Measurements were also obtained for total 
water content. 
2.7.6. Grip Strength 
Grip strength was performed on male and female wild type and incipient congenic 
homozygous animals (EcsitN209I/N209I) at 14 weeks of age. Animal body weights are 
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collected immediately before hand to provide a crude means of normalisation. Grip 
strengths are then measured using a grip strength meter with a grid attachment. To 
obtain a measurement mice are placed on the staging area of the strength meter and 
gently pulled across the grid by their tail. The machine measure the maximum force 
before the animal releases from the grid. To measure the strength of the forepaws, the 
animal’s tail is lifted slightly so that the hind limbs are unable to grip the grid. 3 
measurements are taken ensuring good contact with the grid and no erroneous readings 
are taken, the mean of the 3 measurements is taken.   
2.8. Mapping and Whole-Genome Sequencing 
DNA from affected mice and littermate controls was extracted using Illustra Nucleon 
BACC2 kit (GE Healthcare) according to manufacturer’s protocol and sent to GenProbe 
Life Sciences Ltd. To be run on the Illumina Golden Gate Mouse MD Linkage Panel, 
consisting of 1,449 loci and including approximately 4 SNPs (single nucleotide 
polymorphisms) per 27 Mb interval across the mouse genome 
(https://products.illumina.com). Because the ENU treatment is carried out on the 
C57BL/6J father, the region(s) carrying the causative mutation should be either 
homozygous (recessive line) or heterozygous (dominant lines) for C57BL/6J SNPs in 
affected individuals, whilst control animals should carry C3H.C3pde SNPs in the same 
region.  
After identifying the candidate region that could contain the causative mutation, the 
DNA from the G1  founder of the pedigree was sent for whole genome sequencing (WGS) 
employing the Illumina HiSeq platform (Oxford Genomics Centre, Wellcome Trust 
Centre for Human Genetics). The sequence was then analysed by the bioinformatics 
group based at MRC-Harwell, highlighting the possible coding and non-coding mutations 
and the confidence in each mutation based on read depth of the WGS.  
2.9. Mutation Validation 
To confirm the mutations in Pdgfd, Trpc6 and Ecsit, DNA was extracted from the tail of 
an affected G3 animal and C57BL/6J control animal using the GE Illustra BACC2 kit 
according to manufacturer’s instructions. The relevant locus was then amplified using 
appropriate primers (section 2.2.1).  
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Q5 high fidelity DNA polymerase (New England Biolabs) was used as a polymerase. The 
50µL reaction contained; 10µL 5X Q5 reaction buffer, 1µL 10mM dNTPs, 2.5µL 
10pmol/µL forward primer, 2.5µL 10pmol/µL reverse primer, 5µL 10ng/µL DNA 
template, 28.5µL ddH2O, 0.5µL (1 unit) Q5 high-fidelity DNA polymerase. PCR cycling 
conditions were set with an initial denaturation step of 98oC for 30 seconds followed by 
30 cycles of 98oC for 10 seconds, 58oC for 10 seconds and 72oC for 30 seconds. A final 
elongation step at 72oC for 2 minutes was included before samples were stored at 4oC 
awaiting PCR purification.  
2.9.1. PCR Purification 
All samples were purified using a QIAquick PCR purification kit (Qiagen) according to 
manufacturer’s instructions. Briefly, DNA is bound to a silica membrane in a 
centrifugation column in the presence of a high salt buffer by centrifuging at 17,900xg 
for 60 seconds. Following binding, buffer is discarded and bound DNA is washed once 
using the supplied buffer. Finally, DNA is eluted in low salt buffer by centrifuging at 
17,900xg for 1 minute.  
Following purification samples were sent for Sanger sequencing by Source Bioscience 
(Oxford) and results analysed using Seqman pro (DNASTAR, USA). 
2.9.2. Sanger Sequencing 
All sequencing was performed by Source Bioscience (Oxford) 
(www.sourcebioscience.com). Plasmids (100ng/µl) and PCR products (10ng/µl) from 
genomic DNA using appropriate sequencing primers supplied (3.2ng/µl) (sections 2.2.1 
and 2.2.6).  
2.10. Genotyping 
Genotyping was performed using one of two methods. Initially animals were genotyped 
using a panel of SNVs (single nucleotide variants) across the mapped region with 
pyrosequencing, allowing for both the validation of mutations and the narrowing of the 
causative region. After genotype to phenotype relationship was more certain, 
genotyping was performed using a Lightscanner high resolution melting assay.  
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2.10.1. Pyrosequencing 
Initial genotyping was performed on a panel of 9 SNVs across the region of interest 
identified as part of the next generation sequencing performed on the G1 animal. DNA 
was obtained from ear biopsies taken from G3 animals using KAPA express extract kit 
(KAPA Biosystems) according to manufacturer’s instructions. PCR of the regions of 
interest was performed using Taq PCR master mix (Qiagen) and the primers listed in 
section 2.2.2. 
Reaction mix is as follows for a 10µL reaction; 5µL Taq PCR master mix, 2.6µL ddH2O, 
0.2µL forward primer (table 5.2.2), 0.2µL reverse primer (table 5.2.2), and 2µL template 
DNA. PCR cycling conditions are then set with an initial denaturation step of 95oC for 5 
minutes followed by 45 cycles of 95oC for 15 seconds, 54oC for 30 seconds and 72oC for 
15 seconds with a final elongation step of 72oC for 5 minutes.  
Following PCR the samples are run on a PSQ HS96A pyro sequencer according to 
manufacturer’s protocol using Pyromark reagents (Qiagen), Streptavidin SepharoseTM 
high performance beads (GE Healthcare) and the appropriate sequencing primer for 
each fragment as listed in section 2.2.2.  
2.10.2. Lightscanner 
Routine genotyping was performed by Lightscanner (Idaho technology, USA) high 
resolution DNA melting assay using LCGreen and a Lunaprobe developed by the MRC 
genotyping and mutation detection screens (GEMS) core facility. To distinguish between 
wild type, homozygous, and heterozygous animals for the single point mutation a 3’ 
blocked oligonucleotide (LunaProbe) is designed that sits directly over the SNP and 
exhaustive asymmetric PCR is performed. This creates two products, one is the full PCR 
product between the normal primers (section 2.2.3), whilst the other results from the 
probe annealing to the complementary strand. PCR products are then gradually heated 
and the fluorescence of the bound LCGreen dye is measured. The difference in melting 
temperatures caused by altered affinity of the probe allows for determination of wild 
type, heterozygous and homozygous samples.   
The reaction conditions for a 10μl reaction were 5μl of Hot Shot PCR master mix 
(Diamond, Clent Life Science, UK), 1μl LCGreen, 0.5μl reverse primer (20ng/μl), 0.1μl 
forward primer (20ng/μl), 0.5μl probe (20ng/μl), and 0.9μl ddH2O. 
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Standard PCR cycling conditions were as follows: starting temperature at 95oC for 2 min, 
then 55 cycles of 95°C for 30 seconds, 60°C for 30 seconds and 72°C for 30 seconds. The 
hybridisation step was at 95°C for 30 seconds, 25°C for 30 seconds and 15°C for 30 
seconds.  
2.11. Histology 
Hearts were collected from wild type and EcsitN209I/N209I animals at 0, 1, 2, 4, 6, 8, and 12 
weeks of age to investigate the development of the cardiomyopathy phenotype, no 
preference was made for male or female samples. Animals were culled by cervical 
dislocation, hearts excised and fixed in 10% neutral buffered formalin. Histology was 
prepared by the histology core team at MRC Harwell by embedding the fixed hearts in 
paraffin and sectioning at 4µm using a Finesse ME+ microtome (Thermo Fisher). 
Transverse sections (T/S) were stained with Haematoxylin and Eosin (H&E).  
2.12. Muscle Fibre Typing 
Muscle fibre typing was performed by Mr. Saleh Salman Omairi at the University of 
Reading [276]. Soleus and extensor digitorum longus (EDL) from male wild type and 
EcsitN209I/N209I animals and frozen over isopropanol on liquid nitrogen. Following freezing, 
frozen muscle samples were mounted in Tissue Tech freezing medium (Jung) and cooled 
by dry ice/ethanol. Cryosections taken at 10µM thick were dried for 30 minutes at room 
temperature before being washed three times in PBS and incubated in permeabilisation 
buffer solution (4mM HEPES, 3mM MgCl2, 10mM NaCl, 1.5mM Sodium azide, 60mM 
Sucrose, 0.1% Triton X-100) for 15 minutes. Following permeabilisation, samples were 
washed in wash buffer (1x PBS with 5% foetal calf serum (v/v) and 0.05% Triton X-100) 
for 30 minutes at room temperature.  
Primary antibodies against MHCI, MHCIIA, MCHIIX and MHCIIB were diluted in wash 
buffer and incubated overnight at 4oC. The next day samples are incubated in secondary 
antibody diluted in wash buffer for 1 hour in darkness. Finally, slides were mounted in 
fluorescent mounting medium and myonuclei visualised with 2.5µg/ml DAPI.  
Fluorescence microscopy was performed with Zeiss AxioImegar AI an images captured 
with Axiocam digital camera. Analysis was performed with Zeiss Axiovision computer 
software version 4.8.  
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2.13. Transmission Electron Microscopy 
For transmission electron microscopy (TEM), 1mm3 cubes of left ventricular tissue were 
fixed in 3% glutaraldehyde and 4% formaldehyde in 0.1 M PIPES and post-fixed with 1% 
osmium tetroxide in 0.1 PIPES. Samples were taken from the left ventricular free wall of 
3 wild-type and 3 EcsitN209I/N209I males at 16 weeks of age. After serial dehydration in 
increasing concentration of ethanol, the tissue was embedded in epoxy resin (TAAB) and 
polymerised overnight at 60˚C. Golden ultrathin sections (70-80 nm) were cut with a 
diamond knife and collected on copper/palladium grids. To improve contrast, blocks 
were stained with 2% uranyl acetate and grids were stained with lead citrate. 
Images were collected at the Wolfson bioimaging facility at the University of Bristol using 
a Tecnai 12 Biotwin electron microscope with the assistance of Mrs Judith Mantell. 
Analysis was performed using FIJI software.  
2.14. Mitochondrial DNA quantification 
DNA was extracted from left ventricle heart tissue from wild type and EcsitN209I/N209I male 
and female animals (n=3 per group) using Illustra Nucleon BACC2 kit (GE Healthcare) 
according to manufacturer’s protocol and DNA concentrations measured using a 
Nanodrop 8000 spectrophotometer (Thermo Fisher).  
The relative copy numbers of mitochondrial and nuclear DNA were assessed using 
NovaQUANT™ Mouse Mitochondrial to Nuclear Ratio kit according to manufacturer’s 
instructions. Briefly, purified DNA (1ng/well) is diluted and combined with 2x RT2 Fast 
SYBR® Green Mastermix before being aliquoted into the plate of pre-aliquoted primers 
against 2 mitochondrial (12s, trLEV), and 2 nuclear (BECN1,  NEB) genes. The plate is 
sealed with optically clear lids, briefly centrifuged and copy number assessed using a 
7500 Fast real-time PCR system (Applied Biosystems) with a denaturing step at 95oC for 
10 minutes followed by 40 cycles of 95oC for 3 seconds and 60oC for 30 seconds.  
Analysis was performed using the ‘Relative copy number’ method outlined in the 
manufacturers protocol. Ct values of the 2 gene pairs (trLEV/BECN1, 12s/NEB) are 
compared to obtain the ΔCt value for each pair. The average of the two 2ΔCt values then 
gives the average copy umber of mitochondrial DNA per cell.   
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2.15. Seahorse 
All Seahorse analysis was performed using a Seahorse XF24 extracellular flux analyser 
(Agilent) on cultured cells or isolated mitochondria as described below. In all cases 
seahorse cartridges were hydrated by loading calibration plate with 1ml of calibrant 
(Agilent) and incubating overnight at 37oC in a non-CO2 incubator, any evaporation was 
replaced the following morning to maintain 1ml of calibrant in all wells. The Seahorse 
XF24 was also pre-heated to 37oC for at least 8 hours prior to use.  
2.15.1. Seahorse on Mouse Embryonic Fibroblasts (MEFs) 
MEFs were isolated and cultured as in section 2.24. MEFs were plated on Seahorse XF24 
plates at a concentration of 40,000 cells/well in 250µL of MEF culture media and 
incubated overnight at 37oC, 5% CO2. The following day MEF culture medium was 
replaced with CAS medium (Seahorse DMEM, 25mM glucose, 2mM glutamine, 1mM 
sodium pyruvate, pH 7.2) and incubated at 37oC in a non-CO2 incubator for 90 minutes.  
Seahorse is performed according to protocol laid out in table 2.1 with final 
concentrations of oligomycin (2.0µM), FCCP (carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone) (1.0µM), rotenone (2.0 µM) and antimycin A 
(2.0µM).  
Step Command Time 
(Min.) 
Compound 
/Repeats 
Step Command Time 
(Min.) 
Compound 
/Repeats 
1 Calibrate   31 Mix 2 Repeat 3 
times 2 Mix 2 Repeat 5 
times 
32 Wait 2 
3 Wait 2 33 Measure 4 
4 Measure 4 40 Inject  Anti A/Rot 
17 Inject  Oligomycin 41 Mix 2 Repeat 3 
times 18 Mix 2 Repeat 3 
times 
42 Wait 2 
19 Wait 2 43 Measure 4 
20 Measure 4 50 End   
30 Inject  FCCP     
Table 2.1. Seahorse protocol for measurement of O2 consumption rate and addition of compounds during 
MEF assay.  
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Following Seahorse analysis, the cell plate is retained, washed gently with PBS and total 
live cell count assessed by live/dead viability/cytotoxicity kit for mammalian cells (Life 
Technologies). Cells are incubated in 200µl of PBS containing 2µM calcein AM per well. 
Cells are incubated at room temperature for 30 minutes whilst protecting from light and 
fluorescence measured (excitation/emission 485/530nm) on a Fluostar OPTIMA plate 
reader (BMG Labtech, Aylesbury, UK) to determine live cell concentration per well. 
Seahorse readings are normalised to relative intensity of fluorescent signal rather than 
true cell count.  
2.15.2. Seahorse on Isolated Neonatal Cardiomyocytes 
Neonatal mouse cardiomyocytes were isolated and cultured as in section 2.26. 
Cardiomyocytes were plated into pre-coated seahorse XF24 cell culture plates at a 
variable cell density (25,000, 50,000, 75,000 or 100,000 cells/well) and seahorse 
protocol performed according to procedure laid out in table 2.2 with final 
concentrations of oligomycin (2.0µM), FCCP (1.0µM), rotenone (2.0 µM) and antimycin 
A (2.0µM). 
Step Command Time 
(Min.) 
Compound 
/Repeats 
Step Command Time 
(Min.) 
Compound 
/Repeats 
1 Calibrate   31 Mix 2 Repeat 3 
times 2 Mix 2 Repeat 5 
times 
32 Wait 2 
3 Wait 2 33 Measure 4 
4 Measure 4 40 Inject  Anti A/Rot 
17 Inject  Oligomycin 41 Mix 2 Repeat 3 
times 18 Mix 2 Repeat 3 
times 
42 Wait 2 
19 Wait 2 43 Measure 4 
20 Measure 4 50 End   
30 Inject  FCCP     
Table 2.2. Seahorse protocol for measurement of O2 consumption rate and addition of compounds during 
cardiomyocyte cell density and FCCP concentration titrations. 
Following cell density titration the optimal density was selected and FCCP titration was 
performed by plating freshly isolated cardiomyocytes at this density followed by 
measurements with variable final FCCP titrations (0, 0.5, 1.0, 2.0, 4.0, and 6.0 µM). 
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2.15.3. Seahorse on Isolated Mitochondria 
Mitochondria for seahorse analysis were isolated from freshly dissected hearts and 
brains obtained from 15 week old                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
wild type and EcsitN209I/N209I animals culled by cervical dislocation, no preference was 
made for sex. Samples were kept on ice and homogenised in MSHE+BSA (70mM sucrose, 
210mM Mannitol, 5mM HEPES, 1mM EGTA, 0.2% w/v FFA free BSA, 1M KOH) in a 
Dounce homogeniser using both A and B pestles. Mitochondria are separated from 
lysate by subsequent centrifugation 800xg for 10 minutes at 4oC twice, discarding the 
pellet after each step. The supernatant is retained and centrifuged at 8000xg for 10 
minutes at 4oC. The remaining mitochondrial pellet is suspended in MSHE+BSA and the 
concentration measured using a Bradford assay (Bio-rad). 
Mitochondria are diluted 1:10 in ice cold mitochondrial assay solution (MAS) (70mM 
sucrose, 220mM mannitol, 10mM KH2PO4, 5mM MgCl2, 2mM HEPES, 1mM EGTA, 0.2% 
w/v FFA free BSA, 1M KOH) before diluting further in MAS to the desired concentration 
and loaded onto Seahorse XF24 plates at a concentration of 5µg/well. The plate is 
centrifuged at 2000xg for 20 minutes at 4oC to ensure mitochondria are adherent.  
450µL of MAS containing 10mM pyruvate and 10mM malate is added to the 
mitochondria in the plate and the plate incubated at 37oC for 10 minutes without CO2. 
Measurements are made on the seahorse according to the procedure laid out in table 
2.3. ADP, FCCP and Antimycin A are added to give a final concentration of 40µM, whilst 
oligomycin is added to a final concentration of 20µM.  
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Step Command Time 
(Min.) 
Compound 
 
Step Command Time 
(Min.) 
Compound 
1 Calibrate   14 Mix 1  
2 Mix 1  15 Inject  Oligomycin 
3 Wait 3  16 Mix 0.5  
4 Mix 1  17 Measure 3  
5 Wait 3  18 Mix 1  
6 Mix 0.5  19 Inject  FCCP 
7 Measure 3  20 Mix 0.5  
8 Mix 1  21 Measure 3  
9 Measure 3  22 Mix 1  
10 Mix 0.5  23 Inject  Antimycin 
11 Inject  ADP 24 Mix 0.5  
12 Mix 1  25 Measure 3  
13 Measure 3  26 End   
Table 2.3. Seahorse protocol for measurement of O2 consumption rate and addition of compounds during 
isolated mitochondria assay.  
2.16. Western Blots 
Tissues samples were obtained from terminal wild type and EcsitN209I/N209I male and 
female animals (n=3 per group) and snap frozen at the time of dissection. Heart, liver, 
brain, kidney and skeletal muscle taken from the hind limb were stored at -80oC until 
required. Proteins were extracted from tissue by homogenising in RIPA buffer (150mM 
NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 50mM Tris, pH 7.5) containing phosphatase 
(Roche) and protease (Roche) inhibitors in precellys CK28 homogenisation tubes.  
Proteins were isolated from macrophages by scraping the macrophages from the plate 
and centrifuging to obtain the cell pellet before lysing in RIPA buffer containing 
phosphatase and protease inhibitors.  
Protein concentration was measured by Bradford assay (Bio-rad) and measured on a 
µQuant plate reader (Biotek instruments inc., VT, USA). 20µg of total protein was mixed 
with LDS sample buffer (Invitrogen) and reducing agent (Invitrogen) loaded onto 
85 
 
NuPAGE™ 4-12% Bis-Tris protein gels (Invitrogen). Electrophoresis was performed at 
200V for 60 minutes at room temperature in 1x MOPS. 
PVDF membrane (GE) is activated in absolute methanol for 1 minute and proteins 
transferred using X-Cell blot module (Invitrogen) containing 1x transfer buffer 
(Invitrogen), 20% methanol and 1x anti-oxidant (Invitrogen) according to manufacturer’s 
instructions.  
Following transfer, membranes are blocked in either 5% w/v milk powder in phosphate 
buffered saline (PBS) containing 0.1% tween or 5% BSA (bovine serum albumin) in TBS 
containing 0.1% tween (for phosphorylated proteins) for 60 minutes with shaking. 
Primary antibodies (Section 2.4) diluted in 5% milk/PBS-T or 5% BSA/TBS-T are incubated 
overnight at 4oC before three, 5 minute washes in PBS-T or TBS-T. Secondary antibodies 
(Section 2.5) are diluted in 5% milk/PBS-T or 5% BSA/TBS-T and incubated for 1 hour. 
Fluorescent secondary antibodies are protected from light during this and subsequent 
steps. Membranes are subsequently washed a further 3 times before drying. Blots were 
scanned using a LI-COR Odyssey Cl-x or SA scanner (LI-COR Biosciences, Cambridge, UK). 
Image Studio Lite software (LI-COR Biosciences) is used for quantification and analysis 
(Median, 3 pixel border background).  
2.17. Blue Native PAGE 
Mitochondria were isolated from frozen heart and brain tissue taken from wild type and 
EcsitN209I/N209I male and female animals (n=3 per group).  
Hearts were lysed in 10mL/g of homogenisation medium A (0.32M sucrose, 1mM EDTA, 
10mM tris-HCl, pH7.4, filter sterilised) in an Elvehjem-Potter homogeniser on ice by 
hand. Homogenate was centrifuged at 1000xg or 5 minutes at 4oC and supernatant 
retained. Supernatant was centrifuged for 2 minutes at 9000xg at 4oC before removing 
the supernatant and fluffy coat, leaving behind the mitochondrial pellet. The 
mitochondrial pellet was subsequently resuspended in 100µL of homogenisation 
medium A and centrifuged at 9000xg for 10 minutes at 4oC, discarding the supernatant. 
This wash step is repeated 5 times and the mitochondrial pellet stored at -80oC. 
Brains were lysed in 5mL/g of homogenisation medium AT (0.075M sucrose, 0.225M 
mannitol, 1mM EGTA, 10mM tris-HCl, pH7.4, filter sterilised) in an Elvehjem-Potter 
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homogeniser on ice by hand. Homogenate was centrifuged at 1000xg for 5 minutes at 
4oC and supernatant retained. Supernatant is centrifuged at 12000xg for 10 minutes at 
4oC before removing the supernatant and fluffy coat, leaving behind the mitochondrial 
pellet. The mitochondrial pellet was subsequently resuspended in 100µL of 
homogenisation medium AT and centrifuged at 12000xg for 10 minutes at 4oC, 
discarding the supernatant. This wash step was repeated 5 times and the mitochondrial 
pellet stored at -80oC. 
Mitochondria were resuspended in 100uL of appropriate homogenisation medium and 
the concentration determined by Bradford assay (Bio-rad). 
250µg of mitochondria were resuspended in 50µL of native page sample buffer (12.5µL 
4x native page sample buffer, 10µL digitonin, 1x protease inhibitors), incubated on ice 
for 1 hour, and centrifuged at 20000xg for 30 minutes at 4oC. 6.7µL of Native PAGE G-
250 sample additive is added before loading 30µg of mitochondria on to NativePAGE™ 
3-12% bis-tris gels (Invitrogen). First dimensional electrophoresis was performed with 
an initial step of 150V for 30 minutes at 4oC, 1x NativePAGE™ running buffer (Invitrogen) 
was used at the anode, whilst the cathode contained 1x NativePAGE™ running buffer 
(Invitrogen) with 1x NativePAGE™ cathode buffer additive (Invitrogen). After 30 minutes 
the cathode buffer was exchanged for 1x NativePAGE™ running buffer with 0.1x 
NativePAGE™ cathode buffer additive and run for at 250V for a further 90 minutes at 
4oC.  
First dimensional blots were transferred to PVDF using X-cell blot module containing 
bicarbonate transfer buffer (1mM NaHCO3, 0.3mM NaCO3.10H2O) at 60 volts for 1 hour 
at 4oC. Membranes were blocked in 5% milk in PBS-T (0.1%tween) for 1 hour. Primary 
antibodies (Section 2.4) were diluted in 5% milk/PBS-T and incubated overnight before 
three, 5 minute washes in PBS-T. Secondary antibodies (Section 2.5) were diluted in 5% 
milk/PBS-T and incubated for 1 hour before proteins are visualised using Pierce™ ECL 
reagent (Thermo scientific) and Amersham hyperfilm ECL (GE Life Sciences) developed 
using an Mi-5 x-ray film processor (Medical Index, Germany). 
For second dimension BN-PAGE, first dimensional gels are cut out and incubated in 1% 
SDS with 1% beta-mercaptoethanol for 1 hour before loading into a NuPAGE 4-12% 
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1.0mmx2D well gel. Gels are run at 200V for 50 minutes at room temperature in MOPS. 
Only male samples were used for second dimensional blots.  
Proteins are transferred to PVDF membrane using X-Cell blot module (Invitrogen) 
containing 1x transfer buffer, 20% methanol and 1x anti-oxidant (Invitrogen) according 
to manufacturer’s instructions. Following transfer, membranes are blocked in either 5% 
w/v milk powder in PBS containing 0.1% tween for 1 hour. Primary antibodies (Section 
2.4) diluted in 5% milk/PBS-T are incubated overnight at 4oC before three, 5 minute 
washes in PBS-T. Secondary antibodies (Section 2.5) are diluted in 5% milk/PBS-T and 
incubated for 1 hour, protecting from light. Membranes are subsequently washed a 
further 3 times before drying. Fluorescent blots are scanned using a LI-COR Odyssey Cl-
x or SA scanner (LI-COR Biosciences, Cambridge, UK). Image Studio Lite software (LI-COR 
Biosciences) is used for analysis.  
2.18. In-Gel Activity assay 
As described in section 2.16. mitochondria were isolated from wild type and 
EcsitN209I/N209I male and female hearts and brains and run on first dimensional 
NativePAGE™ 3-12% Bis-Tris gels. First dimensional electrophoresis was performed with 
an initial step of 150V for 30 minutes at 4oC, 1x native PAGE running buffer was used at 
the anode, whilst the cathode contained 1x NativePAGE™ running buffer with 10x 
NativePAGE™ cathode buffer additive. After 30 minutes the cathode buffer was 
exchanged for 1x NativePAGE™ running buffer with 1x NativePAGE™ cathode buffer 
additive and run for at 250V for a further 90 minutes at 4oC. 
Following electrophoresis proteins were not transferred to PVDF membrane but the gels 
removed from the casings and stained as below.  
2.18.1. Complex I 
For complex I activity gels were stained for 1 hour in 10mls of buffer containing 150µM 
NADH, 3mM nitro blue tetrazolium and 2mM Tris-HCl (pH 7.4). The oxidation of NADH 
to NAD+ results in the reduction of the nitro blue tetrazolium dye and the appearance 
of a deep blue staining. The depth of stain is proportional to the activity of complex I in 
the gel. Following 1 hour of incubation, the gels are scanned using a desktop PC scanner 
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and can be analysed by importing the images into Image Studio (Li-Cor Biosciences, 
Cambridge, UK). 
2.18.2. Complex IV 
For complex IV activity gels were stained for 1 hour in buffer containing 2.3mM DAB 
(3,3’-diaminobenzidine), 1g/l cytochrome C, 2mM sucrose and 50mM sodium 
phosphate buffer (pH 7.4). In this case, cytochrome C oxidised by complex IV reacts with 
DAB to give a dark brown stain on the gel corresponding to the activity of complex IV. 
Following 1 hour of incubation, the gel was scanned using a desktop PC scanner and was 
analysed by importing the images into Image Studio (Li-Cor Biosciences, Cambridge, UK). 
2.19. ROS assay 
Reactive oxygen species were measured indirectly by assessing the levels of 4-
hydroxynonenal (4-HNE) in wild type and EcsitN209I/N209I heart tissue. 4-HNE is the 
product of lipid peroxidation by reactive oxygen species and was measured using an HNE 
adduct competitive ELISA from Cell Biolabs Inc. according to manufacturer’s 
instructions.  
Briefly, whole hearts from 3 male and 3 female wild type and EcsitN209I/N209I animals were 
homogenised in PBS and normalised to a protein concentration of 5mgml-1. An ELISA 
plate is coated with HNE adduct before incubation with known and unknown samples 
before addition of anti-HNE polyclonal antibody is added. This is followed by washing 
and incubation with an HRP-conjugated secondary antibody. The plate is washed again 
and substrate added and incubated for up to 20 minutes before stop solution is added. 
Finally, absorbance is measured at 450nm on a Fluostar OPTIMA plate reader (BMG 
Labtech, Aylesbury, UK) and values of unknown samples are determined by comparison 
to a standard curve.  
2.20. ADP:ATP quantification assay 
ADP:ATP ratio was assessed using Enzylight™ ADP/ATP ratio kit (Bioassays systems). For 
this, 5µl of whole heart lysate from 3 male and 3 female wild type and EcsitN209I/N209I 
animals was normalised to a concentration of 5mgml-1 by Bradford assay. The lysate is 
treated sequentially with two solutions to measure the concentration of ATP and ADP 
in the lysate. In the first reaction D-luciferin reacts with ATP in the presence of luciferin 
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to produce a light signal proportional to the concentration of ATP. In the second 
reaction, ADP is converted to ATP via an enzymatic reaction, allowing for the ATP 
concentration to be measured again via the same reaction as the first measurement.  
The ADP:ATP ratio (R) is calculated by subtracting the background signal obtained 
following complete ATP reaction after the first reaction (B) from the ADP reaction signal 
(C) and divide the result by the signal obtained from the initial ATP reaction (A).  𝑅 =
𝐶−𝐵
𝐴
  
2.21. Cloning and Transfection 
Full length Ecsit and Ndufaf1 cDNA clones (Dharmacon) in pCMV-SPORT vector were 
transformed into 100µl of XL-10 gold E.coli (Agilent) by incubating on ice for 30 minutes 
with 4µl of 2-mercaptoethanol before heat shocking at 42oC for 30 seconds and 
returning to ice for a further 2 minutes. Pre-warmed SOC media is added (900µl) is 
added and bacteria plated on 100µg/mL ampicillin LB-agar plates before colonies were 
picked and grown overnight at 37oC with shaking in 100µg/mL liquid LB media. DNA was 
extracted using QIAprep Spin Miniprep Kit (Qiagen) according to manufacturer’s 
protocol. Briefly, bacteria were pelleted and lysed before neutralised lysis buffer is 
centrifuged to pellet cell membranes and organelles. Supernatant is applied to a 
supplied spin column and DNA bound by centrifugation. Bound DNA was briefly washed 
before being eluted in 10mM Tris buffer. 
PCR was performed using primers (Section 2.2.4) against the 3’ and 5’ ends of the 
respective ORFs that introduce restriction enzyme sites (Sgf1, Mlu1). PCR is performed 
using a touchdown protocol with an initial denaturation of 95oC for 10 minutes followed 
by cycles of 95oC for 10 seconds, 62oC (2x), 60oC (2x), 58oC (2x), 56oC (15x) for 20 seconds 
and 72oC for 4 minutes with a final elongation step of 10 minutes.  
PCR amplified ORF was purified using  QIAquick PCR purification kit (Qiagen) (Section 
2.9.1) according to manufacturer’s protocol of binding DNA to a spin column, washing 
briefly and finally eluting in 10mM tris buffer. 
pCMV6-ENTRY and pCMV6-AC-HIS vectors were transformed into XL-10 gold E.coli and 
DNA extracted as above (pCMV6-ENTRY is grown in 25µg/ml kanamycin, pCMV6-AC-HIS 
in 100µg/ml ampicillin LB media). 
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ORF and vector DNA are digested using Sgf1 and Mlu1 restriction enzymes (Promega) in 
restriction buffer C (Promega) for 3 hours at room temperature. Alkaline phosphatase is 
added to vector digestions, but not to ORF, for a final 30 minutes. 
Following digestion, DNA is again purified using QIAquick PCR purification kit (Section 
2.9.1), or QIAquick gel extraction kit (Qiagen) for vector DNA, after being run on a 1.3% 
agarose gel (tris borate EDTA (TBE) and gel-red) at 200V for 90 minutes to separate the 
excised fragment. Gel extraction differed from PCR purification in that the excised 
agarose slice was solubilised at 50oC for 10 minutes in the supplied buffer and 
isopropanol added to a final concentration of 20%, before the DNA was bound to the 
supplied column in the same manner.  
ECSIT ORF was ligated into pCMV6-AC-HIS vector and NDUFAF1 into pCMV6-ENTRY 
using T4 DNA ligase (NEB) for 60 minutes at room temperature. Ligated vector and ORF 
were transformed into XL.10 gold E.coli as before and DNA extracted using a plasmid 
midi kit (Qiagen) according to manufacturer’s protocol (an up-scaled version of the mini-
prep). Correct ligation and orientation was confirmed by Sanger sequencing (Section 
2.9.2) with supplied VP1.5 and XL39 sequencing primers (Section 2.2.6). 
pCMV6-AC-HIS-ECSIT was then used as a template for site directed mutagenesis of the 
N209I mutation using Q5 site-directed mutagenesis kit (NEB) and primers (table 5.2.5) 
designed to introduce the point mutation. PCR is performed according to 
manufacturer’s protocol with an initial denaturation of 98oC followed by 25 cycles of 
98oC for 10 seconds, 62oC for 30 seconds and 72oC for 2 minutes. KLD reaction was 
performed according to the kit instructions for 5 minutes at room temperature before 
mutagenised vector was transformed into 50µL of NEB-5α E.coli by incubating on ice for 
30 minutes and heat shocking at 42oC for 30 seconds. 950 µL SOC media is added and 
plated on 100µg/mL ampicillin LB plates overnight before colonies are picked and grown 
for a further 24 hours in liquid LB (100 µg/mL ampicillin) at 37oC with shaking overnight. 
DNA is again extracted using plasmid midi kit (Qiagen). 
Vector DNA is transfected into HEK-293T cells grown in a 6 well plate using jetPRIME® 
reagent (Polyplus) according to manufacturer’s protocol. Briefly, 2.5x105 cells/well are 
pre-plated 24 hours prior to transfection in DMEM (high glucose, glutamax) 
supplemented with 10% FBS and 100U/ml penicillin-streptomycin (Section 2.23). 2µg of 
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DNA (1µg of each vector for co-transfection) is diluted in 200µL of jetPRIME® buffer and 
4µL of jetPRIME® reagent added. Mixture is incubated at room temperature for 10 
minutes following a brief vortex and centrifugation. Finally, mixture is applied drop-wise 
to media containing cells and incubated at 37oC with 5% CO2 for 48 hours.  
ACAD9, TRAF6 and SMAD4 were purchased pre cloned into the pCMV6-Entry vector and 
transformed into XL.10 gold E.coli, grown and DNA extracted as above.  
2.22. Co-Immunoprecipitation 
48 hours following transfection, HEK293T cells transfected with relevant vectors to 
express ECSIT or associated proteins were briefly washed with PBS and lysed in RIPA 
buffer (150mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 50mM Tris, pH 7.5) with protease 
inhibitors (Roche) with manual scraping. Protein concentration was assessed by 
Bradford assay (Bio-Rad) and protein diluted to 1mg/ml 1ml of protein lysate was pre-
cleared with 20µl of protein G sepharose bead slurry (Sigma) for 1 hour to remove native 
immunoglobulins. Protein G beads were removed by briefly spinning at 1000xg for 1 
minute and the supernatant incubated with 4µg of relevant antibody (Section 2.4) over 
night to bind the protein of interest. Following antibody binding, lysate was incubated 
with 20µl of protein G sepharose bead slurry for 1 hour to bind antibody and attached 
protein/s. Beads were again pelleted by centrifugation at 100xg for 1 minute and 
washed 3 times in RIPA buffer. Beads were left in 30µl of RIPA buffer and 1x LDS sample 
buffer (Invitrogen) and reducing agent (Invitrogen) added before boiling the sample at 
95oC for 10 minutes to dissociate the beads from the bound antibody.  
Samples were loaded onto NuPAGE™ 4-12% Bis-Tris protein gels (Invitrogen) and run as 
with western blots (Section 5.13), before being transferred to PVDF membrane (Section 
2.16).   
2.23. Growth and maintenance of HEK-293T Cells 
HEK-293T cells (ECACC) were maintained in DMEM (high glucose, glutamax) with 10% 
FBS and 100U/ml penicillin-streptomycin. When required, cells were split 1:20-1:40 by 
first washing with pre-warmed D-PBS, and detached using 0.05% trypsin. Following 
detachment of cells, trypsin was deactivated using twice the volume of complete media 
92 
 
and seeded into 20mls total volume of complete DMEM in a T-75 flask or other 
appropriate cell culture container where required.   
2.24. Mouse Embryonic Fibroblast Isolation and Culture 
MEFs were harvested from 12.5-14.5dpc (days post coitum) mouse embryos by 
removing the head, heart and liver and washing gently in ice cold PBS. Harvested 
embryos were minced in 1.5mLs of 0.25% trypsin and incubated at 37oC for 5 minutes 
followed by homogenisation using a 21 gauge needle. Trypsin was deactivated using 
5mLs of MEF culture media (DMEM (high glucose, pyruvate), 10% FBS, 50µM β-
mercaptoethanol, 1x non-essential amino acids, 100U/ml penicillin streptomycin) and 
incubated overnight at 37oC, 5% CO2. The following day media was changed for fresh 
MEF culture media and maintained at 37oC, 5% CO2. When required, MEFS were split 
1:20 after washing with PBS and detaching using 0.25% trypsin. 
2.25. Bone Marrow Derived Macrophage Isolation 
12 week old Wild type and EcsitN209I/N209I animals were sacrificed by cervical dislocation 
and femur, tibia and fibula dissected from both hind limbs without damaging the 
epiphyses of any of the bones. Samples were kept on ice whilst dissection was 
performed.  
In a laminar flow hood, excess muscle was removed by scraping with a scalpel blade and 
the epiphyses of the femur and tibia removed, exposing the bone marrow. Bone marrow 
was flushed from the bone cavity with a 25G needle and syringe containing 1-2mls of 
PBS containing 0.6mM EDTA and flow through collected. Collected cells were pelleted 
by centrifugation at 400xg for 7 minutes at 4oC. Supernatant was removed and cells 
resuspended in 5mls of PBS containing 0.6mM EDTA. Cell suspension was filtered 
through a pre-wetted 70µm cell strainer and the cell strainer washed with 10mls of PBS 
containing 0.6mM EDTA. Cells were again pelleted at 400xg for 7 minutes (4oC). Red 
blood cells were removed by resuspending the pellet in 3mls of red blood cell lysis buffer 
(155mM NH4Cl, 12mM NaHCO3, 0.1mM EDTA) and incubated for 1 minute before 
diluting in 10mls of PBS (0.6mM EDTA) and again pelleted at 400xg. Cells were 
resuspended in PBS (0.6mM EDTA) one last time to measure cell concentration using a 
sceptre cell counter (Merck Millipore). Cells were pelleted and washed once in DMEM 
(pyruvate, glutamine) containing 10% FBS, 100U/ml penicillin-streptomycin to remove 
93 
 
EDTA. Finally, cells were plated at a concentration of 2.5x106 cells/mL in DMEM 
(pyruvate, glutamine) containing 10% FBS, 100U/ml penicillin-streptomycin and 
100ng/ml of macrophage colony stimulating factor (MCSF) (Cell Guidance Systems). 
Cells were maintained at 37oC, 5% CO2 with media changes on day 3 and 6. On day 7 
cells were harvested by manual scraping with PBS (0.6mM EDTA). Cells were counted 
again and re-plated at a concentration of 6x106 cells/well of a 6 well plate in DMEM 
(pyruvate, glutamine), 10% FBS, 100U/ml penicillin-streptomycin, 100ng/mL MCSF. 
Plated cells were activated with 100ng/ml of lipopolysaccharide (LPS) added directly to 
the media and incubated for 24 hours at 37oC, 5% CO2.  
Activated cells were harvested by manual scraping with PBS (0.6mM EDTA) and cells 
pelleted before lysis (Section 2.16). 
2.26. Cardiomyocyte Isolation 
Cardiomyocytes were isolated from wildtype and EcsitN209I/N209I neonatal mice between 
1 and 3 days old, no preference for sex was made. Animals were sacrificed by cervical 
dislocation and skin sterilised with 70% ethanol. Hearts were dissected and gently 
washed in Ca2+/Mg2+ free PBS supplemented with 20mM BDM (2,3-butanedione 
monoxime) before mincing in 250µL of isolation medium (Ca2+/Mg2+ free HBSS 
supplemented with 20mM BDM and 0.0125% w/v trypsin). Minced hearts from 6-10 
animals were incubated overnight in 10mL of isolation medium at 4oC with gentle 
agitation.   
The following day, isolation medium was replaced with 5mLs of digestion medium (L15 
medium, 20mM BDM, 1.5mg/mL Roche collagenase/dispase enzyme mix) and 5mLs of 
L15 medium supplemented with 20mM BDM before oxygenating for 1 minute. The 
oxygenated sample was then incubated for 30 minutes at 37oC with gentle agitation 
before digested fragments were triturated 10-20 times with a 10mL stripette. Cell 
suspension was passed through a pre-wetted 70µM cell strainer and the flow-through 
collected. Cardiomyocytes were pelleted by centrifuging at 100xg for 5 minutes at room 
temperature and resuspended in plating medium (65% DMEM high glucose, 19% M-199, 
10% horse serum, 5% FCS, 100U/ml penicillin-streptomycin) before being plated on 
uncoated 10cm tissue culture plates for 3 hours at 37oC, 5% CO2. Media was washed 
over the plate after 3 hours, leaving the adherent fibroblasts stuck to the plate, this step 
94 
 
was repeated once more before the cardiomyocyte suspension was plated at 1.5x105 
cells/cm2 on collagen coated tissue culture plates.  
24 hours post plating, plating medium was replaced for maintenance medium (78% 
DMEM high glucose, 17% M-199, 4% horse serum, 100U/ml penicillin-streptomycin, 
1µM AraC, 1µM isoproterenol) and cultured at 37oC, 5% CO2 for up to 5 days [277].  
2.27. Immunoprecipitation for Mass-Spec 
Immunoprecipitation was performed by one of 3 methods. For methods 1 and 2 proteins 
were extracted from wild type hearts by homogenisation in precellys tubes in a precellys 
homogeniser (Bertin instruments) in either RIPA buffer (150mM NaCl, 1%NP-40, 0.5% 
DOC, 0.1% SDS, 50mM Tris, pH 7.5) or incomplete RIPA buffer (150mM NaCl, 1% NP-40, 
0.5% DOC, 50mM Tris, pH 7.5) with the inclusion of 1x protease inhibitor cocktail (Roche) 
and 1x phosphatase inhibitor (Riche). 
Lysates were cleared by centrifuging at 10,000xg for 15 minutes at 4oC before protein 
concentration was determined by Bradford assay (Bio rad).  
5mg of total protein at a concentration of 2mg/mL was pre-cleared by incubating for 1 
hour with 30µl of protein G sepharose bead slurry (Sigma) at 4oC for 1 hour with rotation 
to remove native immunoglobulins. Following pre clearance, samples were centrifuged 
at 1,000xg for 1 min to remove protein G beads and supernatant incubated overnight 
with 20µg of antibody.  
Following overnight incubation, antibody was bound by incubation with 30µl of protein 
G sepharose beads for 1 hour at 4oC with rotation. Beads were collected by 
centrifugation (1,000xg, 1 min) and washed 3 times in 500µL lysis buffer. Antibody and 
bound protein were recovered by addition of 30µl of lysis buffer containing 1X LDS 
sample buffer (Invitrogen) and reducing agent (Invitrogen) before samples were run on 
an SDS-PAGE gel as in section 2.16. 
For method 3 proteins were extracted from wild type hearts by homogenisation in 
precellys tubes in a precellys homogeniser (Bertin instruments) in a mild 
homogenisation buffer (0.5% Triton X-100, 50mM HEPES, 150mM NaCl, 1mM MgCl2, 
1mM EGTA, pH 7.5) containing 1x protease inhibitors (Roche). Following lysis, samples 
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were cleared by centrifugation at 16,000xg for 20 minutes at 4oC and concentration 
assessed by Bradford assay (Bio rad).  
Preclearing of 1mg total protein (2mg/mL) was performed by incubation with 50µl of 
Protein A/G sepharose beads for 30 minutes at 4oC with rotation. Beads were removed 
by centrifugation at 16,000xg for 10minutes at 4oC.  
Supernatant was incubated with 1µg of antibody for 1 hour at 4oC with rotation before 
the addition of 30µl of protein A/G sepharose bead slurry and continued incubation 
overnight. Beads are collected by centrifugation (16,000xg, 10 mins, 4oC) and washed 
three times in lysis buffer. Antibody and bound protein were collected by addition of 
30µl of lysis buffer containing 1x LDS sample buffer (Invitrogen) and 1x reducing agent 
(Invitrogen) before western blot was performed.  
2.28. Fluorescence Associated Cell Sorting (FACS) 
FACS analysis was performed by Dr Pratik Vikhe at MRC Harwell. For analysis blood was 
collected by terminal retro-orbital sinus bleed following terminal overdose of 
pentobarbital using lithium heparin capillary tubes and lithium heparin collection tubes. 
25µl of whole blood was diluted in 175µl of FACS buffer (5mM EDTA, 0.5% foetal calf 
serum, PBS) in 96well V bottom plates. Blood was centrifuged at 2000rpm for 2 minutes 
and the pellet resuspended in red blood cell lysis buffer (155mM NH4Cl, 12mM NaHCO3, 
0.1mM EDTA) and incubated at room temperature for 5 minutes before centrifuging at 
2000rpm for 2 minutes. The pellet was resuspended in 200µl of FACS buffer and 
transferred to 96 well FACS analysis plate, centrifuged as previously and washed once 
more in FACS buffer. Following washes the pellet was suspended in 200µl of FACS buffer 
and the Fc receptor blocked by 1µl of CD16/32 antibody followed by incubation at room 
temperature for 10 minutes. Cells were centrifuged again at 2000rpm for 2 minutes and 
pellet suspended in 100µl of staining solution (FACS buffer + anti-F4/80 (1:200), anti-
CD11b (1:200), anti-Ly6g (1:200), anti-Ly6c (1:200) and anti CD5 (1:800) followed by 20 
minutes at room temperature in dark. Cells were washed with FACS buffer and fixed in 
100µl of 0.5% PFA for 10 minutes at room temperature in the dark. Finally, cells were 
washed twice in FACS buffer and resuspended in 210µl of FACS buffer and analysed 
using BD FACSCanto™ II system. FlowJo software (Tree Star™) was used to analyse the 
data.  
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2.29. Quantitaive Real Time PCR 
For Tlx2 expression, E7.5 embryos from wild type x wild type and EcsitN209I/N209I x 
EcsitN209I/N209I matings were collected, pooled and frozen on dry ice. RNA was extracted 
from pooled embryos using RNeasy Micro Kit (Qiagen) according to manufacturer’s 
protocol and concentration measured using a Nanodrop 8000 spectrophotometer 
(Thermo Fisher). Briefly, pooled embryos are lysed in 350µl of RLT buffer before addition 
of 350µl of 70% ethanol. The RNA is then bound to a supplied spin column by 
centrifugation for 15 seconds at 8000xg. Flowthrough is discarded and membrane 
incubated with 70µl of RDD buffer containing DNAse I for 15 minutes at room 
temperature. Following incubation, the membrane is washed once with RW1 buffer, 
once with RPE buffer and once with 80% ethanol with each wash followed by 
centrifugation at 8000xg for 15 seconds. Finally, the RNA is eluted in 14µl of RNAse free 
water and concentration calculated.  
RNA was diluted to a concentration of 100ng/µl and cDNA synthesised using high 
capacity cNDA reverse transcription kit (Thermo Fisher). Briefly, 10µl of diluted RNA is 
combined with 2µl of 10x RT buffer, 0.8µl of 25x dNTP mix (100mM), 2µl of 10x RT 
random primers, 1µl of multiscribe reverse transcriptase and 4.2µl of nuclease free 
water. The solution is then incubated on a PCR block at 25oC for 10 minutes followed by 
37oC for 120 minutes and 85oC for 5 minutes. cDNA is stored at -20oC until qRTPCR is 
run.  
The synthesised cDNA is diluted 1:25 to give a final concentration of 2ng/µl, suitable for 
taqman assay. Diluted cDNA (5µl) is combined with 10µl of 2X Taqman fast universal PCR 
master mix (Thermo Fisher), 1µl of relevant Taqman assay and 4µl of nuclease free 
water. The combined reagents are plated in a MicroAmp Fast Optical 96-wel Reaction 
plate (Thermo Fisher), the plate sealed with optically clear adhesive film and run on a 
7500 fast real-time PCR system (Applied Biosystems). Taqman assays used were specific 
for the target gene Tlx2 (Mm00437109_g1) and the endogenous controls B2m 
(Mm00437762_m1), Gapdh (Mm99999915_g1), and Hprt1(Mm00446968_m1). Hprt 
was selected for comparison as it demonstrated the least variability between samples.  
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2.30. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 7 (GraphPad software, CA, 
USA). Data are presented as mean ± SEM unless otherwise stated. Comparisons between 
2 groups were performed using unpaired Student’s t-test, an F test was performed to 
determine if there was a significant difference in variance between groups and where 
appropriate a Welch’s correction was included. For more than two groups, one (single 
variable) or two way (two variables) ANOVA was used with Bonferroni’s multiple 
comparison test for testing between groups. Correlations were assessed by linear 
regression. Results were considered significant at p<0.05. All phenotyping tests were 
performed blind to genotype of animals and in the case of echocardiograph, analysis 
was too performed blind. However, downstream molecular biology techniques were 
performed with prior knowledge of the genotype of samples being handled.  
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Chapter 3: Phenotypic Characterisation, 
Genetic Mapping and Confirmation of 
Mutation
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3.1. Introduction 
The aim of the Harwell Ageing Screen was to identify new mouse models of diseases 
associated with ageing by mutagenizing male mice and ageing their G3 descendants for 
18 months. During this time, the mice underwent a range of phenotyping tests across a 
range of physiological systems. As a result of this rigorous phenotyping regime a number 
of phenotypes of interest, resulting from ENU-induced mutations, were identified across 
the physiological systems that were part of the screening program [270].  
This chapter will focus on the identification, mapping, sequencing and further 
phenotyping of a small number of mice from pedigree MPC-178, which all exhibited a 
hypertrophic cardiomyopathy phenotype before 6 months of age. The pedigree was re-
derived from original G1 founder DNA in order to continue work after the identified 
affected animals were sacrificed. Whole-genome sequencing identified a candidate 
gene (Ecsit) and further phenotyping and inheritance testing confirmed the recessive 
nature of the trait. Despite Ecsit being thought to be ubiquitously expressed, the 
phenotype appears to be localised primarily to the heart with only small defects in 
weight gain and kidney function being observed.  
3.2. Mapping 
Mice were initially identified as part of the Harwell Ageing Screen when approximately 
15 mice from the initial G3 pedigree (78 mice) showed various signs of ill health (sudden 
weight loss, hunched appearance, piloerect coat, inactivity) or died suddenly. Four of 
these mice were collected for systematic necropsy and were noted to have enlarged 
hearts by visual inspection. Histology from this original pedigree revealed characteristic 
signs of hypertrophic cardiomyopathy: enlargement and disorganisation of the 
cardiomyocytes and the presence of vacuolation (Figure 3.1).  
100 
 
 
Figure 3.1. Histology of wild type and EcsitN209I/N209I heart from original pedigree showing enlargement of 
cardiac muscle with presence of disorganisation and vacuolation of cardiomyocytes in EcsitN209I/N209I heart.  
The number of affected mice (15/78) suggested that this was a recessive mutation and 
no founder G1 or G2 mice were found to be affected. Using the hypertrophic 
cardiomyopathy as the affected trait, the causative mutation was mapped to a 46Mb 
region of C57BL/6J origin at the proximal end of chromosome 9 spanning 8 SNPs of the 
golden gate panel (1449 SNPs total) (Figure 3.2). Mapping is based on SNP variations 
between the C57BL/6J and C3H.Pde6b+ founder strains with the knowledge that any 
ENU induced mutations must lie in a region of the genome inherited from the C57BL/6J 
ancestor. 
 
Figure 3.2. SNP mapping panel results showing results for affected and unaffected animals across the 
region identified. SNP positions demonstrate a region from the proximal end of Chromosome 9 up to 
46.53Mbs as homozygous for C57BL/6J (2.3H) that must contain the causative mutation.  
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3.3. Whole Genome Sequencing 
DNA from the G1 founder male was sent for whole genome sequencing (WGS) to 
determine the nature of the causative mutation. Whole genome sequencing was utilised 
instead of exome sequencing to include the possibility of a mutation in a non-coding 
portion of the DNA being causative of the phenotype. Results were analysed by the MRC 
Harwell bioinformatics team who aligned the sequences with the C57BL/6J reference 
sequence (NCBIM38/mm10), determined read depth and annotated the mutations 
[270]. The results identified 37 high confidence mutations within the mapping region 
(Table 3.1) however none of these were found to cause coding changes in any protein 
coding genes. Twenty-five lay in intergenic regions, whilst eleven were identified as 
intronic variants and 1 was a 3’ UTR variant in the gene Sidt2. Only one missense variant 
was identified in the region of interest, a medium confidence A to T change at position 
916 in the gene Ecsit. The mutation results in an asparagine to isoleucine change at 
residue 209 in the ECSIT protein (N209I). Whilst it is feasible that non-coding mutations 
could result in the observed phenotype, I initially concentrated on those mutations that 
affected protein coding as our experience to date shows that the majority of causative 
mutations cloned within the Harwell Ageing Screen resulted in a change to protein 
sequence. 
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Position Reference Alternate Functional Class Gene Name 
3312365 A G Intergenic variant - 
5017927 T A Intergenic variant - 
5139754 T A Intergenic variant - 
5391313 T G Intergenic variant - 
5726491 T C Intergenic variant - 
6253838 A T Intron variant Pdgfd 
7169444 T C Intron variant Dync2h1 
8532327 G A Intergenic variant - 
8560942 T C Intron variant Trpc6 
8948900 T C Intron variant Pgr 
9282243 T A Intergenic variant - 
12502691 T A Intergenic variant - 
14147347 T C Intergenic variant - 
14360948 T C Intron variant Endod1 
14535993 C G Intergenic variant - 
16632293 T A Intergenic variant - 
17778686 C A Intergenic variant - 
18057518 C A Intergenic variant - 
20231528 T C Intergenic variant - 
20656400 T C Intron variant Pin1 
22074703 A T Missense variant Ecsit 
23247306 T C Intron variant Bmper 
25035963 G A Intergenic variant - 
27226439 T C Intergenic variant - 
27449832 G A Intergenic variant - 
32135464 T C Intron variant Arhgap32 
35578580 G A Intron variant Pate2 
35941372 G A Intergenic variant - 
35960065 G A Intergenic variant - 
36371877 A T Intergenic variant - 
37016075 G T Intron variant Pknox2 
41610811 T C Intron variant . 
42189413 A T Intergenic variant - 
43404358 A G Intergenic variant - 
43593770 A G Intergenic variant - 
44105948 A G Intron variant Rnf26 
45938935 T A 3’ UTR variant Sidt2 
46898334 G A Intergenic variant - 
Table 3.1. List of high confidence mutations in the 46Mb region identified from SNP mapping. The Ecsit 
mutation is shown in grey as the only coding mutation (medium confidence) identified in the region.  
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3.4. Mutation Validation 
To confirm the validity of the WGS, three of the mutations were selected for 
confirmation by Sanger sequencing.  The mutations in Pdgfd (platelet derived growth 
factor d), Trpc6 (transient receptor potential cation channel, subfamily C, member 6) 
and Ecsit (Evolutionarily conserved signalling intermediate in toll pathway) were 
considered to be the most interesting candidate genes given their potential role in 
pathways with a link to cardiac function (Table 3.2). Results from Sanger sequencing of 
a G3 affected animal (Figure 3.3) confirm the WGS results and demonstrate that all three 
mutations are present in the G3 offspring.   
Gene Mutation Link to cardiac function 
Pdgfd Intron 
mutation 
Recruits macrophages and increases blood pressure when 
overexpressed [278]. 
Trpc6 Intron 
mutation 
Forms a calcium permeant cation channel, other calcium 
channels linked to cardiac conditions [279].  
Ecsit N209I Linked to mitochondrial function, dysfunction commonly 
associated with cardiomyopathy [231]. 
Table 3.2. The three genes containing mutations considered most likely to be causative of the phenotype 
in affected animals. Ecsit was considered to be the best candidate at this point due to direct links with 
cardiomyopathy whilst the remaining two only showed tentative links via other proteins with loosely 
similar functions. 
 
Figure 3.3. Sanger sequencing results from Pdgfd, Trpc6 and Ecsit showing confirmation of mutations from 
WGS in a G3 homozygous for the critical interval.  
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3.5. Narrowing the causative region 
In order to begin narrowing the causative region to confirm that Ecsit contained the 
causative mutation the line was rederived from frozen G1 sperm and heterozygous 
offspring crossed to C3H.Pde6b+ females in order to obtain a new cohort. 
Pyrosequencing was performed on ear clips taken from this pedigree, this allowed for 
both genotyping of animals and for confirmation of a number of the remaining intron 
variant mutations. A selection of mutations were used as markers, spanning the region 
to search for recombinants. A number of the single nucleotide variants (SNVs) were 
unsuitable for use in pyrosequencing due to the inability to design pyrosequencing 
primers in the region of the mutation (High GC content, repetitive sequence). The 
validated results shown in figure 3.4 demonstrate the expected pyrosequencing traces 
from each of the validated SNVs for both WT and mutant.  
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Figure 3.4. Example traces from each of the pyrosequencing primer sets used to genotype the SNVs in 
affected and control animals. The results confirm the WGS data for the mutations tested.  
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Pyrosequencing results from the initial cohort of 39 mice showed 7 animals with 
portions of the region of interest that were homozygous for all or some of the 5 SNVs 
tested (7.16, 14.36, 22.07, 23.24 and 32.13). Further SNVs were introduced to genotype 
later pedigrees to further narrow the region where possible. Of the 39 animals, 6 were 
later shown to be affected by cardiomyopathy by echocardiography, with these 6 all 
homozygous for the Ecsit mutation. The one animal without cardiomyopathy (2.1i) was 
only homozygous for SNV 7.16, indicating that this animal carries the mutation Pdgfd 
and thus eliminating this mutation from consideration (Table 3.3).  A further animal 
(1.1b) carried a region resulting from a crossover event between SNVs 14.36 and 22.07 
and was also shown to be affected by the cardiomyopathy phenotype. This allowed for 
the subsequent elimination of both the Pdgfd and Trpc6 mutations from consideration 
as they both lay in this heterozygous region and whilst this animal showed a 
cardiomyopathy phenotype, other animals with heterozygosity across the region 
displayed no phenotype (Table 3.3). 
These data also confirm that the trait is inherited in a recessive fashion as no 
heterozygous animals were found to be affected by the cardiomyopathy phenotype.  
Animal Affected? 9_7.16 9_14.36 9_22.07 9_23.24 9_32.13 
1.1b Yes HET HET HOM HOM HOM 
2.1i No HOM HET HET HET HET 
1.1g No WT WT WT WT WT 
1.1n No HET HET HET HET HET 
1.1i Yes HOM HOM HOM HOM HOM 
Table 3.3. Example pyrosequencing results across the region tested for 5 animals of the initial rederived 
pedigree. Results for animal 1.1b (confirmed affected by echocardiography) eliminate the region up to 
SNV 14.36 (Endod1), thus eliminating Pdgfd and Trpc6 as candidates as they lie upstream of this SNV. 2.1i 
also demonstrates a homozygous region around 7.16 
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3.6. Protein structure prediction 
To predict the effect that the N209I mutation may have on ECSIT, a selection of protein 
prediction algorithms were consulted through their online interfaces. Consistent results 
(Table 3.4) show that the N209I mutation is predicted to cause a deleterious change to 
protein structure or function and may result in disease. Whilst this is only a prediction it 
is informative that all software packages used reached the same conclusion and offered 
a starting point from which to begin work on the ECSIT protein. 
Software PANTHER PhD-SNP SIFT SNAP Meta-SNP SNAP2 Provean 
Score 0.783 0.648 0.000 0.560 0.644 52 -7.252 
Outcome Disease Disease Disease Disease Disease Effect Deleterious 
Table 3.4. Protein prediction scores and expected outcome from a variety of SNP prediction softwares. 
Panther1 (0-1, >0.5 Disease), PhD-SNP1 (0-1, >0.5 Disease), SIFT1 (0-1, <0.5 Disease), SNAP1 (0-1, >0.5 
Disease), Meta-SNP1 (0-1, >0.5 Disease), SNAP22 (-100-100, >50 Effect), Provean3 (-13-4, <-2.5 
Deleterious). 1http://snps.biofold.org/meta-snp, 2rostlab.org/services/snap, 3provean.jcvi.org. 
3.7. Production of phenotyping cohorts 
Further phenotyping was delayed until an incipient congenic line was obtained to reduce 
the potential effects of the mixed genetic background and to eliminate mutations 
outside of the region of interest. To obtain the incipient congenic line EcsitN209I/+ males 
were crossed to C3H.Pde6b+ females for 5 generations. Genotyping was performed by 
pyrosequencing across the region described above at each generation, selecting animals 
heterozygous for the mutation in Ecsit and where possible eliminating any other sections 
of the region. The pyrosequencing panel was expanded to assist with this narrowing of 
the region.  
3.7.1. Inheritance 
As the global deletion of Ecsit in mice is known to be lethal [230], it was important to 
test for the viability of EcsitN209I/N209I animals. To demonstrate that the EcsitN209I mutation 
was not homozygous lethal, the total number of mice for each genotype that were 
obtained as part of the incipient congenic backcross line were compared to predicted 
numbers for typical Mendelian inheritance from Het intercross matings (1:2:1). The total 
number of mice that were genotyped post weaning was 587 throughout the projects 
lifetime giving a Mendelian ratio of 146.75:293.5:146.75. The actual ratio of mice 
genotyped was 158:270:159 (Figure 3.5) giving a chi-square value of 0.1521 (two-tailed 
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Chi square), indicating that the N209I mutation does not result in elevated pre-weaning 
lethality. 
 
Figure 3.5. Total numbers of mice from each genotype from incipient congenic mice.  
3.8. Phenotyping 
Phenotyping was undertaken to examine a number of physiological systems to 
determine if the phenotype observed in the heart was isolated or part of a syndromic 
condition. Some phenotyping tests were unable to be performed at late time points due 
to the sensitivity of affected animals to general anaesthesia and as such were omitted. 
As a result, phenotyping tests shown below focus on metabolism and the function of 
organs with high energy demand such as the heart, liver, kidneys and skeletal muscle. 
Except where stated, all following phenotyping was undertaken on animals from the 
incipient congenic line (Backcross 5 intercross). 
3.8.1. Clinical Chemistry 
The concentrations of a variety of minerals, metabolites and enzymes can provide clues 
to the function of various organs and systems within the body and may indicate which 
organs are most severely affected by the ECSIT N209I mutation. To investigate this, 
terminal plasma samples were collected from 16 week old animals from both the 
original re-derived pedigree (back cross 1) (M:F, WT 11:7, HET 15:6, HOM 5:5)  and from 
the incipient congenic backcross animals (back cross 5) (M:F, WT 13:17, HOM 7:14). 
Samples were taken from wild type, EcsitN209I/+, and EcsitN209I/N209I male and female 
animals, but as no meaningful differences in any tests were seen between wild type and 
EcsitN209I/+ animals, EcsitN209I/+ animals were excluded from further analysis. No 
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significant differences were observed between male and female animals and as a result, 
values were not separated.  
The electrolytes sodium, potassium and chloride are responsible for a variety of roles in 
the body, including signalling, blood pressure homeostasis, maintaining cellular 
pressure, propagating action potentials and acid-base homoeostasis amongst others. 
The levels of the electrolytes sodium and chloride (Figure 3.6) show no significant 
changes indicating that the N209I mutation in ECSIT is not affecting the maintenance of 
these ions. However, average potassium concentration in EcsitN209I/N209I animals was 
significantly elevated over control animals in both backcrosses tested, which may be 
caused by failure of the kidneys to remove high levels of potassium from the blood.  
 
Figure 3.6. Plasma concentrations of the electrolytes, sodium (A), potassium (B) and chloride (C) in 
backcross 1 and 5 animals. Results show no significant differences in sodium or chloride concentration 
between any genotypes tested but do demonstrate a significant elevation in potassium levels in 
EcsitN209I/N209I animals over controls in both backcrosses. Mean ± SEM, *p<0.05, **p<0.01, ***p<0.001. 
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Kidney function can be assessed by measuring the levels of urea and creatinine in plasma 
as these two compounds are typically filtered out by the kidneys during normal healthy 
function. EcsitN209I/N209I animals show a significant elevation of both urea and creatinine 
in EcsitN209I/N209I animals (Figure 3.7) compared to controls in both the backcross 1 and 
incipient congenic lines. Taken together with the elevation of potassium (Figure 3.6) 
these data could indicate a loss of function of the kidney filtration barrier as potentially 
harmful compounds are not being removed effectively from the blood. 
 
Figure 3.7. Plasma concentrations of the kidney function markers urea (A) and creatinine (B) in backcross 
1 and 5 animals. Results demonstrate a significant elevation of both Urea and Creatinine in EcsitN209I/N209I 
animals over controls in both backcrosses. Mean ± SEM, *p<0.05, **p>0.01, ****p<0.0001. 
The liver is essential to normal metabolic function and there are many compounds that 
can measure different aspects of liver function (Figure 3.8). Proteins such as albumin are 
produced by the liver to regulate oncotic pressure of the blood and as a carrier for 
compounds with low solubility in water [280]. Total protein content and albumin 
concentration of plasma show no significant difference between EcsitN209I/N209I animals 
and controls in either backcross tested indicating that this function of the liver is 
unaffected.  
Bilirubin concentration shows mild elevation in EcsitN209I/N209I animals compared to 
controls in both backcrosses. As bilirubin has a potential role as an antioxidant, this may 
indicate an upregulation due to increased reactive oxygen species either in the liver, the 
circulation or other tissues [281]. However, the difference between the groups is very 
small and may not be biologically relevant, despite being statistically significant.  
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Alkaline Phosphatase (ALP) dephosphorylates compounds throughout the body and 
elevated levels may be associated with a variety of liver conditions [282]. However, 
whilst the differences seen between EcsitN209I/N209I and wild type animals here (Figure 
3.8) are statistically significant, the levels seen in EcsitN209I/N209I are not outside of the 
reference ranges established at MRC Harwell for wild type animals (57-136 U/l)  
indicating that this elevation may not be biologically significant.  
Aspartate transaminase (AST) and alanine transaminase (ALT) are enzymes that catalyse 
the conversion of aspartate and α-ketoglutarate to oxaloacetate and glutamate, and L-
alanine and α-ketoglutarate to pyruvate and L-glutamate, respectively. These reactions 
are reversible and serve to provide the substrates of a variety of metabolic processes.  
ALT and AST both show no significant differences between genotypes in the backcross 
1 animals tested (Figure 3.8). Interestingly, AST does show a slightly elevated average 
AST level in EcsitN209I/N209I animals from the incipient congenic backcross (Figure 3.8). 
However, with the exception of a single outlier, these values all lie within the ranges 
established for wild type mice at MRC Harwell (37-104 U/l) and are unlikely to truly 
represent a liver phenotype.  
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Figure 3.8. Plasma concentrations of the liver function markers total protein (A), albumin (B), bilirubin (C), 
ALP (D), AST (E) and ALT (F) in backcross 1 and 5 animals. Results show no significant differences in either 
total protein, or the specific protein, albumin, levels between any genotypes in either backcross. Bilirubin 
and ALP levels are elevated in EcsitN209I/N209I animals over heterozygotes in the original backcross and over 
wild types in the incipient congenic line. AST also demonstrates a difference between wild type and 
EcsitN209I/N209I animals in the incipient congenic line although no differences were apparent in the original 
backcross line. Finally, ALT shows no significant differences between any groups tested. Mean ± SEM, 
*p<0.05, **p>0.01, ***0<0.001, ****p<0.0001. 
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Calcium and inorganic phosphate levels in all groups from both backcross lines show no 
significant differences between genotypes indicating that there are no changes in the 
maintenance of these minerals, which are typically associated with bone health (Figure 
3.9).  
 
Figure 3.9. Plasma concentrations of the minerals calcium (A) and inorganic phosphate (B) in backcross 1 
and 5 animals. Results show no significant differences in either mineral between any of the groups 
compared. Mean ± SEM. 
The lipids, cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL) 
are primarily synthesised as part of cell membranes and for the transport of fat between 
cells. Elevated levels of cholesterol and LDL are significant risk factors for atherosclerosis 
whilst HDL is considered protective. Whilst results (Figure 3.10) show no significant 
differences in total cholesterol levels, HDL levels in EcsitN209I/N209I animals appears 
significantly decreased when compared to control animals. Crucially, this is coupled with 
an elevation of LDL in EcsitN209I/N209I animals compared to wild types in the incipient 
congenic line. However, it is apparent from figure 3.10 that whilst the averages of these 
compounds differ, there is significant overlap between the ranges seen in wild type and 
EcsitN209I/N209I animals.  
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Figure 3.10. Plasma concentrations of the lipids, cholesterol (A) high-density lipoprotein (HDL) (B) and 
low-density lipoprotein (C) in backcross 1 and 5 animals. Results show no changes in total cholesterol 
levels in any of the groups compared, however, HDL levels are marginally reduced in EcsitN209I/N209I animals 
in both backcross when compared to controls. Also of interest is the marginal elevation of LDL in 
EcsitN209I/N209I in the incipient congenic backcross animals when compared to wild types. Mean ± SEM, 
*p<0.05. 
Circulating triglycerides are a high energy density molecule that is broken down via 
lipolysis into glycerol and free fatty acids (FFA) which are then metabolised as part of 
glycolysis, gluconeogenesis or beta-oxidation to provide substrates for the TCA cycle. 
Ketone bodies are produced by the liver from free fatty acids during periods of fasting 
to provide the body with a substrate which can be converted into acetyl-CoA and enter 
the TCA cycle.  
There were no significant differences (Figure 3.11) between genotypes in the backcross 
1 animals. However, in the incipient congenic line, EcsitN209I/N209I animals show a 
significant reduction in circulating triglycerides, and an elevation of both glycerol and 
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ketone bodies when compared to wild type animals. Taken together these data suggest 
an increase in metabolism of triglycerides in the liver to form substrates for the TCA 
cycle, similar to what is seen during periods of fasting [283].  
 
Figure 3.11. Plasma concentrations of the fatty acid metabolism products, triglyceride (A), glycerol (B) and 
free fatty acids (FFA) (C) in backcross 1 and 5 animals. Ketone bodies (D) were only tested in the incipient 
congenic backcross and not in the earlier backcross. Results show no differences in any of the metabolites 
between genotypes in the backcross 1 animals. However, in the incipient congenic animals there is a 
marginal decrease in total triglyceride levels and a similarly marginal elevation of glycerol in EcsitN209I/N209I 
animals compared to wild types. Ketone bodies also show a significant elevation in EcsitN209I/N209I animals 
compared to wild types. Mean ± SEM, *p<0.05. 
Glucose and fructosamine are typically elevated in plasma in diabetes mellitus as the 
glucose is unable to be taken into tissues and subsequently reacts with an amine group 
to form fructosamine resulting in elevated levels of this compound too. Results here 
(Figure 3.12) demonstrate a reduction in plasma glucose levels and a corresponding 
reduction in fructosamine in EcsitN209I/N209I animals in the incipient congenic backcross 
116 
 
animals. This may indicate an increased metabolism of glucose which in turn results in a 
reduction in fructosamine levels however, these results are taken from non-fasted 
animals and these results may not be representative of real differences between 
genotypes.  
 
Figure 3.12. Plasma concentrations of the diabetic markers glucose (A) and fructosamine (B) in backcross 
1 and 5 animals. Glucose levels show a significant reduction in EcsitN209I/N209I animals compared to wild 
types in the incipient congenic line, whilst the back-cross 1 animals show a marginal decrease which does 
not reach a significant level. Meanwhile, fructosamine levels are significantly reduced in EcsitN209I/N209I 
animals compared to controls in both backcross groups. Mean ± SEM, *p<0.05, **p<0.01, ****p<0.0001. 
Lactate dehydrogenase and creatine kinase are enzymes which are typically contained 
within cells and their presence in plasma can be indicative of tissue damage. Cytosolic 
creatine kinase is comprised of two different subunits, B – Brain and M – Muscle, and 
there are 3 possible isoforms as a result, MM, BB and MB, each with varying proportions 
in different tissues. In humans CK-MM is the majority cytosolic form in skeletal muscle 
(97%), CK-BB is the predominant form found in brain, colon, stomach and bladder, whilst 
CK-MB is relatively uncommon in most tissues (2-3% of skeletal muscle) but is found in 
considerable amounts in heart tissue (15-40%) along with CK-MM. Following cardiac 
injury, serum levels of total and CK-MB are known to rise peaking roughly 24 hours after 
injury and returning to baseline after about 72 hours in humans [284]. In contrast, the 
mouse heart has very low levels of CK-MB and the predominant form is CK-MM, 
accounting for roughly 90-95% of cytosolic CK activity, with CK-MB only contributing 
roughly 5% to total cytosolic CK activity [285].  
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Results illustrated here (Figure 3.13) show no significant changes in CK levels between 
wild type and EcsitN209I/N209I animals. However, this test does not distinguish between 
the CK isoenzymes and only measures total CK levels, however, had a difference been 
apparent, further investigation would have been relatively simple with the use of an 
ELISA.  
Lactate dehydrogenase catalyses the conversion of lactate to pyruvic acid and is a 
tetramer primarily composed of different subunits LDH-M and LDH-H. Through varying 
the proportions of the 2 subunits in the tetramer there are 5 main isoenzymes that are 
present in different tissues (LDH-1 (4H), 2 (3H1M), 3 (2H2M), 4 (1H3M), and 5 (4M)). 
Under typical conditions LDH-2 is the form found in plasma, however following cardiac 
damage LDH-1 levels may become elevated in the plasma and result in a shift in the ratio 
of LDH-1:LDH-2 [286]. From the results illustrated here (Figure 3.13) it is apparent that 
there are no significant changes in total LDH levels and no further investigation was 
undertaken.  
As neither of these enzymes show elevation at the total enzyme level it was therefore 
unnecessary to investigate the ratios of the two to determine if there is significant tissue 
damage. Further investigation could have been undertaken using cardiac troponin levels 
as a more accurate test of myocardial infarction [287] but given that these samples were 
taken from animals prior to any signs of ill-health, this is unlikely to be informative.  
 
Figure 3.13. Plasma concentrations of the tissue damage markers lactate dehydrogenase (LDH) (A) and 
creatine kinase (B) in backcross 1 and 5 animals. Neither compound shows a significant difference 
between wild type and EcsitN209I/N209I animals in either of the backcrosses tested. Mean ± SEM, *p<0.05. 
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Finally, iron is a major constituent of heme and differences in iron levels may indicate 
blood disorders or a nutritional deficiency. Results (Figure 3.14) show no differences in 
iron concentration in the plasma of any animals tested.  
 
Figure 3.14. Plasma concentrations of iron in backcross 1 and 5 animals showing no difference between 
any of the genotypes in either backcross tested. Mean ± SEM. 
Individually these clinical chemistry results do not appear to reflect any major changes 
in organ function or general metabolism, with many differences being either small or 
falling within the expected ranges established for wild type animals. However, when 
considered together these results demonstrate an impairment of kidney as well as liver, 
although to lesser extent. In addition results seem to demonstrate an increase in the 
metabolism of both glucose and triglycerides which may reflect a change in the general 
metabolic phenotype of EcsitN209I/N209I animals.  
3.8.2. Body weight 
Body weight was measured every 2 weeks from 6 weeks of age up until 16 weeks of age. 
Males and females were separated for the purpose of analysis due to sex differences in 
the wild type controls. From the results it is apparent that EcsitN209I/N209I animals display 
a reduced body weight from as early as 6 weeks of age, and whilst they do show a small 
increase in body weight over time, this is mostly accounted for by growth up to the age 
of 10 weeks which then plateaus (Figure 3.15). The slope of the curve, representing the 
growth curve from 6 to 16 weeks of age, is significantly different (simple linear 
regression) between wild type and EcsitN209I/N209I animals in both males (p=0.0026) and 
females (p=0.04).  
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Despite the differences in overall body weight, measurements of the femur (Figure 3.16) 
show no significant differences between wild types (n=23) and mutants (n=24). This 
indicates that despite differences in body weight, the growth of the mutant animals is 
not stunted and is attributable to lean and fat mass accumulation rather than overall 
reduced body size.  
 
Figure 3.15. Weight against time of male and female wild type and EcsitN209I/N209I animals. Results show a 
significant difference between genotypes from 6 weeks of age with the rate of growth of mutant 
animals (simple linear regression) significantly reduced compared to wild types. Each time point was 
also tested for significance with a standard t-test, demonstrating that differences in weights are 
apparent from 6 weeks of age. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
120 
 
 
Figure 3.16. Length of femurs (mm) measured from wild type and EcsitN209I/N209I animals. (Mean ± SEM). 
3.8.3. Body Composition 
To determine the fat and lean mass composition of wild type and EcsitN209I/N209I animals 
Echo-MRI was performed. Echo-MRI is a simplified form of nuclear magnetic resonance 
imaging (MRI) that gives only a composition analysis instead of the images typically 
associated with the technique. Echo-MRI performed on wild type and EcsitN209I/N209I 
animals demonstrates significant differences in total body weight, lean mass and fat 
mass (both absolute and expressed as a % of total body weight). EcsitN209I/N209I animals 
show a reduction in body weight, fat mass and lean mass when compared to sex and 
age matched wild type animals. Sexes were separated as differences were seen between 
wild type males and females across all time points (graph not shown), n numbers shown 
in table 3.5. The results show that mutant animals do not increase in overall body mass 
(Figure 3.17) from 8 weeks of age primarily due to a lack of accumulation of fat mass 
(Figure 3.18) and lean mass (Figure 3.19) in both sexes. 
At 8 weeks of age, wild type and EcsitN209I/N209I animals are statistically indistinguishable 
from their sex matched counterparts in terms of all 3 parameters measured, indicating 
normal growth up to this point. However, after 8 weeks of age, differences begin to 
emerge. By 10 weeks, males have measurably less fat mass than wild type animals 
(Figure 3.18) and females overall body mass is statistically different from that of wild 
types (Figure 3.17). At 14 weeks, greater differences are apparent in body weight in both 
sexes in terms of both body weight (Figure 3.17) fat mass (Figure 3.18). Finally, at 18 
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weeks differences can be seen in fat, lean and total mass in both sexes when comparing 
to wild type controls.  
Time 
Point 
Male WT Female WT Male EcsitN209I/N209I Female 
EcsitN209I/N209I 
8 Weeks 9 8 12 12 
10 Weeks 6 10 4 7 
14 Weeks 6 10 3 5 
18 Weeks 7 6 3 6 
Table 3.5. n Numbers for each time point and genotype used in Echo-MRI experiment.  
 
Figure 3.17. Body weight of wild type and EcsitN209I/N209I animals demonstrates that whilst wild types 
increase in size between 8 and 18 weeks of age, mutant (male or female) animals do not grow in terms of 
absolute body mass beyond 8 weeks of age when compared to wild type controls. Mean ± SEM,*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. Any comparison not labelled should be considered non-significant 
(ns). 
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Figure 3.18. Absolute fat mass measurements show that both male (A) and female (B) wild type animals 
continue to accumulate fat mass beyond 8 weeks of age whilst EcsitN209I/N209I animals do not. This 
becomes more apparent as the animals age (Mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001). Any comparison not labelled should be considered non-significant (ns). 
 
Figure 3.19. Absolute lean mass measurements show that both male (A) and female (B) wild type 
animals continue to accumulate lean mass beyond 8 weeks of age whilst EcsitN209I/N209I animals do not. 
By 14 weeks of age this difference is apparent in male animals and at 18 weeks of age both sexes show a 
significant reduction in lean mass compared to sex matched wild type controls.  (Mean ± SEM, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001). Any comparison not labelled should be considered non-
significant (ns). 
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3.8.4. Grip Strength 
Grip strength was assessed in 14 week old male (WT:10, HOM: 8)  and female (WT:9, 
HOM:13) animals to determine if a muscular phenotype was associated with the 
cardiomyopathy phenotype seen in EcsitN209I/N209I animals. This might be expected with 
a systemic myopathy as is common with complex I disorders and might be associated 
with a mutation in an assembly factor such as ECSIT. Male and female results were not 
separated as no significant differences were present between sexes. Grip strength 
results can be demonstrated as raw values, or expressed as a value normalised to the 
animal’s body weight. Below (Figure 3.20), the absolute values show no difference in 
grip strength between wild type (n=19) and EcsitN209I/N209I (n=21) animals either in the 
fore paws only or in all 4 paws. However, when the data is normalised to body weight 
(Figure 3.21) the mutant animals demonstrate an increased grip strength of both the 
fore paws and all 4 paws. This is most likely due to the decreased body weight of the 
mutant animals as is seen in section ‘3.8.2 – Body Weight’ and ‘3.8.3 – Body 
Composition’. 
 
Figure 3.20. Absolute grip strength measurements of fore paws (A) and all paws (B) showing no 
differences between wild type and EcsitN209I/N209I animals. (Mean ± SEM). 
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Figure 3.21. When normalised to body weight, grip strength results show a significant increase in both the 
fore (A) and all paw (B) measurements in EcsitN209I/N209I animals over wild type controls. (Mean ± SEM, 
*<0.05, ***p<0.001). 
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3.8.5. IPGTT 
An intraperitoneal glucose tolerance test (IPGTT) measures the ability to take up glucose 
into tissues following a glucose challenge. It reflects the ability to both sense glucose, 
secrete insulin and to respond to insulin in key insulin sensitive tissues. In type 2 diabetes 
there will be insulin resistance and defects in insulin secretion. Impaired glucose 
tolerance typically precedes the development of a diabetic phenotype.  
An inability to effectively regulate glucose levels is typically indicative of a diabetic 
phenotype which may be related to mitochondrial dysfunction in certain tissues (heart, 
muscle and liver) [288]. Results from wild type and EcsitN209I/N209I male (WT:10, HOM:10) 
and female (WT:8, HOM:10) animals reveals a small but significant difference in blood 
glucose levels 60 minutes post injection. This difference takes the form of a decrease in 
plasma glucose levels rather than the increase that would be expected in a diabetic 
phenotype. Male and female results were not separated as no significant differences 
were seen between sexes. This difference does not persist across all time points (Figure 
3.22) suggesting that the affected animals demonstrate no long term benefits to glucose 
metabolism and are unlikely to have a real primary phenotype as a result of the N209I 
mutation. These data reflect a minor change in the ability to dispose of glucose but are 
unlikely to significantly affect the maintenance of normal glucose homeostasis.  
 
Figure 3.22. IPGTT results from wild type (n=18) and EcsitN209I/N209I (n=18) animals. (Mean ± SEM, 
**p<0.01). 
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3.8.6. Tissue Weights 
Tissue weights were assessed at the time of death (16 weeks) to assess the 
cardiomyopathy phenotype and which other tissues may be affected as a result of 
congestion of the left or right heart. Male (WT:10, HOM:10) and female (WT:12, 
HOM:14) samples were not separated as no difference in sexes was observed. Heart, 
lung and liver weights can be analysed as absolute values or normalised to the animal 
size either as a % of total body weight or by normalising to the length of the long bones, 
such as the femur. Below the weights of these tissues are expressed in all three ways. 
These three tissues were selected to assess the hypertrophy of the heart. Left ventricular 
hypertrophy would lead to increased lung weight due to congestion of the pulmonary 
circulation. Similarly, an increase in liver size would indicate right ventricular 
hypertrophy due to congestion of the systemic circulation.  
Heart weights show a significant increase in EcsitN209I/N209I (n=24) animals over wild type 
controls (n=22) in terms of absolute values (Figure 3.23) as well as both types of 
normalisation used (Figures 3.24 and 3.25), indicating a robust enlargement of the heart 
muscle that is not affected by animal size or weight. Similarly, lung weights demonstrate 
the same trend across the board, suggesting that the left ventricle is hypertrophied and 
causing congestion in the pulmonary circulation. In contrast, liver weights do not show 
an increase across any of the three categories. Absolute liver weights (Figure 3.23) are 
decreased in EcsitN209I/N209I animals compared to controls, and the same holds true when 
normalised to femur length (Figure 3.25). However, when liver weight is normalised 
according to the animal’s overall bodyweight (Figure 3.24) there are no significant 
differences in tissue weights between the genotypes. In summary these data 
demonstrate that there is no increase in liver weight and it is possible to speculate that 
there is little to no hypertrophy of the right ventricle.  
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Figure 3.23. Absolute values for all tissue weights, showing an increase in heart weight and lung weight 
and a decrease in liver weight of EcsitN209I/N209I animals compared to healthy wild type controls. (Mean ± 
SEM, ***p<0.001, ****p<0.0001) 
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Figure 3.24. Tissue weights normalised to total body weight of the animal. Heart and lung weights still 
demonstrate a significant elevation in EcsitN209I/N209I animals over wild type. Whilst liver does not show 
any significant difference. (Mean ± SEM, ****p<0.0001) 
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Figure 3.25. Tissue weights normalised to femur length, expressed as mg of tissue weight per mm length 
of femur. Similarly to the un-normalised tissue weights in figure 3.23 heart and lung weights reveal a 
significant increase in EcsitN209I/N209I animals compared to wild type controls, whilst liver weights show the 
reverse trend. (Mean ± SEM, ****p<0.0001). 
3.8.7. Histology Time Course 
Hearts were taken from 3 wild type and 3 EcsitN209I/N209I animals (2 sections per animal) 
at various time points to assess the development of the cardiomyopathy. No 
preferences were made for sex of the animals as this was unreliable at very early time 
points. EcsitN209I/N209I hearts show signs of cardiomyopathy from as early as 6 weeks of 
age (Figure 3.26), with the development of mineralisation (yellow arrows Figure 3.27) 
which progresses over time to become apparent at 12 weeks of age. Vacuolation is 
apparent in some areas of the heart at 6 weeks of age (black arrows Figure 3.27) and 
progresses so that the majority of 12 week old heart tissue shows signs of severe 
vacuolation. Also present, but difficult to quantify, is cardiomyocyte hypertrophy and 
disorganisation. In wild type hearts (Figure 3.27) cardiomyocytes can be seen in well 
organised striated patterns.  At 6 weeks of age EcsitN209I/N209I hearts show regions where 
cardiomyocytes appear to be marginally enlarged and no longer form this organised 
structure. At 12 weeks, EcsitN209I/N209I cardiomyocytes no longer show any signs of 
structure and appear completely disorganised.  
129 
 
 
Figure 3.26. Time course of histology (1.25x) on wild type and EcsitN209I/N209I hearts showing development 
of cardiomyopathy in mutant animals. Enlargement of EcsitN209I/N209I hearts is first apparent around 6 
weeks of age and progresses up to 12 weeks of age where a significant enlargement is apparent. Scale bar 
= 2.5mm. 
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Figure 3.27. Histology time course at 20x magnification demonstrating structure of the cardiac tissue 
and showing vacuolation (black arrows) and mineralisation of tissue (yellow arrows) in EcsitN209I/N209I 
hearts from 4-6 weeks of age which is not seen in wild type controls. Also present are signs of 
cardiomyocyte hypertrophy and disorganisation from 4 weeks of age.   Scale bar= 100µm. 
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3.8.8. Echocardiography 
Echocardiography, performed on incipient congenic backcross mice at 10 weeks of age 
shows significant differences in heart size and contractility (Male WT:7, HOM:9, Female 
WT:6, HOM:9). During diastole both the anterior and posterior left ventricular walls 
show a significant increase in thickness in EcsitN209I/N209I animals compared to wild type 
(Figure 3.28). This is also reflected in the left ventricular interior diameter (Figure 3.29) 
which shows a significant increase in EcsitN209I/N209I animals during both diastole and 
systole.  During systole the posterior wall no longer shows a significant increase in 
thickness in EcsitN209I/N209I animals, whilst the anterior wall remains significantly enlarged 
(Figure 3.28).  
 
Figure 3.28. Echocardiographic measurements of the left ventricular anterior (A) and posterior (B) walls 
during diastole and systole showing a significant increase in anterior wall thickness during both systole 
and diastole and a significant thickening of the posterior wall during diastole which is unchanged during 
systole. (Mean ± SEM, **p<0.01, ****p<0.0001). 
Left ventricular volume and mass show a significant increase in EcsitN209I/N209I animals 
during both systole and diastole (Figure 3.29) indicating an enlargement of not only the 
muscle mass but also a dilation of the heart cavity. The ejection fraction in EcsitN209I/N209I 
animals is significantly reduced, demonstrating a reduction in the contractility of the 
heart muscle (Figure 3.30). Heart rate taken during the echocardiograph measurements 
(Figure 3.30) shows a reduction in average beats per minute (BPM) in EcsitN209I/N209I 
animals, which was not seen earlier in the ECG measurements. Heart rate is coupled 
with stroke volume (end diastolic volume – end systolic volume) (Figure 3.30) to allow 
for the calculation of cardiac output (stroke volume x heart rate) (Figure 3.30), giving an 
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overall impression of the function of the heart in EcsitN209I/N209I animals. Taken together 
these data indicate a profound cardiomyopathy with characteristics that may be 
attributed to both dilated and hypertrophic cardiomyopathy. 
 
Figure 3.29. Left ventricular interior diameter (A) measured by echocardiograph and volume (B) calculated 
from changes in diameter, both showing an enlargement of the left ventricle in EcsitN209I/N209I animals 
during both diastole and systole, suggestive of a dilated cardiomyopathy. Calculated left ventricular mass 
(C) indicates an overall enlargement of the left ventricle. (Mean ± SEM, ****p<0.0001). 
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Figure 3.30. Ejection fraction (A) demonstrates a significant reduction in EcsitN209I/N209II animals compared 
to wild types. Heart rate (B) measured during echocardiography readings can be coupled with the 
calculated stroke volume (C) to give an overall cardiac output (D).  (Mean ± SEM, ****p<0.0001). 
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3.8.9. Cardiac Electrophysiology 
Electrocardiogram (ECG) was performed on 12 week old wild type (M:6, F:5), EcsitN209I/+ 
(M:9, F:3) and EcsitN209I/N209I (M:5, F: 5) animals from an early cohort prior to 
backcrossing to C3H.Pde6b+ for 5 generations to obtain the incipient congenic line. 
Results were obtained by signal averaging across the length of the trace obtained. No 
significant differences were detected in any of the parameters measured (Figure 3.31) 
showing that the N209I mutation has no effect on signal transduction through the 
cardiac tissue. This result is unsurprising as the cardiomyopathy would not necessarily 
be reflected by changes in the conductive tissue of the heart and hence in ECG 
abnormalities.  Given this result, further phenotyping was not performed on later 
backcrosses so as to reduce the strain on animals under anaesthesia.  
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Figure 3.31. ECG parameters measured in 12 week old wild type (n=11), EcsitN209I/+ (n=12) and 
EcsitN209I/N209I (n=10) animals. Results show no significant differences in R-R interval (A), PR interval (B), P 
duration (C), QRS duration (D), QT interval (E), corrected QT interval (QTc) (F) or heart rate (G).  (Mean ± 
SEM). 
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3.8.10. Muscle Fibre Typing 
Muscle fibre typing was performed on soleus and extensor digitorum longus (EDL) 
muscles isolated from 3 wild type and 3 EcsitN209I/N209I male animals by Saleh Salman 
Omairi at the University of Reading. Fibres were classified as either oxidative or non-
oxidative according to profiling of succinate dehydrogenase (SDH) and were classified 
according to myosin heavy chain (MHC) proportions of MHC I, MHCIIA, MHC IIX, and 
MHC IIB. Results show no differences in the proportion of oxidative to non-oxidative 
fibres in either the EDL or the soleus (Figure 3.33) indicating that the mutation of ECSIT 
does not affect the metabolic profile of these muscles.  
 
Figure 3.32. Percent oxidative and non-oxidative fibres in (EDL) and soleus muscles from wild type and 
EcsitN209I/N209I animals.  Results show no significant differences between genotypes in either of the muscles 
investigated. Mean ± SEM. 
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Following MHC profiling, muscle fibres were counted and cross sectional area measured 
in both the EDL and the soleus. From these data (Figure 3.33) we can see that there are 
no significant differences in the MHC ratio in either muscle. Soleus is primarily a slow 
twitch muscle type with a predominance of MHC I and IIA fibres, this is unchanged in 
EcsitN209I/N209I animals when compared to wild types (Figure 3.33). EDL is a faster twitch 
muscle type with high levels of MHC IIB fibres which again is not significantly altered in 
EcsitN209I.N209I animals compared to wild-types.  
 
Figure 3.33. Percent of each fibre type in EDL (A) and soleus (B) in wild type and EcsitN209I/N209I animals 
showing no significant differences between genotypes in either muscle investigated. Mean ± SEM. 
Cross sectional area (CSA) was determined from the average of 100 CSAs of each fibre 
type in each sample. Results here show a significant reduction in all fibre types in both 
muscles measured in EcsitN209I/N209I animals compared to wild types (Figure 3.34). This 
reduction in CSA in all fibre types in EcsitN209I/N209I animals is likely to be related to the 
reduction in overall lean mass seen in section 3.8.3. 
Collectively, these data do not demonstrate a significant alteration to the muscular 
phenotype of EcsitN209I/N209I animals when compared to wild type controls.  
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Figure 3.34. Cross sectional areas of fibre types in EDL (A) and soleus (B) showing a significant reduction 
in all fibre type sizes in EcsitN209I/N209I animals compared to wild type controls. Mean ± SEM, *p<0.05. 
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3.9. Compound Heterozygote Phenotyping 
To confirm that the Ecsit N209I mutation is causative of the hypertrophic 
cardiomyopathy seen in homozygous animals, compound heterozygotes (EcsitN209I/-) 
were generated from the intercrossing of EcsitN209I/+ and Ecsit+/- animals. Ecsit+/- animals 
were obtained from the laboratory of Professor Sankar Ghosh at Columbia University 
Medical Centre (NY, USA).  
The EcsitN209I/- offspring are heterozygous for the N209I mutation and the surrounding 
region inherited from the original C57BL/6J mutagenized parent, and hence should not 
exhibit the cardiomyopathy phenotype without a complementary knockout allele of the 
causative gene, in this case Ecsit. Similarly, Ecsit+/- animals are not known to exhibit any 
cardiomyopathy phenotype, indicating that Ecsit is haplosuffcient with regards to this 
phenotype.  
All 4 possible genotypes of the intercross were assessed for heart weight (absolute and 
normalised) at 10 weeks of age. In all cases (Figure 3.35), hearts from EcsitN209I/- animals 
show a significant increase in mass when compared to all other genotypes. This 
demonstrates that the N209I mutation is the causative allele inherited from the ENU 
mutagenized C57BL/6J ancestor and also confirms that Ecsit is haplosufficient in relation 
to the cardiomyopathy phenotype.  
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Figure 3.35. Absolute (A), and normalised to; body weight (B); and femur length, (C) heart weights from 
wild type (n=9 (M:3, F:6)), EcsitN209I/+ (A, B: n=16 (M:9, F:7) , C: n=12 (M:6, F:6)), Ecsit+/- (A, B, n=17 (M:9, 
F:8), C: n=12 (M:6, F:6)) and EcsitN209I/- (A, B: n=18 (M:9, F:9), C: n=10 (M:5, F:5)) animals. By all methods 
of assessment, EcsitN209I/- animals show a significant increase in tissue weight over all control genotypes. 
Mean ± SEM, **p<0.01, ***p<0.001, ****p<0.0001. 
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3.10. Discussion 
Through SNP mapping and whole genome sequencing a single coding mutation was 
identified in a good candidate gene, Ecsit, which results in an asparagine to isoleucine 
change at position 209 of the protein. Through successive back crosses and using Sanger 
and pyro sequencing, together with the complementation assay, the mutation was 
confirmed as causative of the primary cardiomyopathy phenotype seen in affected 
animals.  Protein prediction softwares indicate that the mutation has a deleterious effect 
on the structure or function of the protein. Given that the domains of mouse ECSIT are 
homologous to those of the human protein we can infer that the mutation lies in the 
pentatricopeptide (PPR) region of the protein, which is potentially involved in 
mitochondrial processes through binding and stabilising RNA molecules. 
The compound heterozygote of EcsitN209I and Ecsit knock-out was produced to confirm 
the genotype-phenotype interaction in the EcsitN209I/N209I- animals. A lack of phenotype 
in heterozygote (EcsitN209I/+) animals indicates that Ecsit is haplosufficient and a single 
copy of the mutant allele is insufficient to cause a phenotype. This is also seen in the 
heterozygous knockouts (Ecsit+/-), where no phenotype is present despite the loss of one 
allele.  
ECSIT is known to bind and stabilise the complex I assembly factor NDUFAF1 and to be 
involved in complex I assembly as part of the mitochondrial complex I assembly (MCIA) 
complex, however the domain responsible for this role is unclear. With this role in mind, 
phenotyping focused on traits typically associated with mitochondrial complex I 
deficiency, including lactic acidosis, failure to thrive, myopathy, cardiomyopathy, sight 
loss and encephalopathy.  
Through analysis of plasma taken from both the original backcross 1 animals, and from 
the incipient congenic line it is apparent that there are some key differences in some of 
the metabolites measured and that this reflects a change in the function of the kidney. 
Elevated potassium as well as urea and creatinine are indicative of failure of the kidney’s 
filtration barrier, indicating that the N209I mutation in ECSIT is affecting the function of 
the kidney. It is unclear if this is primary (direct effect of loss of mitochondrial function 
in kidneys) or secondary (altered cardiac function leading to kidney failure) or whether 
this may be an effect of one of the other pathways ECSIT is involved in.  
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In addition, elevated bilirubin, ALP and AST, indicate that there may be a loss of function 
of the liver including elevated bilirubin, ALP and AST. However, the differences seen 
between wild type and EcsitN209I/N209I animals in all of these metabolites is very small, 
and with the exception of a small number of outliers the ranges of the EcsitN209I/N209I 
animals overlap the wild types considerably, furthermore these values do not exceed 
the reference ranges established at MRC Harwell for these tests.  
Plasma levels of triglycerides, glycerol, ketone bodies, glucose and fructosamine, 
suggest an increased metabolism of both glucose and triglycerides and may reflect an 
energy deficiency of the heart and/or other tissues which the body is attempting to 
compensate for by increasing overall metabolism of substrates. Intra peritoneal glucose 
tolerance test (IPGTT) results show a significant improvement in glucose tolerance of 
EcsitN209I/N209I animals at one time point (T=60 minutes). Whilst this is not consistent 
across all time points it may indicate an improvement in glucose tolerance due to 
reduced fat mass in EcsitN209I/N209I animals or it may be directly related to the reduced 
glucose levels seen in the clinical chemistry results. Taken together these data may 
suggest an alteration in the metabolic phenotype of EcsitN209I/N209I animals, either 
towards metabolising glucose, as is often seen in the failing heart, or in a general 
increase in metabolism of all substrates, potentially in an attempt to compensate for a 
loss of complex I efficiency.  
Mutant animals are indistinguishable from wild type littermates up to the age of 6-8 
weeks when differences in body weight first become apparent. It is around the same 
time point that differences in cardiac tissue can first be seen, with very early tell-tale 
signs of cardiomyopathy beginning to develop, including mineralisation of tissue and 
some signs of cardiomyocyte disorganisation. At 12 weeks of age, the phenotype has 
progressed to a distinct and severe cardiomyopathy of the left ventricle with no signs of 
right ventricular involvement, and is ultimately lethal. The cardiomyopathy is 
hypertrophic in nature but has some traits typically associated with dilated 
cardiomyopathy, including an increased left ventricular volume.  
ECG measurements show no significant changes from wild type to EcsitN209I/N209I animals, 
despite the cardiomyopathy changes. Indicating that the cause of the cardiomyopathy 
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phenotype is unrelated to an electrophysiological defect and that conductive tissues are 
unaffected by the ECSIT N209I mutation.  
Whilst mutant animals appear smaller in terms of overall bodyweight and lean/fat mass, 
the length of long bones such as the femur is unchanged in comparison to wild types 
indicating that growth is normal. It is primarily the accumulation of fat that leads to 
overall body weight differences. This is further reflected in the relatively small 
differences in lean mass as late as 14 weeks of age. 
Despite profound differences in cardiac muscle, differences in skeletal muscle measured 
by grip strength were less robust, with EcsitN209I/N209I animals actually showing a 
moderately increased grip strength compared to wild types when normalised to overall 
body weight. This again is likely a reflection of the reduction in fat mass without a 
significant loss of lean or muscle mass, which would distort the normalised results. 
Further to this, muscle fibre typing shows no significant differences in fibre numbers or 
types of either soleus or EDL. EcsitN209I/N209I animals do show a reduction in cross 
sectional area of all fibre types measured in both the soleus and EDL which may be 
reflective of the loss in lean mass seen in animals at later time points. However, given 
the lack of any grip strength phenotype, this is unlikely to be a pathological loss and 
unlikely to represent a true myopathy phenotype.  
Taking into consideration the phenotypes assessed, and the lack of any obvious 
encephalopathy or neurological phenotype observed, it appears that EcsitN209I/N209Imice  
are affected by a left ventricular hypertrophic cardiomyopathy with no effects on brain, 
muscle or liver function. Some significant changes in kidney function are apparent from 
clinical chemistry analysis however it is unclear without further investigation, what the 
nature of the kidney defect is and whether it is a primary, or secondary phenotype 
associated with the severe cardiomyopathy. The overall metabolic profile of the 
EcsitN209I/N209I animals is likely significantly altered from that of the wild types, with an 
increase in glucose and triglyceride metabolism, and further work on the function of the 
mitochondria may reveal more about the causes of this.   
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Chapter 4: Effect of mutation on the Toll-
Like Receptor and Bone Morphogenetic 
Protein Pathways 
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4.1. Roles of ECSIT 
ECSIT has a diverse set of roles including as a key signal intermediary in the toll-like 
receptor response and as a co-factor of SMAD4 in the bone-morphogenetic protein 
(BMP) pathway. Previous studies have shown that knocking out ECSIT can lead to 
increased susceptibility to intracellular bacteria via a suppression of the TLR response 
[229] and embryonic lethality due to failure of gastrulation via loss of expression of 
genes under the control of the BMP pathway [230]. Either of these pathways could be 
implicated in the development of the cardiomyopathy phenotype and it was 
investigated whether either of them were affected by the N209I mutation of ECSIT.   
4.2. Toll like receptor response 
ECSIT’s role in the TLR pathway was assessed to confirm that this did not contribute to 
the phenotype observed, as an enlargement of the cardiac muscle could be attributed 
to a pro-inflammatory phenotype. Alongside its role in traditional innate immune 
response, the TLR response has been implicated in the development of myocardial 
inflammation. The most highly expressed TLR in heart is TLR4 which can cause the 
expression of pro-inflammatory cytokines via the MYD88 dependant and independent 
activation pathways, both of which involve the activation of ECSIT’s binding partner, 
TRAF6 [289]. 
To investigate the TLR response in wild type and EcsitN209I/N209I animals, three different 
approaches were used. Firstly, circulating leukocytes were assessed to determine if 
there was a shift to a pro-inflammatory phenotype. Secondly, the role of ECSIT in the 
TLR pathway was determined by assessing its interaction with the known TLR pathway 
binding partner TRAF6. Finally, bone marrow derived monocytes were isolated and 
derived into macrophages which were in turn activated with lipopolysaccharide (LPS) to 
determine if the TLR pathway was activated as normal in EcsitN209i/N209I animals.  
4.2.1. Flow cytometry of immune cells 
Fluorescence associated cell sorting (FACS) allows for the determination of proportions 
of leukocytes of each type and from this it is possible to infer if the ECSIT N209I results 
in a significant alteration of the immune phenotype of EcsitN209I/N209I animals. FACS was 
performed on whole blood collected from wild type and EcsitN209I/N209I animals and the 
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percentage of lymphocytes, monocytes, neutrophils and macrophages expressed as a % 
of total leukocytes (Figure 4.1).  
Results show no differences in the levels of monocytes or neutrophils when comparing 
wild type and EcsitN209I/N209I animals. However, a statistically significant difference is 
visible in both lymphocytes and macrophage counts, where both show a significant 
reduction in EcsitN209I/N209I animals when compared to wild type controls.  
This reduction in lymphocytes and macrophages reflects a reduced immune response in 
both innate and adaptive immunity. Unfortunately, as macrophages exist as both pro- 
(M1) and anti- (M2) inflammatory populations; and this analysis is unable to distinguish 
between the two; it is not immediately possible to determine if this result truly reflects 
a reduction in systemic inflammation or if the ratio of M1:M2 macrophages may be 
shifted towards a pro-inflammatory phenotype.  
 
Figure 4.1. Percent of leukocyte types as a % of total leukocytes identified by FACS analysis. Mono(cytes) 
and neutro(phils) show no significant changes whilst lympho(cytes) and macro(phages) both show a 
significant reduction in EcsitN209I/N209I animals compared to wild type controls. FACS analysis performed by 
Dr. Pratik Vikhe – MRC Harwell. Mean ± SEM, *p<0.05. 
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4.2.2. Co-Immunoprecipitation of ECSIT and TRAF6 
Full length wild type and mutant ECSIT created by site directed mutagenesis (AC-HIS) as 
well as TRAF6 (Entry (C, DDK-Myc)) were cloned into pCMV6 vectors (Origene) and 
transiently transfected into HEK293T cells (ECACC 12022001). Co-immunoprecipitation 
of the proteins from cell lysate using antibodies against the relevant tags (Figure 4.2) 
shows that both proteins are expressed in transfected cells (lane 2 and 3) but not in 
untransfected cells (lane 1). Co-transfecting wild type ECSIT with TRAF6 and 
immunoprecipitating with either anti-His (lane4) or anti-Myc (lane 6) primary antibody 
show that the two proteins interact and can be co-immunoprecipitated. Transfecting 
N209I ECSIT with wild type TRAF6 demonstrates that the introduction of the mutation 
by site-directed mutagenesis does not affect the interaction with TRAF6. Control lanes 
using empty His (lanes 5 and 9) and entry (Myc) vector (lanes 7 and 11), that only express 
the tag and neither of the proteins of interest, with the respective primary antibody 
demonstrate that the co-immunoprecipitation is not possible without the respective 
interacting partner protein expressed. Therefore it is possible to conclude that the N209I 
mutation of ECSIT has no effect on the interaction with TRAF6.  
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Figure 4.2. Immunoprecipitation of wild type and mutant ECSIT (His tagged) (45 and 50kDa) with full 
length wild type TRAF6 (Myc tagged) (60kDa). (A) Shows combined channels with secondary antibodies 
against mouse (green – Myc) and rabbit (red – His). (B) and (C) show the separated channels of 
demonstrating the anti-rabbit (Anti-His) and anti-mouse (Anti-Myc) secondary antibodies respectively. 1. 
Untransfected input lysate, 2. Wild type ECSIT(His) + wild type TRAF6(Myc) input lysate 3. ECSIT N209I(His) 
+ wild type TRAF6(Myc) input lysate, 4. Wild type ECSIT(His) + wild type TRAF6(Myc) anti-His 
immunoprecipitation, 5. Empty AC-His vector + wild type TRAF6(Myc) anti-His immunoprecipitation, 6. 
Wild type ECSIT(His) + wild type TRAF6(Myc) anti-Myc immunoprecipitation, 7. Wild type ECSIT(His) + 
empty entry(Myc) vector anti-Myc immunoprecipitation, 8. N209I ECSIT(His) + wild type TRAF6(Myc) anti-
His immunoprecipitation, 9. Empty AC-His vector + wild type TRAF6(Myc) anti-His immunoprecipitation, 
10. N209I ECSIT(His) + wild type TRAF6(Myc) anti-Myc immunoprecipitation, 11. N209I ECSIT + empty 
entry(Myc) vector anti-Myc immunoprecipitation.  
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4.2.3. Macrophage Stimulation with Lipopolysaccharide 
To determine if the mutation of ECSIT significantly affects activation of the toll like 
response, monocytes were isolated from the bone marrow of wild type and 
EcsitN209I/N209I animals and differentiated into macrophages before treating with 
lipopolysaccharide. Macrophages are immune cells that form part of the innate immune 
response and are typically rich in toll like receptors, including TLR4, which recognises 
LPS and acts upstream of ECSIT in the TLR response [237].  
Bone marrow derived macrophages isolated from wild type and EcsitN209I/N209I animals 
were exposed to 100ng/ml of LPS to induce the TLR response and assess the role of ECSIT 
in activating JNK, p38 MAPK and NFκB via MAP3K1 and TAK1 which form one of the final 
steps in the TLR response. The phosphorylation of the 3 proteins was assessed and 
compared to total protein expression levels to determine activation level.  
 
Figure 4.3. Quantification of p38-MAPK phosphorylation in cultured BMDMs activated with LPS. 
Representative blot shows total and phosphorylated p38-MAPK. Results indicate there are no significant 
changes between wild type and EcsitN209I/N209I BMDMs. (Mean ± SEM). 
The phosphorylation of p38MAPK was assessed on the same immunoblot as the total 
protein and phosphorylated protein primary antibodies were raised in different species 
and hence could be overlaid and separated in the green and red channels. Results show 
no increase in phosphorylation levels of p38MAPK in bone marrow derived 
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macrophages induced by LPS from EcsitN209I/N209I animals (Figure 4.3) compared to wild 
type controls. 
JNK phosphorylation was assessed across two individual immunoblots as the total and 
phosphorylated primary antibodies were raised in the same species. Protein levels were 
normalised to α-tubulin and then the level of phosphorylation determined. Results show 
no differences in total JNK protein expression (Figure 4.4) whilst levels of 
phosphorylated JNK (Figure 4.4) show a trend towards a reduction in overall 
phosphorylation but do not achieve significance. It is possible that further repeats of the 
experiment would increase the level of significance but as these results tend towards a 
reduction in inflammatory phenotype and not a pro-inflammatory phenotype, as might 
cause hypertrophy, this was not performed.  
 
Figure 4.4. Quantification of total and phosphorylated (T183/Y185) JNK and normalised to the loading 
control α-tubulin. Phosphorylated JNK is normalised to total JNK levels. Representative blots show total 
and phosphorylated JNK as well as the loading control, α-tubulin. (Mean ± SEM). 
Levels of NFκB, both total and phosphorylated, were unable to be assessed due to a lack 
of signal from both primary antibodies. This may have been due to poor storage of the 
lysates, although the same lysates were used for both the p38 MAPK and JNK 
immunoblots so this is unlikely, or it may have been due to an old or unreliable batch of 
antibody. As this was part of a larger section of work, and all other results showed a 
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trend in the same direction, it was decided not to persevere with this particular protein 
as its contribution to the overall results was likely insignificant. 
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4.3. Assessment of developmental pathways in mutant ECSIT mice 
The role of the BMP pathway has primarily been investigated in relation to the 
developing myocardium, especially the growth and differentiation of myocardium 
precursors from the primitive streak of the early embryo. However, there is an emerging 
role for BMP signalling in the differentiation of adult stem cells into cardio myocytes, 
with BMP2 seemingly playing an important role in the regeneration of cardiac tissue 
following myocardial infarction [290].  
The indispensable role of ECSIT in the bone morphogenetic protein (BMP) pathway 
occurs at a very early time point and it is difficult to tell from existing literature whether 
this pathway could contribute significantly to the cardiomyopathy phenotype. Knockout 
animals display embryonic lethality long before it would be possible to detect any 
cardiac phenotype [230]. Similarly, knockouts of ECSITs partner in the BMP pathway, 
SMAD4, also show early stage embryonic lethality. It is noteworthy that whilst this 
embryonic lethality occurs before complete heart development, it does appear that this 
process is impaired in these embryos. Cardiac cell lineages appear to begin to 
differentiate normally but normal heart development is impaired, with only primitive 
features being visible [291, 292].  Conditional knockout mice with a cardiac specific 
deletion of SMAD4 also demonstrate embryonic lethality, although this was at the 
slightly later time point of E13.5-14.5. Histology from knockout embryos revealed a 
defective alignment of cardiac outflow tracts. Despite this marked effect, heterozygous 
animals (Smad4flox/+) developed normally despite a reduction in growth factor signalling 
[293]. 
These previous studies would suggest that any significant impairment of this pathway 
should result in embryonic lethality. However, it is important to determine whether or 
not this pathway is affected by the N209I mutation and therefore if it could possibly 
have any role in cardiac phenotype development, potentially due to a reduction in 
growth factor signalling that is insufficient to result in embryonic lethality.   
4.3.1. Co-Immunoprecipitation of ECSIT and SMAD4 
The interaction of ECSIT and SMAD4 was previously demonstrated by co-
immunoprecipitation of the two proteins in mouse embryonic carcinoma cells (P19 cells) 
[230]. To determine if the N209I mutation may affect this binding event full length wild 
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type and mutant Ecsit as well as full length Smad4 were cloned into pCMV6 vectors in 
order to generate a tagged protein (Ecsit – His, Smad4 – Myc). Expression of the plasmids 
in Hek293T cells was confirmed and co-immunoprecipitation performed to assess the 
interaction of both the wild type proteins and the mutant ECSIT with wild type SMAD4. 
Co-immunoprecipitation was performed using antibodies against the relevant tags 
(mouse anti-myc, rabbit anti-6xHis) and immunoblotting visualised using the same 
primaries with fluorescent secondaries (anti-mouse alexafluor 568, anti-rabbit 
alexafluor 488). Lanes 1, 2 and 3 of figure 4.5 show the un-transfected, wild type 
ECSIT(50/45kDa)/wild type SMAD4 (60kDa) and mutant ECSIT(45/50kDa)/wild type 
SMAD4 cell lysates prior to immunoprecipitation, confirming successful transfection and 
the expression of the tagged proteins. Lane 4 (Figure 4.5) shows the wild type ECSIT co-
transfected with SMAD4 and immunoprecipitated using anti-His antibody which should 
draw down the ECSIT protein and the partnered SMAD4 protein. However, whilst it is 
possible to see the 45kDa ECSIT protein (the 50kDa protein is masked by the 50kDa 
immunoglobulin) confirming successful immunoprecipitation, the 60kDa SMAD4 is not 
present in this lane. The same is true when the reverse immunoprecipitation is 
performed (Lane 6, Figure 4.5), pulling down using the anti-Myc antibody we can see no 
presence of either of the ECSIT isoforms. Unfortunately, without the ability to confirm 
the immunoprecipitation results from Xiao et al. (2003) [230] in wild type proteins it is 
impossible to determine whether or not the N209I mutation is affecting the interaction. 
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Figure 4.5. Immunoprecipitation of wild type and mutant ECSIT (His tagged) (45 and 50kDa) with full 
length wild type SMAD4 (Myc tagged) (60kDa). (A) shows combined channels with secondary antibodies 
against mouse (green – Myc) and rabbit (red – His). (B) and (C) show the separated channels 
demonstrating the anti-rabbit (Anti-His) and anti-mouse (Anti-Myc) secondary antibodies respectively. 1. 
Untransfected input lysate, 2. Wild type ECSIT(His) + wild type SMAD4(Myc) input lysate 3. ECSIT 
N209I(His) + wild type SMAD4(Myc) input lysate, 4. Wild type ECSIT(His) + wild type SMAD4(Myc) anti-His 
immunoprecipitation, 5. Empty AC-His vector + wild type SMAD4(Myc) anti-His immunoprecipitation, 6. 
Wild type ECSIT(His) + wild type SMAD4(Myc) anti-Myc immunoprecipitation, 7. Wild type ECSIT(His) + 
empty entry(Myc) vector anti-Myc immunoprecipitation, 8. N209I ECSIT(His) + wild type SMAD4(Myc) 
anti-His immunoprecipitation, 9. Empty AC-His vector + wild type SMAD4(Myc) anti-His 
immunoprecipitation, 10. N209I ECSIT(His) + wild type SMAD4(Myc) anti-Myc immunoprecipitation, 11. 
N209I ECSIT + empty entry(Myc) vector anti-Myc immunoprecipitation.  
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4.3.2. Embryonic Expression of Tlx2 
The interaction of ECSIT with SMAD4 leads to the expression of the gene Tlx2 and 
knocking out Ecsit results in a loss of Tlx2 expression [230]. To assess if the N209I 
mutation had any effect on Tlx2 expression and therefore may be affecting the BMP 
pathway and embryogenesis, Tlx2 expression was assessed by qRT-PCR in E7.5 day 
embryos. Litters of embryos from wild type x wild type or mutant x mutant crosses were 
pooled in order to increase overall RNA yields.  
Results (Figure 4.6) indicate an approximately 50% reduction in Tlx2 expression in 
EcsitN209I/N209I embryos compared to wild types indicating that the mutation of ECSIT may 
have an effect on the BMP pathway and accordingly on the expression of downstream 
genes. However, statistical analysis was not performed as one WT sample had to be 
excluded due to inconsistent results.  
 
Figure 4.6. Relative gene expression of Tlx2 in wild type and EcsitN209I/N209I pooled embryos shows a 
reduction in the expression of Tlx2 expression in EcsitN209I/N209I embryos at E7.5. Mean ± SEM. 
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4.4. Discussion 
The role of ECSIT in both the TLR and BMP response has the potential to explain the 
cardiomyopathy phenotype observed. Such functional studies will also help define 
important functional domains with the ECSIT protein. However, from the results 
obtained here it isn’t possible to draw meaningful conclusions about the role of these 
pathways in the development of this phenotype, or indeed that this mutation can be 
considered pathogenic in either of these pathways. Further investigation into these 
pathways specifically in heart tissue may reveal more about the individual contribution 
of these pathways to HCM, or how ECSIT may link these pathways to a metabolic 
impairment, ultimately leading to HCM.  
Results from experiments assessing the TLR pathway and its activation appear to show 
that ECSIT is still able to perform its role normally with respect to binding to TRAF6 and 
activating downstream proteins through indirect phosphorylation. The interaction of 
ECSIT with TRAF6 in human is known to occur between amino acids 200 and 257 of the 
human ECSIT protein [239], which aligns well with the mouse protein. This would place 
the N209I mutation at the start of this region and make this pathway an obvious 
candidate to suffer a significant loss of function. However, as can be seen from the co-
immunoprecipitation performed with TRAF6, it does not appear that the mutation 
affects the binding of the two proteins and given its position, it is unlikely to affect the 
ubiquitination of ECSIT at K372 [238]. Furthermore, the downstream phosphorylation of 
2 of the 3 key proteins (p38 MAPK and JNK) that are activated by this interaction show 
no significant changes in phosphorylation levels and are unlikely to result in a pro-
inflammatory phenotype that could cause inflammation or enlargement of the cardiac 
muscle. Unfortunately, due to the issues with antibodies against NFκB it wasn’t possible 
to determine if the N209I mutation may affect the formation of the TAK1-ECSIT-TRAF6 
complex [239] that would lead to activation of IKK proteins and ultimately NFκB 
phosphorylation. 
Despite gaps in the data, results do not implicate the effect of the N209I mutation on 
the TLR response as the main driving force behind the phenotype development. As this 
work was undertaken in macrophages, there may still be a great deal to learn from 
investigating the pathway further in heart tissue, or specifically in cardiomyocytes.  
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Unfortunately, results relating to the role of ECSIT in the BMP pathway are mixed. There 
are no signs of reduced viability of EcsitN209I/N209I embryos indicating that the pathway is 
not significantly impacted. However, there is a reduction in the expression of Tlx2 in 
EcsitN209I/N209I embryos at E7.5 suggesting that the mutation of ECSIT does affect 
signalling through the pathway to a measurable degree. It is important to note that 
these results are taken from pooled embryos and it is difficult to age match embryos at 
such a small and early time point, and to ensure that the entire embryo is collected 
correctly.  
The co-immunoprecipitation of ECSIT with SMAD4 may have provided much needed 
clarity on the issue however as this was unsuccessful, further investigation is warranted.  
Taken together these data seem to indicate that the mutation of ECSIT does not result 
in a null allele with regards to its function in the BMP pathway, as embryos that are 
homozygotes are born at the expected mendelian ratio and Tlx2 expression, whilst 
reduced, is present.  
Overall these data provide an incomplete picture of the role of ECSIT in the BMP and 
TLR pathways and further investigation is warranted. However, given the minimal 
changes seen in these pathways, it seems prudent to investigate a mitochondrial role 
for ECSIT further before focusing on small changes to these pathways.  
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Chapter 5: Characterisation of 
Mitochondrial Function 
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5.1. Introduction 
With data implicating the toll like receptor response and the bone morphogenetic 
pathway as causes of the phenotype seen in EcsitN209I/N209I animals mixed, the focus 
shifted towards the more obvious candidate pathway; ECSIT’s role in complex I 
assembly. Several papers had shown how ECSIT interacts with a number of other 
complex I assembly factors (ACAD9, NDUFAF1, TMEM126B and TIMMDC1) to form the 
mitochondrial complex I assembly (MCIA) complex and assist in the assembly process. 
As it is established that defects in mitochondrial function can lead to cardiomyopathy, 
amongst other phenotypes, this process warranted in depth investigation. Assessment 
of mitochondrial function began with structural analysis and quantification before 
determining the protein levels and function of the electron transport chain through a 
variety of methods including seahorse analysis of cultured cells and isolated 
mitochondria. ECSIT protein levels and its interaction with known binding partners was 
also assessed by SDS-PAGE and co-immunoprecipitation, revealing a previously 
undescribed 16kDa fragment detected by the antibody in wild type cardiac tissue but 
absent from mutants, offering a potential mechanism for the tissue specific phenotype 
seen.  
Once dysfunction was established, it was possible to begin looking at how the mutation 
of ECSIT affects the construction of complex I and investigate this across tissues. This 
work demonstrates that ECSIT may work differently in heart and brain, leading to tissue 
differences in complex I assembly. 
Finally, work was undertaken to identify the 16kDa fragment detected in wild type 
cardiac tissue using immunoprecipitation and mass-spectrometry.    
5.2. Structure and Quantification 
Structure of mitochondria as well as total mitochondrial mass are assessable via a variety 
of methods. Mitochondrial structure was assessed by transmission electron microscopy 
examining the cross sectional area of mitochondria as well as the structure of the cristae. 
Quantification of mitochondria was attempted using a variety of different methods due 
to the variability between them. Mitochondrial DNA quantification does not necessarily 
reflect an increase or decrease in total mitochondrial mass due to a non-linear 
relationship between mtDNA and actual mass. Inner and outer mitochondrial 
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membrane proteins may give a better reflection of total mitochondrial mass however 
variation between the two membranes can occur with variations in mitochondrial 
structure.  
5.2.1. Transmission Electron Microscopy 
Transmission electron microscopy (TEM) images of wild type and EcsitN209I/N209I cardiac 
mitochondria demonstrate some qualitative changes in mitochondrial ultrastructure in 
mutant animals (Figure 5.1). Both interfibrillar and perinuclear mitochondria in wild type 
samples show a characteristic shape and evenly stacked cristae structure with no signs 
of disorganisation or mitochondrial swelling. Sub-sarcolemmal mitochondria were not 
imaged due to limitations with sample preparation and access to TEM facilities. When 
compared to wild type controls, interfibrillar mitochondria from EcsitN209I/N209I hearts 
have some signs of highly condensed cristae, forming uneven stacks through the 
mitochondria. Also apparent are disorganised cristae which do not form the clean, 
uniform stacks seen in wild type mitochondria. Perinuclear mitochondria from 
EcsitN209I/N209I hearts also show signs of cristae disorganisation, although no signs of 
hyper condensed cristae were seen in this sub-population. It is difficult to quantify what 
proportion of mitochondria display these characteristics in each population as the 
cristae are not clearly visible in each mitochondria to the same degree, many 
mitochondria in EcsitN209I/N209I tissues did not show any of the cristae abnormalities 
mentioned here.   
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Figure 5.1. Representative TEM images of wild type and EcsitN209I/N209I interfibrillar and perinuclear 
mitochondria from cardiac tissue demonstrating structural abnormalities observed in EcsitN209I/N209I 
samples. Wild type interfibrillar (A) and perinuclear (B) mitochondria demonstrate consistent evenly 
stacked cristae with no signs of disorganisation. Mutant interfibrillar mitochondria demonstrate 
phenotypes such as hyper condensed (C) and disorganised cristae (D). Perinuclear mitochondria from 
mutant hearts also demonstrate disorganisation (E and F) although hyper packed cristae were not 
observed. Scale bars = 500nm.  
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To determine if there was any mitochondrial swelling present in EcsitN209I/N209I cardiac 
mitochondria, cross sectional areas of mitochondria from all populations were assessed 
in FIJI (Image J) by manually drawing around whole visible mitochondria and measuring 
the area within the double membrane (Figure 5.2). Mitochondria without a complete 
membrane in view in an image were excluded from this analysis. Contrary to what might 
be expected, results demonstrate a small reduction in cross sectional area of both 
interfibrillar and perinuclear mitochondria in EcsitN209I/N209I cardiac tissue, although this 
result is not statistically significant with the small n number used.  
 
Figure 5.2. Cross sectional areas of mitochondria were assessed in wild type and EcsitN209I/N209I animals in 
both interfibrillar and perinuclear mitochondria populations. Results demonstrate a small reduction in 
mitochondrial sizes in EcsitN209I/N209I populations which does not achieve statistical significance. 
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5.2.2. Nuclear to Mitochondrial DNA ratio 
A crude method for quantification of total mitochondria is to assess the ratio of 
mitochondrial DNA (mtDNA) to nuclear DNA (nDNA) in a tissue or cell sample of interest. 
DNA was isolated from heart tissue taken from 16 week old wild type and EcsitN209I/N209I 
animals and assessed using NovaQUANT™ mouse mitochondrial to nuclear ratio kit. This 
kit uses quantitative PCR to determine the copy number of 2 nuclear (Becn1 and Neb) 
and 2 mitochondrial genes (trLEV and 12S) and through comparison of copy number it 
is possible to determine mtDNA copy number compared to nDNA. Three male and 3 
female wild type EcsitN209I/N209I animals were compared, however, results from one plate 
(female samples) showed no amplification from nuclear genome DNA and were 
excluded from the final analysis. Results (Table 5.1) show no significant differences in 
the copy number of the mtDNA between wild type and EcsitN209I/N209I animals (Figure 
5.3). However, a significant caveat to this observation is the great deal of variance in the 
EcsitN209I/N209I samples in comparison to the tightly clustered wild type samples, 
furthermore, small N numbers limit meaningful interpretation of the results. Taking this 
result as it is, there do not appear to be gross differences in the mtDNA copy number 
between wild type and EcsitN209I/N209I animals in heart tissue, although further 
investigation is warranted.  
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Figure 5.3. Novaquant™ mouse mitochondrial to nuclear ratio kit results showing mitochondrial DNA copy 
number in cardiac left ventricle tissue as a multiple of nuclear DNA copy number. Results show no 
significant difference in the mean of the two genotypes. (Mean ± SEM)  
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Sample Target Ct ΔCt 2ΔCt 
Average copy mtDNA 
number 
Ecsit+/+ 1 
trLEV 19.082 
10.810 1795.3 
1822 
Becn1 29.892 
12S 17.662 
10.852 1848.3 
Neb 28.514 
Ecsit+/+ 2 
trLEV 18.187 
10.592 1543.5 
1567 
Becn1 28.779 
12S 16.795 
10.635 1590.2 
Neb 27.43 
Ecsit+/+ 3 
trLEV 18.303 
10.667 1625.9 
1881 
Becn1 28.97 
12S 16.952 
11.061 2136.5 
Neb 28.013 
EcsitN209I/N209I 1 
trLEV 16.081 
12.168 4601.9 
4484 
Becn1 28.249 
12S 14.767 
12.092 4365.7 
Neb 26.859 
EcsitN209I/N209I 2 
trLEV 15.563 
11.242 2422.0 
2172 
Becn1 26.805 
12S 14.269 
10.908 1921.5 
Neb 25.177 
EcsitN209I/N209I 3 
trLEV 15.732 
10.351 1306.1 
1290 
Becn1 26.083 
12S 14.549 
10.315 1273.9 
Neb 24.864 
 
Table 5.1. Novaquant™ mouse mitochondrial to nuclear ratio kit results showing mitochondrial DNA copy 
number in cardiac left ventricle tissue as a multiple of nuclear DNA copy number. Nuclear and 
mitochondrial genes are divided into 2 pairs (mtNDA/nDNA) for analysis (trLEV/Becn1, 12S/Neb).  
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5.2.3. Protein 
In contrast to mtDNA copy number, which may vary regardless of mitochondrial mass, 
mitochondrial membrane proteins may be quantified for a more accurate 
representation of overall mitochondrial mass when normalised to a cytosolic protein 
such as α-tubulin. Two proteins were quantified, TOMM20, a mitochondrial outer 
membrane protein, and COXIV, a mitochondrial inner membrane protein. The 
quantification of these two proteins may also provide clues about changes in 
mitochondrial morphology, as a differential change in one over the other may represent 
a change in the abundance of one membrane over the other. Results (Figure 5.4) show 
no significant differences between wild type and EcsitN209I/N209I inner or outer 
mitochondrial membrane proteins in cardiac tissue.  This result indicates that the 
mitochondrial mass per cell in the heart is unchanged, although as could be seen in 
histology, cell size is increased so it is possible to interpret that the overall mitochondrial 
mass of the heart is increased accordingly.  
 
Figure 5.4. Normalised protein expression levels of inner mitochondrial membrane protein COXIV (A) and 
outer mitochondrial membrane protein TOMM20 (B). Showing no differences in protein levels between 
wild type and EcsitN209I/N209I animals. (Mean ± SEM). 
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5.2.4. Biogenesis 
In addition to determining the existing mass of mitochondria within cardiac tissue, it is 
also possible to determine the cellular demand for the production of new mitochondria, 
or mitochondrial biogenesis in tissues. Protein levels of the master regulator of 
mitochondrial biogenesis, PGC1α, show a significant upregulation in cardiac tissue of 
EcsitN209I/N209I animals over wild types indicating increased mitochondrial biogenesis, 
although this is not reflected in actual mitochondrial mass. Other tissues tested, liver, 
kidney and brain do not reflect the upregulation of PGC1α indicating that this is a tissue 
specific change in demand, isolated to the heart tissue. 
 
Figure 5.5. Quantified protein levels and representative immune blots of mitochondrial biogenesis 
regulator PGC1α normalised to VDAC are elevated in cardiac tissue of EcsitN209I/N209I animals compared to 
wild type controls (A). Levels in other tissues, brain (B), kidney (C) and liver (D) remain significantly 
indistinguishable from wild types. Mean ± SEM, **p<0.01. 
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5.3. Electron Transport Chain Function 
As results indicated that the N209I mutation in ECSIT was unlikely to result in a pro-
inflammatory phenotype through the TLR response and differences in the BMP pathway 
were inconclusive, further work was focused on the role of ECSIT in the assembly of 
mitochondrial complex I. To determine if and how this role was affected, complex I levels 
and activity as well as the assembly process was assessed in a variety of tissues. As the 
primary phenotype was cardiac, initial characterisation took place in mitochondria and 
tissue lysates from the heart. Further investigation was also carried out in brain tissue 
as this is a tissue typically associated with complex I deficiency related phenotypes. 
Where possible comparisons have also been made to kidney, liver and muscle samples. 
5.3.1. Electron transport chain proteins 
Quantification of electron transport chain proteins was used as a crude assessment of 
overall complex levels and activity across all tissues available. Tissues tested were taken 
from male (n=3) and female (n=3) wild type and EcsitN209I/N209I animals at 16 weeks of 
age. Results show a consistent reduction in complex I protein (NDUFB8) levels across 
tissues tested (Figures 5.6-5.10) with the exception of skeletal muscle. The most 
significantly affected of these tissues is the heart, with a >95% reduction in total complex 
I protein levels. Other tissues form a continuum from no (muscle) or very mild (brain) 
affect to a moderate reduction (liver) indicating that the effect of the N209I mutation in 
ECSIT does not uniformly affect complex I production across all tissue and cell types. 
None of the tissues tested show a reduction in any of the remaining electron transport 
chain proteins tested, and interestingly, none show an elevation of the remaining 
proteins as might be seen with a potential compensatory effect.  
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Figure 5.6. Quantification of cardiac electron transport chain proteins (A) NDUFB8 (CI), SDHA (CII), 
UQCRC2 (CIII), MTCO1 (CIV) and ATP5A (CV) from wild type and EcsitN209I/N209I. Results show a significant 
reduction in the complex I protein NDUFB8 in EcsitN209I/N209I heart tissue, with no changes in any of the 
remaining complexes. Representative blots (B) reflect this change with a profound loss of NDUFB8 seen 
in EcsitN209I/N209I (HOM) samples. Mean ± SEM, **p<0.01. 
 
Figure 5.7. Quantification of brain electron transport chain proteins (A) NDUFB8 (CI), SDHA (CII), UQCRC2 
(CIII), MTCO1 (CIV) and ATP5A (CV) from wild type and EcsitN209I/N209I. Results show a significant reduction 
in the complex I protein NDUFB8 in EcsitN209I/N209I brain tissue, with no changes in any of the remaining 
complexes. Representative blots (B) reflect this change with a slight reduction of NDUFB8 seen in 
EcsitN209I/N209I (HOM) samples. Mean ± SEM, ***p<0.001. 
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Figure 5.8. Quantification of kidney electron transport chain proteins (A) NDUFB8 (CI), SDHA (CII), UQCRC2 
(CIII), MTCO1 (CIV) and ATP5A (CV) from wild type and EcsitN209I/N209I. Results show a significant reduction 
in the complex I protein NDUFB8 in EcsitN209I/N209I kidney tissue, with no changes in any of the remaining 
complexes. Representative blots (B) reflect this change with a slight reduction of NDUFB8 seen in 
EcsitN209I/N209I (HOM) samples. Mean ± SEM, **p<0.01. 
 
Figure 5.9. Quantification of liver electron transport chain proteins (A) NDUFB8 (CI), SDHA (CII), UQCRC2 
(CIII), MTCO1 (CIV) and ATP5A (CV) from wild type and EcsitN209I/N209I. Results show a significant reduction 
in the complex I protein NDUFB8 in EcsitN209I/N209I liver, with no changes in any of the remaining complexes. 
Representative blots (B) reflect this change with a moderate reduction in NDUFB8 seen in EcsitN209I/N209I 
(HOM) samples. Mean ± SEM, **p<0.01. 
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Figure 5.10. Quantification of skeletal muscle electron transport chain proteins (A) NDUFB8 (CI), SDHA 
(CII), UQCRC2 (CIII), MTCO1 (CIV) and ATP5A (CV) from wild type and EcsitN209I/N209I. Results show no 
significant changes in any of the electron transport chain proteins assessed. Representative blots (B) show 
no consistent changes between wild type and mutant samples. Mean ± SEM. 
5.3.2. Other Complex I proteins 
As complex I is a large protein with many sub-complexes and a convoluted assembly 
process, it is foreseeable that the reduction in NDUFB8 levels seen in the previous 
section may not hold true for all complex I proteins or subcomplexes. To investigate this, 
a selection of proteins from each of the complex I sub-complexes was blotted to 
determine protein levels in both heart (Figure 5.11) and brain (Figure 5.12) tissue. 
Tissues tested were taken from male (n=3) and female (n=3) wild type and EcsitN209I/N209I 
animals at 16 weeks of age. The proteins tested show a significant reduction in the levels 
of all complex I sub-complexes but not in all proteins tested. NDUFV2 is a constituent of 
the N sub-complex and shows a reduction in both heart and brain tissue, however, as 
with NDUFB8 this reduction is more severe in cardiac tissue (>95%) than in brain tissue 
(~25%). Constituent proteins of the Q sub-complex, NDUFS2 and S8, show a less 
significant reduction in heart tissue (70-90%) than NDUFV2, whilst the protein NDUFS3 
does not show a significant reduction at all in heart tissue. In the brain this same pattern 
is seen, however, the level of reduction of the affected proteins is less severe in brain 
tissue (30-40%) than in cardiac, with NDUFS3 unchanged. One of the proteins of the 
proximal portion of the membrane arm, NDUFC2 shows the same pattern of significant 
reduction in heart (>95%) with only a moderate decrease in brain (~50%). The other, 
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NDUFA8 shows a steep reduction in heart (>95%) with no difference in brain. 
Unfortunately, MT-ND1, which shows no difference in cardiac tissue was unable to be 
detected in brain tissue. The proteins of the distal portion of the membrane arm 
demonstrate the most consistent results in both tissues NDUFB11 and B3 show a greater 
reduction in cardiac tissue (70-80%) than in brain tissue (~25%). Finally, the accessory 
protein, NDUFA10 maintains the trend with a greater than 95% reduction in heart tissue 
and only a 25% reduction in brain tissue. Taken together, these data suggest that the 
effect of the N209I mutation in ECSIT is not observed uniformly across all proteins and 
sub-complexes of complex I with proteins of the membrane arm more consistently 
affected than those in the N or Q subunits. It is also noteworthy that the mitochondrially 
encoded protein MT-ND1 was the only protein of the membrane arm tested that 
showed no significant reduction in cardiac tissue.  
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Figure 5.11. Quantification (A) and representative blots (B) of other complex I proteins in heart tissue. The 
proteins tested represent the various subcomplexes of complex I, N (V2), Q (S2, S3, S8), PP (ND1, A8, C2), 
PD (B11, B3) and the accessory protein NDUFA10. Quantification (Normalised to VDAC, relative to WT 
average) shows a significant reduction in protein levels of all except 2 proteins, NDUFS3 and MT-ND1. 
Mean ± SEM, *p<0.05, ***p<0.001. 
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Figure 5.12. Quantification (A) and representative blots (B) of other complex I proteins in brain tissue. As 
in heart tissue proteins tested represent the various subcomplexes of complex I, N (V2), Q (S2, S3, S8), PP 
(ND1, A8, C2), PD (B11, B3) and the accessory protein NDUFA10. Quantification (Normalised to VDAC, 
relative to WT average) shows a significant reduction in protein levels of NDUFS2, S8, C2, B11, B3, A10. 
NDUFV2, S3 and A8 show no significant changes in protein levels in brain tissue and MT-ND1 was 
undetectable on blots. Mean ± SEM, *p<0.05, **p<0.01, ****p<0.0001. 
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5.3.3. Electron Transport Chain Proteins in 2 Week Old Hearts 
The changes in complex I protein levels are most distinct in cardiac tissue with a >95% 
reduction in complex I protein levels whilst other tissues show a comparatively modest 
reduction. As the tissue samples used for previous immunoblotting were obtained from 
16 week animals, long after the onset of the cardiac phenotype, it is difficult to 
determine if the complex I deficiency is causative of the cardiac phenotype, or if the 
ECSIT N209I mutation affects the tissue in a different manner and the complex I 
deficiency is secondary to this effect.  
To investigate this further, cardiac tissue was collected from 2-week old wild type and 
EcsitN209I/N209I animals to determine if the mitochondrial dysfunction precedes the 
cardiac phenotype first seen at around 4 weeks of age. Western blots were performed 
in the same manner as those shown previously. Results (Figure 5.13) demonstrate a 
reduction in complex I protein levels (NDUFB8) as was seen in 16-week old cardiac tissue 
though at this time point it is of a smaller magnitude (~60%). As with the 16 week old 
hearts, no changes in any other mitochondrial complexes are apparent in the 2 week old 
hearts.  
 
Figure 5.13. Quantification of cardiac electron transport chain proteins (A) NDUFB8 (CI), SDHA (CII), 
UQCRC2 (CIII), MTCO1 (CIV) and ATP5A (CV) from wild type and EcsitN209I/N209I 2 week old hearts. Results 
show a consistent reduction in the complex I protein NDUFB8 in EcsitN209I/N209I heart tissue, as well as a 
consistent elevation of complex IV protein MTCO1. Representative blots (B) reflect the changes seen in 
the quantification. (Mean ± SEM), **p<0.01. 
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5.3.4. In Gel Activity 
Whilst a reduction in complex I proteins gives an idea of how much complex I is available 
to function as part of the electron transport chain, it does not reflect the true levels of 
the fully assembled complex or the activity of those fully assembled units. By isolating 
intact mitochondria from tissue and running on native first dimensional PAGE it is 
possible to isolate the intact complex I and assess its activity by supplying substrate in 
the form of NADH. This assay couples the oxidation of NADH to the reduction of the 
compound nitro-blue tetrazolium which forms a dark blue stain when reduced. 
Accordingly, the depth of the staining corresponds directly to the activity of the fully 
assembled complex I. Mitochondria were isolated from male (n=3) and female (n=3) wild 
type and EcsitN209I/N209I animals at 16 weeks of age. 
Whilst difficult to quantify, the results in figure 5.14 demonstrate a reduction in complex 
I activity in EcsitN209I/N209I hearts when compared to wild type. Furthermore, whilst a 
significant reduction in complex I protein levels was seen in brain, the same difference 
is not apparent in the activity of complex I seen in figure 5.14. It is also worth noting the 
presence of super-complexes in the wild type lanes of the heart, and in both wild type 
and mutant lanes in the brain. The formation of these super-complexes is dependent on 
the presence of complex I and the absence of any super-complexes in the EcsitN209I/N209I 
lanes of the heart assay is another indication that complex I levels are significantly 
reduced.  
In addition to complex I activity, it is also possible to assess complex IV activity by a 
similar means. In this case, complex IV is isolated as with complex I above, and supplied 
with reduced cytochrome C as a substrate. The oxidised cytochrome C then oxidizes DAB 
to form a brown stain corresponding to the level of complex IV activity. As can be seen 
in figure 5.15, and as with the protein levels shown previously, this assay demonstrates 
no changes in complex IV activity between wild type and EcsitN209I/N209I animals in either 
heart or brain tissue. This supports the hypothesis that ECSIT is only involved in complex 
I assembly and plays no role in the activity of other electron transport chains.  
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Figure 5.14. In gel activity assay of complex I in mitochondria isolated from heart and brain tissue of wild 
type and EcsitN209I/N209I animals. Depth of stain corresponds to complex I activity with deeper staining 
reflecting greater activity. Results show a reduction in complex I activity of EcsitN209I/N209I hearts, whilst 
brains show no differences between genotypes.  
 
Figure 5.15. In gel activity assay of complex IV in mitochondria isolated from heart and brain tissue of wild 
type and EcsitN209I/N209I animals. Depth of stain corresponds to complex IV activity with deeper staining 
reflecting greater activity. Results show no differences between wild type and EcsitN209I/N209I animals in 
either mitochondria isolated from heart or brain.  
5.3.5. Complex I Assay 
Due to the difficulty in accurately quantifying the in gel activity of complex I, a further 
experiment using a plate based assay was performed. This assay captures the intact 
complex I on the plate using a monoclonal antibody before a substrate is supplied 
allowing complex I to couple the oxidation of NADH to NAD+ to the reduction of a die 
that absorbs light at 450nm. The increase in absorbance at 450nm over time can then 
be plotted, with the slope of the line corresponding to the level of complex I activity.  
For this assay, complex I from both heart (WT n=6, HOM n=6) and brain (WT n=6, HOM 
n=6) lysates was used to determine the activity of complex I in wild types and 
EcsitN209I/N209I in both tissues. From figure 5.16 it is apparent that the slope of the lines 
in both EcsitN209I/N209I heart and brain differs significantly from the wild type. Figure 5.16-
A shows the individual plotted averages from heart samples at each time point with 
error, demonstrating that EcsitN209I/N209I samples give a negative slope with regards to 
176 
 
optical density over time. This would indicate that complex I is either not present or is 
completely inactive in this tissue as no change in NADH oxidation can be observed. 
Complex I activity in both wild type and EcsitN209I/N209I brains show a positive slope and 
whilst the difference in slope is significant (Figure 5.16) the EcsitN209I/N209I samples show 
a similar slope to wild type samples taken from the heart tissue of the same animals.   
Taken together these data indicate that there is a significant impairment of complex I 
activity in the heart tissue of EcsitN209I/N209I animals and there is a significant although 
less profound reduction in the complex I activity in brains of these same animals when 
compared to wild types. It is important to note that this assay is antibody based and if 
the complex I in heart is unable to bind to the antibody then no activity would be 
observed. It is also noteworthy that EcsitN209I/N209I brain shows a similar level of complex 
I activity to wild type heart.  
 
Figure 5.16. Plotted average optical density (OD) at 450nm, against time in heart (A) and brain (B) of wild 
type (n=6) and EcsitN209I/N209I (n=6) samples.  Average slope for each genotype (C) reveals significant 
differences between wild type and EcsitN209I/N209I animals in both tissues, however, EcsitN209I/N209I in brain 
shows a similar level of activity to wild type hearts. Mean ± SEM, *p<0.05, ***p<0.001. 
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5.3.6. Seahorse Analysis of Mouse Embryonic Fibroblasts 
To determine if the loss of complex I protein levels and activity translated to an in vitro 
loss of electron transport chain function, mouse embryonic fibroblasts (MEFs) were 
cultured from wild type and EcsitN209I/N209I embryos and seahorse was performed to 
measure the response of the cells to a variety of metabolically active compounds.  
Basal rates of both oxygen consumption (OCR) and extra cellular acidification (ECAR) 
were initially measured for 5 cycles to determine the typical respiration rates of the cells 
without the introduction of any compounds to induce metabolic stress. Under basal 
conditions no significant differences were observed in either OCR (Figure 5.17-A) or in 
ECAR (Figure 5.17-B) in cultured MEFs.  
Following the basal measurements, oligomycin is added which inhibits the ATP synthase 
and blocks the electron transport chain. This test indicates whether there is an increased 
‘leakiness’ of the mitochondrial membrane. This is due to the fact that the electron 
transport chain is unable to continue to function as the H+ gradient builds up across the 
inner membrane without the activity of ATP synthase gradually transporting protons in 
order to power ATP synthesis. Again, no differences can be seen in either OCR or ECAR 
between wild type and EcsitN209I/N209I MEFs.  
To measure maximal oxygen consumption without the inhibitory effect of the H+ ion 
gradient across the mitochondrial inner membrane FCCP is added which collapses the 
gradient. Under these conditions a small but not statistically significant difference can 
be seen between wild type and EcsitN209I/N209I MEFs indicating that there may be small 
reduction in the electron transport chain function of these cells, potentially due to the 
loss of complex I protein.  
Finally, rotenone and antimycin A act as complete blocks in the electron transport chain 
by inhibiting ubiquinone and complex III and preventing the passage of electrons 
through the chain. Measurements taken at this point represent non-ETC oxygen 
consumption and can be compared to measurements taken under the influence of 
oligomycin to determine the oxygen consumption as a result of H+ ion leakage across 
the inner mitochondrial membrane. As with the measurements taken in the presence of 
oligomycin there are no differences in either OCR or ECAR between wild type and 
EcsitN209I/N209I MEFs.  
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Taken together these data suggest that the ECSIT N209I mutation has no effect on the 
ECAR of cultured MEFs, indicating that glycolysis levels are maintained at normal levels 
despite the loss of complex I protein. Results also demonstrate a small reduction in the 
maximal OCR of cultured EcsitN209I/N209I MEFs when compared to wild type controls 
which does not achieve statistical significance. Without any changes in basal or minimal 
oxygen consumption rates, these data suggest that these mitochondria do not have a 
significant structural defect and are capable of functioning under normal, ‘un-stressed’ 
conditions and may only contribute to a phenotype under stressed conditions. However, 
without statistical significance, further investigation is required to determine if this small 
effect is relevant to the phenotype observed in EcsitN209I/N209I animals.  
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Figure 5.17. Oxygen consumption rate (A) and extra cellular acidification rate (B) of cultured wild type 
(n=4) and EcsitN209I/N209I (n=4) mouse embryonic fibroblasts. Compounds to induce different respiration 
states are added to the media between measurements and oxygen consumption at each state is 
measured. Results show no significant changes in oxygen consumption between wild type and 
EcsitN209I/N209I MEFs in either oxygen consumption or extra cellular acidification rates. Mean ± SEM.  
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5.3.7. Seahorse Analysis of Isolated Neonatal Cardiomyocytes 
As relatively small, non-significant differences were seen in MEFs from wild type and 
EcsitN209I/N209I animals and given the tissue specific results seen in protein levels in 
addition to activity levels it would appear that tests on MEFs would not accurately 
represent the potential complex I deficiency seen in EcsitN209I/N209I cardiac tissue. To 
account for this seahorse measurements on cultured neonatal mouse cardiomyocytes 
were attempted to better investigate the observed in vivo defect. To begin with, 
neonatal cardiomyocytes were isolated and cultured only from wild type animals to 
validate the protocol and perform titrations of cell concentration and compounds for 
optimum seahorse results. Results (Figure 5.18) from these titrations showed a cell 
concentration of 100,000 cells/well was optimal to give a robust OCR curve without 
affecting oxygen partial pressure. For FCCP, a concentration of 4µM was selected as it 
gave a more robust response than any lower levels and higher concentrations gave 
negligible increase in OCR whilst increasing the likelihood of toxic effects. 
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Figure 5.18. Oxygen consumption rates of wild type neonatal cardiomyocytes under cell (A) and FCCP (B) 
titration conditions. Results indicate that 100K cells/well provides the best oxygen consumption curve and 
that 4µM FCCP gave a robust response. 
Despite these early successes in culturing and measuring oxygen consumption in wild 
type cardiomyocytes, it was not possible to obtain any results from EcsitN209I/N209I 
cardiomyocytes. When isolated EcsitN209I/N209I failed to thrive in tissue culture and 
showed none of the characteristic signs of spontaneous contraction and spreading as 
was seen in the wild type. Nonetheless, seahorse experiments were attempted and 
oxygen consumption curves showed no response of mutant cells to any of the 
compounds (oligomycin, FCCP, rotenone/antimycin A) added to the media during OCR 
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measurements. As a result, this approach was abandoned in favour of isolated 
mitochondria.  
5.3.8. Seahorse Analysis of Isolated Mitochondria 
Because of difficulties using both MEFs and cardiomyocytes, and to further investigate 
mitochondrial function in the relevant tissues, mitochondria from wild type and 
EcsitN209I/N209I heart and brain were isolated and seahorse analysis was performed. This 
assay determines if the defects in complex I assembly in multiple tissues result in an ex 
vivo loss of mitochondrial function or if mitochondria were capable of functioning 
relatively normally despite a reduction in complex I levels. For this assay, mitochondria 
were isolated from hearts and brains of wild type and EcsitN209I/N209I animals and plated 
on a seahorse XF24 plate. The seahorse then measures oxygen consumption of the 
mitochondria as various compounds are added to induce different mitochondrial 
respiration states.  
Mitochondria begin in state II (pseudo state IV) where substrate is available in the form 
of glutamate and malate but the absence of ADP forces the mitochondria into a low 
oxygen consumption state. Readings taken at this time (Figure 5.19) demonstrate no 
difference between any of the four groups tested. After adding ADP mitochondria 
increase their oxygen consumption as respiration increases into state III, and is limited 
only by the speed of the respiratory chain. Here it is apparent that mitochondria from 
EcsitN209I/N209I hearts have a deficiency in respiratory chain activity (Figure 5.19) as can 
be seen by the reduction in oxygen consumption compared to wild type heart 
mitochondria as well as both wild type and EcsitN209I/N209I brain mitochondria. The 
addition of oligomycin inhibits the ATP synthase and blocks respiration through the 
electron transport chain, resulting in a dramatic decrease in oxygen consumption. This 
is an artificial state IV (state IVo), as the rate of respiration is decreased by the presence 
of oligomycin and not by a lack of ADP in the substrate. At this point there are no 
differences between any of the mitochondrial groups tested. FCCP then uncouples 
oxygen consumption by the ETC from ATP production and allows for maximal oxygen 
consumption during an uncoupled state III (state IIIu). In state IIIu, mitochondria from 
EcsitN209I/N209I hearts show no significant changes in oxygen consumption from the state 
III rate measured previously, whilst wild type heart mitochondria show an increase in 
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oxygen consumption rate. This lack of increased O2 consumption demonstrates a lack of 
reserve capacity of the EcsitN209I/N209I heart mitochondria and is reflected in a significant 
difference between wild type and EcsitN209I/N209I heart mitochondria at this 
measurement, no significant differences were observed between wild type and 
EcsitN209I/N209I brain mitochondria. The final measurement takes place in the presence of 
antimycin a, which binds to and blocks complex III, preventing any oxygen consumption 
by the electron transport chain. At this point, oxygen consumption rates should be 0, 
however this is rarely the case due to incomplete binding, leakage and other cellular or 
mitochondrial processes. As with the state IVo, there are no significant differences 
between any of the groups measured.  
 
Figure 5.19. Seahorse oxygen consumption rate measurements from wild type and EcsitN209I/N209I heart 
and brain mitochondria. Compounds to induce different respiration states are added to the media 
between measurements and oxygen consumption at each state is measured. Significant differences can 
be seen between wild type and EcsitN209I/N209I heart mitochondria during state III and state IIIu respiration. 
No differences are seen between wild type and EcsitN209I/N209I brain mitochondria. Mean ± SEM, *p<0.05. 
Taken together these data demonstrate a loss of function of the electron transport chain 
of EcsitN209I/N209I heart mitochondria. However, the mitochondria do retain some residual 
activity that appears to be sufficient for low steady state respiration, but insufficient to 
increase respiration during periods of high demand. Furthermore, brain mitochondria 
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from both genotypes show no significant changes in respiration despite a decrease in 
complex I protein levels demonstrated previously.  
5.4. ECSIT 
Whilst it is apparent that complex I protein levels, activity and assembly are affected by 
the N209I mutation in ECSIT, it was also relevant to look at how the mutation affected 
the expression of ECSIT protein, as well as its interactions with known binding partners 
and complex I proteins. This may provide clues to the mechanism of ECSIT in complex I 
assembly and to how the N209I mutation affects this mechanism.  
5.4.1. ECSIT protein blots 
ECSIT is known to have two different isoforms in mouse tissue, a 50kDa cytosolic full 
length isoform, and a 45kDa mitochondrially localised isoform [231]. The 45kDa isoform 
is formed from the full length 50kDa isoform via the loss of a 5kDa N-terminal 
mitochondrial localisation signal (amino acids 1-48) that is cleaved upon transport into 
the mitochondria. As the N209I mutation is approximately 150 amino acids downstream 
of the N-terminal targeting sequence it is unlikely that it interferes with the importation 
machinery of ECSIT, but the processing of ECSIT was investigated to determine if there 
was any effect of the mutation on this process. Tissues tested were taken from male 
(n=3) and female (n=3) wild type and EcsitN209I/N209I animals at 16 weeks of age. 
Interestingly, both 50kDa and 45kDa ECSIT protein show increased levels in cardiac 
tissue of EcsitN209I/N209I animals compared to wild type controls (Figure 5.20). This could 
indicate a compensatory upregulation of ECSIT to compensate for its reduced capacity 
to produce fully assembled complex I. On further investigation however, I observed a 
third, previously undescribed band detected with the ECSIT antibody of approximately 
16kDa. This 16kDa fragment is almost completely absent from the cardiac tissue of 
EcsitN209I/N209I animals, whilst it is present in the wild type heart tissue (Figure 5.20). This 
upregulation of 50 and 45kDa ECSIT protein is unique to the heart, with no change in the 
protein levels of either isoform in brain, kidney, liver or skeletal muscle (Figure 5.21). In 
contrast to heart tissue, none of these tissues showed any presence of the 16kDa 
fragment of ECSIT in either wild type or EcsitN209I/N209I samples. Taken together these 
data suggest that heart tissue processes ECSIT protein in a different manner to other 
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tissues and this may explain why EcsitN209I/N209I animals are absent other major defects, 
and only display a significant cardiac phenotype.   
 
Figure 5.20. Quantification (A) and representative blots (B) or ECSIT protein, normalised to loading control 
VDAC. Results show an increase in both 50kDa and 45kDa ECSIT protein in EcsitN209I/N209I animals compared 
to wild type controls. In contrast, 16kDa ECSIT demonstrates a significant reduction in EcsitN209I/N209I 
animals, to the point where it is essentially undetectable in cardiac tissue from these animals. Mean ± 
SEM, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 5.21. Quantification and representative blots from Brain (A), Kidney (B), Liver (C) and skeletal 
muscle (D) of wild type and Ecsit-N209I/N209I animals. In contrast to results from heart tissue, none of the 
tissues tested show any increase of either 50 or 45kDa ECSIT protein isoforms and the 16kDa fragment 
seen in heart tissue was undetectable in any of the remaining tissues tested. Mean ± SEM. 
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5.4.2. ECSIT Protein in 2 Week Old Hearts 
I investigated whether or not the elevation or reduction of ECSIT protein preceded the 
development of the cardiac phenotype by immunoblotting proteins from 2-week-old 
hearts, where there is no overt sign of cardiomyopathy. 
Results (Figure 5.22) show a similar reduction in ECSIT protein in regards to the 
unconfirmed 16kDa fragment. However, 50 and 45kDa ECSIT protein isoforms do not 
show the same elevation that was seen in the 16-week hearts. This may be a factor of 
the age of the hearts, with older hearts accumulating these larger fragments with time 
as they are unable to undergo the normal degradation process due to the mutation, or 
build up in an attempt to improve complex I assembly efficiency. These data confirm 
that the absence of the 16kDa fragment precedes the development of the 
cardiomyopathy phenotype.  
 
Figure 5.22. Quantification (A) and representative blots (B) or ECSIT protein, normalised to loading control 
VDAC from wild type and EcsitN209I/N209I 2 week old cardiac tissue. Results show an increase in both 50kDa 
and 45kDa ECSIT protein in EcsitN209I/N209I animals compared to wild type controls. 16kDa ECSIT 
demonstrates a reduction in EcsitN209I/N209I animals as was seen in 16 week old cardiac tissue. Mean ± SEM. 
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5.4.3. NDUFAF1 protein blots 
NDUFAF1 is a binding partner of ECSIT, as part of the MCIA complex and the interaction 
of these two proteins is key to the assembly of complex I. As ECSIT protein levels were 
elevated in cardiac tissue it was prudent to investigate the protein levels of NDUFAF1 in 
at least the same tissue. However, commercial antibodies against NDUFAF1 proved to 
be unsuitable as no protein could be detected in cardiac tissue. To combat this an 
antibody against human NDUFAF1 was obtained from the lab of Dr Leo Nijtmans 
(Radboud University Medical Centre). Unfortunately, this antibody resulted in a large 
number of non-specific binding events and it is impossible to tell which band on the 
immunoblot membrane belongs to the NDUFAF1 protein. As a result it was not possible 
to quantify NDUFAF1 protein levels.   
  
189 
 
5.4.4. ACAD9 protein blots 
As with NDUFAF1, ACAD9 is a binding partner of ECSIT and another member of the MCIA 
complex. Immunoblots were performed to assess the ACAD9 protein levels in various 
tissues (Figure 5.23). Tissues tested were taken from male (n=3) and female (n=3) wild 
type and EcsitN209I/N209I animals at 16 weeks of age. Results show no significant changes 
in the ACAD9 protein levels in any of the tissues tested. These results were expected for 
the brain, kidney and liver, as no differences were seen in ECSIT protein levels in these 
tissues. However, as ECSIT protein levels were altered in cardiac tissue it may have been 
expected that ACAD9 would also show differential levels of protein expression in cardiac 
tissue. This may indicate that whilst ECSIT protein is not fully functional in complex I 
assembly its interaction with ACAD9 is unaffected.  
 
Figure 5.23. Quantification and representative blots of ACAD9 in wild type and EcsitN209I/N209I tissues. Heart 
(A), brain (B), kidney (C) and liver (D) show no differences in ACAD9 protein levels. Mean ± SEM. 
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5.4.5. Co-Immunoprecipitation with NDUFAF1 
To investigate the interaction of ECSIT protein with the known binding partner 
NDUFAF1, both full length proteins were cloned into expression vectors (pCMV6) to 
produce tagged proteins (ECSIT – His, NDUFAF1 – Myc). Site directed mutagenesis was 
used to introduce the N209I point mutation into the ECSIT ORF to produce the mutant 
protein. Wild type or N209I ECSIT was then co-transfected into HEK293T cells with the 
NDUFAF1 clone. Cell lysates were used for immunoprecipitation against one of the 
protein tags used and the products run on SDS-PAGE to determine if the proteins were 
interacting. Results (Figure 5.24) show that both wild type (lane 2) and mutant ECSIT 
(lane 3) as well as NDUFAF1 (lanes 2 and 3) were successfully expressed in HEK293T cells 
whilst untransfected (lane 1) cells show no expression of either protein. Furthermore, 
both proteins can be seen expressed as both a cytosolic (ECSIT – 50kDa, NDUFAF1 – 
42kDa) and mitochondrially localised (ECSIT – 45kDa, NDUFAF1 – 37kDa) isoforms. 
Immunoprecipitation against the His tag of wild type ECSIT (lane 4) shows that both 
isoforms of ECSIT as well as both isoforms of NDUFAF1 are pulled down, indicating that 
wild type ECSIT is interacting with NDUFAF1 in both the cytosol and the mitochondria. 
This is confirmed by the reverse reaction, of pulling down NDUFAF1 via its Myc tag, 
showing the same proteins precipitated (lane 6). Lanes 5 and 7 are empty vector controls 
confirming that the His tag alone is incapable of pulling down the Myc tagged NDUFAF1 
protein, and the Myc tag is incapable of pulling down the His tagged ECSIT. Lanes 8 and 
11 demonstrate the same experimental procedure using the mutant N209I form of the 
ECSIT protein instead of the wild type. This again shows that in both cases the ECSIT and 
NDUFAF1 proteins are interacting and capable of being co-immunoprecipitated. 
Ultimately, these data are important in telling us that the N209I mutation has no impact 
on the interaction of ECSIT with NDUFAF1 and that the two proteins interact not only in 
the mitochondria, but also in the cytosol as is demonstrated by the presence of both 
cytosolic isoforms in all of the co-immunoprecipitation lanes.  
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Figure 5.24. Immunoprecipitation of wild type and mutant ECSIT (His tagged) (45 and 50kDa) with full 
length wild type NDUFAF1 (Myc tagged) (42 and 37kDa). (A) shows combined channels with secondary 
antibodies against mouse (green – Myc) and rabbit (red – His). (B) and (C) show the separated channels 
demonstrating the anti-rabbit (Anti-His) and anti-mouse (Anti-Myc) secondary antibodies respectively. 1. 
Untransfected input lysate, 2. Wild type ECSIT(His) + wild type NDUFAF1(Myc) input lysate 3. ECSIT 
N209I(His) + wild type NDUFAF1(Myc) input lysate, 4. Wild type ECSIT(His) + wild type NDUFAF1(Myc) 
anti-His immunoprecipitation, 5. Empty AC-His vector + wild type NDUFAF1(Myc) anti-His 
immunoprecipitation, 6. Wild type ECSIT(His) + wild type NDUFAF1(Myc) anti-Myc immunoprecipitation, 
7. Wild type ECSIT(His) + empty entry(Myc) vector anti-Myc immunoprecipitation, 8. N209I ECSIT(His) + 
wild type NDUFAF1(Myc) anti-His immunoprecipitation, 9. Empty AC-His vector + wild type 
NDUFAF1(Myc) anti-His immunoprecipitation, 10. N209I ECSIT(His) + wild type NDUFAF1(Myc) anti-Myc 
immunoprecipitation, 11. N209I ECSIT + empty entry(Myc) vector anti-Myc immunoprecipitation.  
 
192 
 
5.4.6. Co-Immunoprecipitation with ACAD9 
As with NDUFAF1, ACAD9 is known to interact with ECSIT as part of the MCIA complex 
and the potential for the interaction to be destabilised or affected by the N209I 
mutation in the ECSIT protein was assessed to confirm whether or not this was the cause 
of the complex I deficiency. As previously, full length wild type and mutant ECSIT were 
cloned in the pCMV6-AC-His vector (Origene) to produce a His tagged ECSIT protein 
containing either the wild type asparagine or mutant isoleucine residue at position 209. 
Similarly, ACAD9 was expressed with a Myc tag in the pCMV6-ENTRY vector (Origene). 
Transfection of both vectors into HEK293T cells was performed and cell lysates assessed 
for the presence of the proteins by immunoblotting (Figure 5.25). Whereas ECSIT 
produces tagged proteins of 50 and 45kDa in size, ACAD9 is expressed as two protein 
isoforms of 69 (cytosolic) and 64 (mitochondrial) kDa. Successful transfection is 
confirmed in lanes 2 and 3 of figure 5.25, showing the presence of both ECSIT and both 
ACAD9 isoforms and the absence of either in lane 1 confirms a lack of contamination in 
the cell line. Lane 3 demonstrates that immunoprecipitation of the wild type ECSIT by 
anti-His antibody co-immunoprecipitates both isoforms of the Myc tagged ACAD9 
protein. The same is demonstrated in lane 6 by immunoprecipitation of the ACAD9 by 
anti-Myc antibody showing the presence of the 50 and 45kDa ECSIT isoforms, although 
the 50kDa isoform shows very minimal quantities. The same procedure with the mutant 
N209I ECSIT shows that the interaction in both ways is unaffected by the presence of 
the mutation. The absence of any ECSIT or ACAD9 in the empty vector controls lanes 5, 
7, 9 and 11 confirm that the interaction is a result of the protein:protein interaction of 
ECSIT with ACAD9 and not between the His and Myc tags, or cross specificity of the 
antibody used.  
Taken together, these data confirm that ECSIT and ACAD9 interact within the 
mitochondria, most likely as part of the MCIA complex. It also suggests that there is 
some interaction between the proteins in the cytosol although this is a very small 
proportion of the overall interaction visible. Introducing the N209I mutation into ECSIT 
has no effect on the interaction of the two proteins, suggesting it is not through the 
binding of ACAD9 that the ECSIT N209I mutation leads to complex I deficiency.  
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Figure 5.25. Immunoprecipitation of wild type and mutant ECSIT (His tagged) (45 and 50kDa) with full 
length wild type ACAD9 (Myc tagged) (69 and 64kDa). (A) shows combined channels with secondary 
antibodies against mouse (green – Myc) and rabbit (red – His). (B) and (C) show the separated channels 
demonstrating the anti-rabbit (Anti-His) and anti-mouse (Anti-Myc) secondary antibodies respectively. 1. 
Untransfected input lysate, 2. Wild type ECSIT(His) + wild type ACAD9(Myc) input lysate 3. ECSIT 
N209I(His) + wild type ACAD9(Myc) input lysate, 4. Wild type ECSIT(His) + wild type ACAD9(Myc) anti-His 
immunoprecipitation, 5. Empty AC-His vector + wild type ACAD9(Myc) anti-His immunoprecipitation, 6. 
Wild type ECSIT(His) + wild type ACAD9(Myc) anti-Myc immunoprecipitation, 7. Wild type ECSIT(His) + 
empty entry(Myc) vector anti-Myc immunoprecipitation, 8. N209I ECSIT(His) + wild type ACAD9(Myc) anti-
His immunoprecipitation, 9. Empty AC-His vector + wild type ACAD9(Myc) anti-His immunoprecipitation, 
10. N209I ECSIT(His) + wild type ACAD9(Myc) anti-Myc immunoprecipitation, 11. N209I ECSIT + empty 
entry(Myc) vector anti-Myc immunoprecipitation.  
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5.5. Complex I Assembly 
As ECSIT is a known complex I assembly factor, work was undertaken to determine which 
step in complex I assembly was primarily affected by the N209I mutation. To do this, 
mitochondria are isolated from tissue using gentle homogenisation and differential 
centrifugation. Isolated mitochondria can then be run on Native PAGE to separate the 
intact complexes and investigate the proteins that comprise these complexes. This is 
done both in first dimension as a semi-quantitative assessment, and in second 
dimension where complexes are then denatured, as a more qualitative assessment 
[294]. 
5.5.1. 1st Dimensional Blue Native PAGE 
First dimensional blue native polyacrylamide gel electrophoresis (BN-PAGE) was 
performed on mitochondria isolated from hearts of male (n=3) and female (n=3) wild 
type and EcsitN209I/N209I animals. These were probed using antibodies against complex I 
subunits, as well as ECSIT itself to determine the level of each protein within the fully 
assembled complex I. 
5.5.1.1. Complex I subunits 
Antibodies against each of the main complex I subunits were used to confirm their 
compatibility with native conditions, and to confirm that the isolation and gel 
electrophoresis was not destructive of the fully assembled complex I. Figure 5.26 shows 
the bands corresponding to the proteins incorporated into fully assembled complex I for 
each of the antibodies tested. NDUFV2 (N), S2 (Q), B11 (PD-a), B1 (PD-b), B8 (PD-c) and 
A10 (accessory) all confirm the reduction of fully assembled complex I seen in earlier 
denaturing blots (Section 5.3.2). NDUFC2 (PP) does not show any banding at the level of 
fully assembled complex I in either wild type or EcsitN209I/N209I heart mitochondria, 
possibly indicating an incompatibility with native conditions, or an inability of the 
antibody to bind to the epitope as it is hidden within the complex structure.  
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Figure 5.26. First dimensional BN-PAGE blots showing only fully assembled complex I in mitochondria 
isolated from hearts of wild type and EcsitN209I/N209I animals. Rest of blots is not shown as no other banding 
was seen.  
5.5.1.2. ECSIT 
First dimensional BN-PAGE of ECSIT (Figure 5.27) confirms the reduction of fully 
assembled complex I in EcsitN209I/N209I cardiac mitochondria, in comparison to wild type 
controls. This result is unexpected as the ECSIT antibody shows a band of fully assembled 
complex I in the wild type mitochondria, despite previous knowledge suggesting that 
ECSIT is not a constituent of fully assembled complex I. It also suggests that this may be 
the 16kDa fragment noted in cardiac western blots as both 45 and 50kDa ECSIT were 
significantly upregulated in previous experiments.  
 
Figure 5.27. First dimensional BN-PAGE blot of ECSIT demonstrating localisation of ECSIT protein with 
fully assembled complex I. 
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5.5.2. 2nd Dimensional Blue Native PAGE 
Second dimensional blue native PAGE allows for further understanding of the assembly 
process of complex I, by revealing the proteins involved in each sub-assembly and where 
the process may be getting ‘stuck’ as a result of the ECSIT N209I mutation. To investigate 
this, samples were first run under the native first dimensional conditions, before the gel 
slice was excised and treated with SDS to denature the proteins in the gel. The slice was 
run under denaturing conditions to separate the individual proteins from the fully 
assembled complex. Samples were taken from male wild type (n=3) and EcsitN209I/N209I 
(n=3) animals. As with the first dimensional BN-PAGE, antibodies against proteins in 
each of the complex I subassemblies were used to determine which, if any, the ECSIT 
N209I mutation had a great effect on. Mitochondria from both heart and brain of wild 
type and EcsitN209I/N209I animals were used to compare the assembly pathway in the 
affected heart tissue to that of the seemingly unaffected brain tissue.  
Results (Figure 5.28) show a reduction in most of the proteins at the level of complex I 
without the accumulation of any assembly intermediates, making it difficult to 
determine at which point in the assembly process is affected. NDUFS2, NDUFB8 and 
NDUFA10 show no differences between wild type and EcsitN209I/N209I mitochondria from 
heart, with the majority of these proteins being present in a band of a size corresponding 
to fully assembled complex I. NDUFS2, also shows some evidence of assembly 
intermediates with a size slightly smaller than fully assembled complex I, but again this 
is not different between the wild type and EcsitN209I/N209I heart samples. NDUFV2, 
NDUFC2 and NDUFB1 show a reduction or absence of the protein in complete complex 
I but do not show an accumulation of assembly intermediates, either because these are 
broken down rapidly, or do not accumulate as any that is produced is incorporated into 
complex I, albeit at a much lower total amount. Only NDUFB11 shows a change in the 
patterning of the blot, with an accumulation of a smaller assembly intermediate, with a 
modest reduction in the amount incorporated into complete complex I.  
Of the proteins investigated in heart tissue, only those with significant differences were 
investigated further in mitochondria from brain tissue. Of these 4 proteins, NDUFV2, 
NDUFC2 and NDUFB11 did not show the same reduction in complete complex I or an 
accumulation of any assembly intermediates as was seen in heart mitochondria. 
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NDUFB1 was undetectable in brain tissue, likely not due to an absence of the protein, 
but perhaps a reduction in the amount of complex I or a loss of effectiveness of the 
antibody.  
Overall these data show that the loss of ECSIT function in EcsitN209I/N209I animals is more 
profound in heart tissue than in the brain, and that not all of the subunits of complex I 
are affected. From the work of Guerrero-Castillo et al. (2016) [72] it is known that ECSIT 
is bound to proteins of the PP subassembly and potentially operates in its assembly. 
These data support that, with a difference seen in NDUFC2. However, the difference in 
the PD-a protein of NDUFB11 also suggests that ECSIT may play a role either in the 
assembly of the PD subunit or in the marrying of the two subunits together during 
complex I assembly.   
5.5.2.1. Complex I Subunits 
Results (Figure 5.28) show a reduction in most of the proteins at the level of complex I, 
without the accumulation of any assembly intermediates, thus making it difficult to 
determine which point in the assembly process is affected. NDUFS2, NDUFB8 and 
NDUFA10 show no differences between wild type and EcsitN209I/N209I mitochondria from 
heart, with the majority of these proteins being present in a band of a size corresponding 
to fully assembled complex I. NDUFS2, also shows some evidence of assembly 
intermediates with a size slightly smaller than fully assembled complex I, but again this 
is not different between the wild type and mutant heart samples.  
NDUFV2, NDUFC2 and NDUFB1 show a reduction or absence of the protein in complete 
complex I but do not show an accumulation of assembly intermediates. This is likely to 
be either because these are broken down rapidly, or do not accumulate as any that are 
produced are incorporated into complex I, albeit at a much lower total level. Only 
NDUFB11 shows a change in the patterning of the blot, with an accumulation of a 
smaller assembly intermediate, with a modest reduction in the amount incorporated 
into complete complex I.  
Of the proteins investigated in heart tissue, only those with overt differences were 
investigated further in mitochondria from brain tissue. Of these 4 proteins, NDUFV2, 
NDUFC2 and NDUFB11 did not show the same reduction in complete complex I or an 
accumulation of any assembly intermediates as was seen in heart mitochondria. 
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NDUFB1 was undetectable in brain tissue, which is unlikely to be due to an absence of 
the protein, but more likely a reduction in the amount of complex I or a loss of 
effectiveness of the antibody.  
Overall these data shows that the reduction of ECSIT function with regard to complex I 
assembly in EcsitN209I/N209I animals is more profound in heart tissue than in the brain, and 
that not all of the subunits of complex I are affected. From the work of Guerrero-Castillo 
et al. [72] it is known that ECSIT is bound to proteins of the PP subassembly and 
potentially operates in its assembly. These data support that, with a significant reduction 
difference seen in NDUFC2. However, the difference in the PD-a protein of NDUFB11 also 
suggests that ECSIT may play a role in either the assembly of the PD subunit or in the 
marrying of the two subunits together during complex I assembly.   
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Figure 5.28.  Representative 2nd dimensional BN-PAGE blots from wild type and EcsitN209I/N209I hearts and 
brains. Brain mitochondria were only run where a difference was seen in heart mitochondria. In each 
panel, the high molecular weight complexes are on the left and the low molecular weight on the right.  
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5.5.2.2. ECSIT 
Given the unexpected result in the first dimensional BN-PAGE of ECSIT it was prudent to 
run the 2nd dimensional blots to determine if the hypothesis about the first dimension 
was correct i.e. that it was the 16kDa fragment that was co-migrating with complex I. 
Mitochondria from wild type and EcsitN209I/N209I hearts and brains were run in the first 
dimension and then in the second dimension to determine which fragments of ECSIT 
were co-migrating with which complexes of the mitochondria.  
2D BN-PAGE blots from wild type and EcsitN209I/N209I hearts (Figure 5.29-A/B) show the 
presence of the 50kDa band of ECSIT sitting to the left hand side of the blot at a first 
dimensional size much larger than complex I. Indicating that the 50kDa fragment may 
be associated with a very large complex or structure, this could be in the form of a 
mitochondrial import machinery or ribosome.  
The 45kDa ECSIT band shows two patches, one small, to the right of the blot, which may 
be unbound ECSIT, free in the mitochondria, or may be a small protein complex such as 
MCIA. There are also signs of 45kDa ECSIT at a much larger size in the middle of the blot 
likely as part of a much larger complex, potentially as part of a complex I assembly 
intermediate. Importantly for both the 50 and 45 kDa fragments, no differences can be 
seen between wild type and EcsitN209I/N209I hearts.  
Where a difference is visible is the 16kDa fragment, as was seen with the standard SDS-
PAGE, the 16kDa fragment is reduced to the point where it is not visible in the 
EcsitN209I/N209I heart (Section 5.4.1). This blot also confirms that it is the 16kDa fragment 
that co-migrates with complex I, suggesting that it may form part of the complete 
complex.  
In the brain (Figure 5.29-C/D) 50kDa ECSIT appears as part of a large complex, as it does 
in heart tissue, however there is no evidence of either the 45 or 16 kDa fragments in 
either the wild type or EcsitN209I/N209I samples. This is in contrast to the SDS-PAGE of brain 
tissue where 45kDa ECSIT could be seen albeit at a reduced level, but is in line with the 
SDS-PAGE with respect to the 16kDa fragment that was not visible in brain tissue.  
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Figure 5.29. Second dimensional BN-PAGE in heart (A and B) and brain (C and D) of wild type and 
EcsitN209I/N209I animals. Proteins associated with large complexes lie to the left of the blot, and smaller or 
unbound proteins to the right. Heart shows the presence of 50 (1) and 45 kDa (2) ECSIT in both wild type 
and EcsitN209I/N209I blots whilst 16kDa (3) is only visible in the wild type. Brain shows only the presence of 
the 50kDa ECSIT (4).  
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5.6. Nature of 16kDa fragment 
The 16kDa fragment identified initially in SDS-PAGE and later in BN-PAGE appears to be 
key to complex I assembly in cardiac tissue. However, this may not be the case in all 
tissues, as even those without the presence of 16kDa in wild type blots show some 
degree of complex I assembly defect (kidney, liver and brain). To determine the nature 
of this protein fragment and provide clues as to how the N209I mutation may affect its 
formation I have attempted to isolate it for mass-spectrometric analysis. 
5.6.1. Immunoprecipitation 
Immunoprecipitation was performed using a variety of techniques in an attempt to find 
a method that successfully immunoprecipitated the 16kDa fragment of ECSIT so that it, 
as well as the 45 and 50 kDa fragments, could be sent for reliable mass-spectrometry.  
Initial immunoprecipitation used a method similar to that used for the co-
immunoprecipitations of ECSIT with ACAD9, TRAF6 and SMAD4 shown previously. 
Protein was isolated from wild type heart tissue in RIPA buffer and immunoprecipitated 
with anti-ECSIT antibody (Abcam) and protein G sepharose beads. Following western 
blot (Figure 5.30-A) however, no ECSIT protein could be seen indicating that the protein 
was not immunoprecipitated by the antibody under these conditions, despite all 
isoforms being visible in the original input protein. 
A second attempt was made using a milder incomplete RIPA buffer which should have 
reduced the chance of loss of binding affinity between the antibody and the protein 
(Figure 5.30-B). Results show the presence of both the 50 and 45 kDa isoforms in the 
input lane, however the 16kDa fragment is very faint and none of the isoforms are visible 
following immunoprecipitation. This may indicate that this lysis buffer is insufficient to 
liberate the 16kDa fragment from this tissue but given the failure of the 
immunoprecipitation there appears to be little chance of this protocol being successful.  
In a final attempt to immunoprecipitate ECSIT using the original Abcam antibody 
(Ab21288) immunoprecipitation was performed using a lysis buffer containing triton x-
100 instead of SDS and NP-40 as was described by Soler-López et al. (2011) [295] and 
recommended by the manufacturer as part of trouble shooting procedures. Results 
(Figure 5.30-C) show robust extraction of all isoforms of ECSIT as seen in the input lane, 
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however, immunoprecipitation was still unsuccessful with no protein visible in the IP 
lane. No control is shown.  
 
Figure 5.30. Western blots following immunoprecipitation using original Abcam ab21288 anti-ECSIT 
antibody with proteins extracted using RIPA (A), mild RIPA (B) and triton lysis buffer (C). Westerns of 
immunoprecipitations using alternative antibodies from Abcam (ab66380) (D) and Atlas (HPA042979) (E) 
show successful detection and immunoprecipitation of 50 and 45kDa ECSIT but not the 16kDa fragment 
of interest.  
As the ab21288 Abcam antibody appeared unsuitable for immunoprecipitation I decided 
to try the original RIPA protein extraction protocol with alternative antibodies to 
determine if mass-spec could be performed in this manner. Anti ECSIT antibodies from 
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Abcam (ab66380) (Figure 5.30-D) and Atlas (HPA042979) (Figure 5.30-E) both 
demonstrated an ability to detect and immunoprecipitate the larger fragments of ECSIT, 
but neither detected or was able to immunoprecipitate the 16kDa fragment.   
5.6.2. Mass Spec Results 
With the inability of the antibodies used to immunoprecipitate the 16kDa fragment of 
ECSIT I decided to attempt mass-spectrometry on gel slices taken from 2D BN-PAGE to 
provide the cleanest possible result and give an overview of the proteins in association 
with ECSIT at each position in the gel. Four fragments, 50kDa, 45kDa complex bound, 
45kDa unbound and 16kDa ECSIT, were excised from a 2D BN-PAGE run using wild type 
heart mitochondria and showing the presence of all 3 isoforms of ECSIT (Figure 5.31). 
 
Figure 5.31. Image of wild type 2nd dimensional BN-PAGE showing the 4 fragments excised from the gel 
and sent for mass-spec. 50kDa ECSIT (A), 45kDa complex bound ECSIT (B), 45kDa unbound ECSIT (C) and 
16kDa ECSIT (D). 
Mass spectrometric analysis (Appendix 1) failed to identify ECSIT in any of the gel 
fragments sent for sequencing. Although the presence of a large number of complex I 
proteins representing all sub-assemblies of complex I was confirmed in gel slice D, 
confirming the co-migration of this potential ECSIT fragment with complex I.  
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5.6.3. Validation of ECSIT antibody 
As it was not possible to confirm the nature of any of the ECSIT isoforms by mass-
spectrometry, confirmation that the antibody was detecting ECSIT protein reliably was 
tested by transfecting HEK293T cells with the His tagged ECSIT produced for the CO-IP 
experiments and running lysate on an SDS-PAGE gel. Following western blotting 
membranes were incubated with both the anti His antibody and the Abcam anti-ECSIT 
(ab21288) antibody used for the majority of experiments. Co-localisation of the two 
antibody signals confirmed the specificity of the ab21288 antibody (Figure 5.32). The 
results are confounded slightly by the presence of the native ECSIT protein in the 
HEK293T cells that were not transfected, and by the presence of what appears to be 
extra bands in the transfected cells. However, in reality these extra bands are the 
combination of both the untagged and tagged protein which will be 1kDa larger than 
the untagged protein due to the size of the 6x His tag. Unfortunately, as the 16kDa 
fragment of ECSIT is not produced in HEK293T cells it was not possible to determine if 
this was a specific antibody interaction or not.  
 
Figure 5.32. Immunoblots of transfected and un-transfected HEK293T cells showing the binding of both 
the anti-ECSIT (Abcam ab21288) and anti HIS antibodies binding to the tagged ECSIT protein at both 45 
and 50 kDa. (A) shows the combined channels (Red – Anti ECSIT, Green – Anti HIS). (B) shows only the red 
channel and (C) only the green. Native ECSIT protein is visible in the un-transfected cells in the red channel.   
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5.7. Discussion 
Results indicate a mild structural defect in EcsitN209I/N209I cardiac mitochondria with a 
tendency towards highly compacted and disorganised cristae, as well as a reduction in 
mitochondrial size. This may reflect a tendency of mitochondria to form more 
fragmented networks or may simply be an artefact of the way the TEM slides were cut, 
further investigation using TEM to image mitochondria from other tissues may help to 
determine if this is a valid result.  
Investigating nDNA:mtDNA ratio and mitochondrial inner and outer membrane proteins 
in cardiac showed mixed results. nDNA:mtDNA hinted at some differences between wild 
type and EcsitN209I/N209I mitochondria quantities but with limited successful results this 
method was abandoned for more robust methods. Inner and outer membrane proteins 
showed that there was no difference in total mitochondrial mass in cardiac tissue and 
as such this was not further investigated in other tissues where no phenotype was seen. 
Finally, the levels of the master regulator of mitochondrial proliferation, PGC1α, showed 
a slight upregulation in cardiac tissue, with no changes in other tissues measured. This 
result, when coupled with the two previous tests suggests that the cells of the heart are 
attempting to upregulate total mitochondrial mass through the action of PGC1α but the 
elevation of mitochondrial mass is impaired, either due to impaired synthesis, or 
increased degradation.  
This section also attempted to determine why a mutation in a ubiquitously expressed 
complex I assembly protein (ECSIT) appears to have such a devastating effect on cardiac 
tissue without devastating body wide phenotypes, as is typical with complex I deficiency.  
Firstly, these data demonstrate that whilst the phenotype seen in EcsitN209I/N209I animals 
is primarily cardiac, the loss of complex I protein level is more universal. The reduction 
in complex I varies significantly from tissue to tissue with an almost complete loss of 
complex I protein in heart and only mild reductions in kidney and brain. This alone hints 
at the cause of the tissue specific phenotype. This loss of NDUFB8 in heart tissue is also 
supported by the loss of a number of other complex I proteins in heart tissue. However 
not all proteins are reduced, indicating that the N209I mutation in ECSIT may affect 
different subassemblies of complex I to different degrees. Again, this loss of proteins in 
cardiac tissue is also seen in brain tissue, to only a mildly reduced level, hinting again at 
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a tissue specific level of activity of ECSIT in complex I assembly. Work was also 
undertaken to show that a loss of functional complex I protein precedes the cardiac 
phenotype observed. Secondly, it suggests two possibilities for the regulation of 
NDUFB8 protein levels, the first being that NDUFB8 levels are lost over time with the 
N209I mutation leading to cardiomyopathy, or secondly that NDUFB8 protein levels 
increase over time with the development of the cardiac tissue and the ECSIT N209I 
mutation inhibits this.  
To investigate the mechanism by which ECSIT is involved in complex I assembly, protein 
levels of ECSIT in multiple tissues were assessed. Initial results showed a surprising 
upregulation of both 50 and 45 kDa ECSIT in EcsitN209I/N209I hearts compared to wild 
types. No similar upregulation of these isoforms was seen in brain, kidney, liver or 
muscle. Furthermore, during this investigation a previously undescribed 16kDa fragment 
was identified by the antibody used in wild type cardiac tissue. This fragment was absent 
from EcsitN209I/N209I cardiac samples and was not identified in any of the other tissues 
tested, providing the first evidence of a potential tissue specific mechanism of ECSIT in 
complex I assembly. As with the complex I protein levels, ECSIT protein levels I cardiac 
tissue were also assessed in 2 week hearts to confirm that the upregulation of 50 and 
45 kDa ECSIT and the loss of the putative 16kDa fragment preceded the development of 
cardiomyopathy. As expected, 50 and 45kDa ECSIT protein is elevated above wild types 
in EcsitN209I/N209I hearts and there is a loss of 16kDa ECSIT in EcsitN209I/N209I hearts isolated 
from 2 week old animals. These data suggest that the loss of the 16kDa fragment 
precedes the onset of hypertrophy in .EcsitN209I/N209I animals. 
As ECSIT is known to be part of the MCIA complex, its binding to other members of this 
complex was assessed. The two key members of the MCIA complex that were assessed 
were NDUFAF1 and ACAD9. ACAD9 protein levels showed no differences in heart, 
kidney, liver or brain, but it was not possible to accurately measure NDUFAF1 due to a 
lack of reliable antibody. Further investigation focused on the use of Co-
immunoprecipitation using tagged proteins to determine if the interaction of ECSIT with 
ACAD9 and NDUFAF1 was affected by the N209I mutation. Results showed that the 
mutation had no effect on the interaction of these proteins, indicating that mutant ECSIT 
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is still capable of forming part of the MCIA complex and at least initiating complex I 
assembly.  
Complex I assembly itself was assessed by blue native PAGE which shows the formation 
of subcomplexes and the isoforms of each protein present in each subassembly. These 
data showed that EcsitN209I/N209I animals show a defect in complex I assembly in cardiac 
tissue but not in brain tissue. This defect is most apparent when looking at the PP and PD 
subunits especially the PD-a which demonstrated a shift towards unincorporated 
protein. Taken together these data support the work of Guerrero-Castillo et al. (2016) 
[72] which showed ECSIT is involved in the assembly of the membrane arm of complex 
I. BN-PAGE also demonstrated that the putative 16kDa ECSIT fragment is a constitutive 
part of fully assembled complex I. This may be as a result of a tissue specific cleavage of 
the protein during the complex I assembly process, although the reasons for having such 
a mechanism remain elusive.  
Finally, mass-spectrometry was employed to determine the nature of the 16kDa 
fragment seen in wild type hearts but absent from mutant hearts and other tissues 
examined. As ECSIT was not detected in any samples despite its presence being known 
at 45 and 50kDa sizes this leaves an open ended question that justifies further 
investigation.  Determining the nature of this fragment is of utmost importance to the 
project and could possibly be done through the use of cultured wild type cardiomyocytes 
transfected with a tagged protein and immunoprecipitated using an antibody against 
the tagged protein. Unfortunately, cardiomyocytes are not readily transfectable and 
given the lack of the 16kDa protein in other tissue types, it is unlikely other cell types 
would produce the required fragment.  
In summary, results from this leave us with a working hypothesis that ECSIT exists as 3 
potential proteins. A 50kDa cytosolic isoform that localizes to mitochondria when poly-
ubiquitinated and is imported following the cleavage of a 5kDa mitochondrial targeting 
sequence. This process leaves a 45kDa mitochondrially localised isoform that is present 
in most tissues and required for the production of complex I through the MCIA complex. 
To this point, there is evidence to support this mechanism across all tissues and cell 
types and that the mutation of ECSIT only mildly inhibits this assembly process resulting 
in mild reduction of functional complex I and no obvious phenotypes in tissues outside 
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the heart. However, the data obtained during this project suggests that this is also the 
point where heart tissue diverges from other tissues in the way complex I is assembled. 
It would appear that at this point the 45kDa ECSIT protein is cleaved in heart tissue 
allowing for the incorporation of the 16kDa fragment into complex I and the process to 
continue, resulting in fully assembled complex I. The N209I mutation of ECSIT seems to 
inhibit this cleavage process, resulting in a premature arrest of the complex I assembly 
process and an accumulation of both 45 and 50Kda ECSIT in cardiac tissue.  
This difference in heart tissue may be due to the increased energy demands of the heart 
and hence in this situation ECSIT acts not only as an assembly factor, but also as a 
supernumerary subunit to improve complex I efficiency, a role that is not required in 
other tissues.  
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Chapter 6: Mitochondrial Response to 
Complex I Dysfunction 
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6.1. Changes in Mitochondrial Network Dynamics 
Mitochondrial fusion and fission are the methods by which mitochondria form large 
dynamic networks in order to exchange DNA, ETC elements and maintain membrane 
potential (Δψm). Fusion is governed by the GTPases MFN1, MFN2 and OPA1 whilst fission 
is mainly centred on the protein DRP1, which has various phosphorylation sites that 
either inhibit (Ser637) or activate (Ser616) the mechanism of the protein. Under typical 
circumstances mitochondria form dynamic networks with balanced levels of fusion and 
fission resulting in a variety of mitochondrial network sizes. During periods of 
mitochondrial stress or dysfunction the balance between fusion and fission may become 
disturbed, leading to a shift, one way or the other, resulting in highly fragmented or 
inefficient networks that do not function normally. As a result, the levels of 
mitochondrial fusion and fission proteins were assessed to determine if this pathway 
was affected by the mutation in ECSIT. Samples analysed are from male (n=3) and female 
(n=3) wild type and EcsitN209I/N209I hearts at 16 weeks of age.  
 
Figure 6.1. Quantification and representative blots of total MFN2 protein in cardiac tissue of wild type 
and EcsitN209I/N209I animals. Results show a significant elevation of MFN2 in EcsitN209I/N209I animals 
suggesting an increase in mitochondrial fusion as a result of the ECSIT N209I mutation. Mean ± SEM, 
**p<0.01. 
Results here show an increased amount of MFN2 protein (Figure 6.1) in the hearts of 
EcsitN209I/N209I animals when normalised to the mitochondrial loading control VDAC. This 
may indicate a shift towards mitochondrial fusion and an increase in the amount of 
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mitochondria incorporated into large networks. In addition, the protein levels of OPA1 
(Figure 6.2) were assessed in the same samples as this protein works in tandem with 
MFN2 to cause mitochondrial fusion. It is noteworthy that OPA1 has 6 known isoforms 
in mouse tissue whilst only 3 were identifiable here, further investigation is required 
with additional techniques. Unfortunately, time restraints prevented this from being 
possible. Regardless, these three isoforms were quantified, and whilst there is no 
difference in levels between wild type and EcsitN209I/N209I animals in the smallest size 
band, the larger two do show a significant reduction in protein levels in EcsitN209I/N209I 
animals. This is suggestive of a reduction in fusion of the inner membrane.  
 
Figure 6.2. Quantification and representative blots of total OPA1 protein in cardiac tissue from wild type 
and EcsitN209I/N209I animals. Of the 6 known OPA1 isoforms in mouse, only 3 were identifiable and only 
these 3 were analysed. Of these 3 bands the first 2 show a significant reduction of protein levels in 
EcsitN209I/N209I hearts whilst the 86kDa band shows no significant changes.  The remaining 3 bands showed 
faint traces on the blot but could not be visualised without overexposing the 3 bands shown here. Mean 
± SEM, *p<0.05. 
Mitochondrial fission was assessed by measuring the phosphorylation of DRP1 (Figure 
6.3) at two known serine residues. Overall DRP1 levels were unchanged between wild 
type and EcsitN209I/N209I hearts indicating that if changes in the fission rate were apparent 
it must come from varying phosphorylation of the protein sites. Phosphorylation of the 
two serine residues have opposing roles, with serine 637 being inhibitory to the 
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activation of DRP1 whilst serine 616 is the activating site. Both residues show no 
significant alterations in the amount of phosphorylation that has occurred, indicating 
that mitochondrial fission shows no change in regulation.  
 
Figure 6.3. Quantification (A) and representative blots (B) of total DRP1, DRP1(P)Ser637 (inhibitory) and 
DRP1(P)Ser616 (activating). Results show no significant differences in the level of total protein or in the 
phosphorylation of either of the serine sites within DRP1. Mean ± SEM. 
Taken together these data hint at an increase in mitochondrial outer membrane fusion 
with an increase in MFN2 levels. However, fusion of the inner membrane is likely 
reduced due to a reduction in levels of long chain OPA1 isoforms. These results also 
indicate that there is not a cellular response leading to elevated mitochondrial fission as 
levels of the fission protein DRP1 show no changes in expression levels of 
phosphorylation of either activating or inhibitory residues.  
6.2. Regulation of Mitophagy in response to mitochondrial 
Dysfunction 
Mitophagy is the process by which dysfunctional mitochondria are removed from the 
cell through the action of PINK1, Parkin and autophagosomes. Typically, PINK1 
accumulates on the mitochondria and is broken down by being internalised and 
degraded. Where mitochondria are defective PINK1 accumulates on the outer 
membrane and marks mitochondria for degradation. Samples analysed are from male 
(n=3) and female (n=3) wild type and EcsitN209I/N209I hearts at 16 weeks of age.  Results 
below (Figure 6.4) show a significant elevation of PINK1 protein levels in the hearts of 
EcsitN209I/N209I animals indicating that there is an increase in defective mitochondria 
present in this tissue and PINK1 is accumulating as a result.  
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These data suggest that the mutation of ECSIT leads to a significant level of 
mitochondrial dysfunction leading to attempts by the cell to remove dysfunctional 
mitochondria via this mitophagy pathway.  
 
Figure 6.4. Quantification and representative blots of PINK1 in wild type and EcsitN209I/N209I heart tissue. 
Results demonstrate a significant increase in PINK1 protein in EcsitN209I/N209I hearts indicating an increase 
in mitophagy. Mean ± SEM, ***p<0.001. 
6.3. Regulation of Mitochondrial Unfolded Protein Response 
The mitochondrial unfolded protein response is upregulated as a reaction to the 
accumulation of unfolded proteins in the mitochondria. In the case of EcsitN209I/N209I 
hearts it might be expected that this response is activated to deal with the accumulation 
of complex I assembly intermediates that are not incorporated into functional complex 
I and may inhibit other mitochondrial processes by remaining in the inter membrane 
space (IMS). Samples analysed are from male (n=3) and female (n=3) wild type and 
EcsitN209I/N209I tissues at 16 weeks of age. 
Protein levels of key UPRmt proteases and chaperones were assessed for any significant 
alterations to protein levels in the cardiac tissue of EcsitN209I/N209I animals when 
compared to wild types. Results (Figure 6.5) show an elevation of the proteases CLPP as 
well as LONP1 indicating that there is an increase in protease activity in response to the 
accumulation of complex I assembly intermediates. In addition, the chaperone protein 
HSP60 also shows a significant elevation in EcsitN209I/N209I hearts in comparison to wild 
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types. Of the proteins assessed, only the chaperone GRP75 does not show any elevation 
in EcsitN209I/N209I animals.  
To contrast this these same proteins were measured in brain tissue (Figure 6.6) to show 
that the activation of the UPRmt corresponds to the blockage in complex I assembly seen 
in heart and not just as a result of mutant ECSIT being present in mitochondria. Results 
from brain show no significant changes in the levels of the 4 proteins measured (CLPP, 
LONP1, HSP60 and GRP75) thus confirming that it is not mutant ECSIT that activates the 
UPRmt but the accumulation of misfolded complex I assembly intermediates.  
In addition to the protein levels of these key chaperones and proteases, the 
phosphorylation of the translation initiation factor EIF2α was assessed (Figure 6.7). This 
protein is phosphorylated by PKR to suppress protein translation in response to the 
accumulation of misfolded proteins. Results do not show a significant increase in the 
phosphorylation levels of EIF2α in EcsitN209I/N209I heart tissue. 
Whilst the list of proteins assessed here is not exhaustive, and does not include the 
transcription factors CLPP or CEBPβ that are responsible for initiation, these data 
suggest that there is activation of some arms of the UPRmt.  
 
Figure 6.5. Quantification (A) and representative blots (B) in heart of the proteases CLPP and LONP1 and 
the chaperones HSP60 and GRP75 which are known to be part of the UPRmt. Results show significant 
elevation of CLPP, LONP1 and HSP60, suggesting a robust activation of the UPRmt in response to the 
accumulation of assembly intermediates created by the loss of ECSIT function in cardiac tissue. Mean ± 
SEM, *p<0.05, ****p<0.0001. 
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Figure 6.6. Quantification (A) and representative blots (B) in brain of the proteases CLPP and LONP1 and 
the chaperones HSP60 and GRP75 which are known to be part of the UPRmt. In contrast to heart tissue, 
results in brain show no significant changes in the expression of any of the UPRmt proteins measured here. 
Mean ± SEM. 
 
Figure 6.7. Quantification and representative blots of total and phosphorylated EIF2α in wild type and 
EcsitN209i/N209I hearts. Results show no change in overall EIF2α protein levels or in the level of 
phosphorylation of the protein. Mean ± SEM.  
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6.4. Regulation of Reactive Oxygen Species Production Following 
Complex I Dysfunction 
Reactive oxygen species (ROS) are produced as a by-product of oxidative 
phosphorylation during normal mitochondrial function. However, defects in the 
electron transport chain can lead to elevated levels of ROS created by the mitochondria 
which normal anti-oxidant mechanisms are unable to cope with. In situations like this 
ROS leads to mitochondrial and cellular damage and ultimately to cell death and 
inflammation. Due to previous difficulties in culturing neonatal cardiomyocytes it was 
difficult to measure superoxide or H2O2 species production in vitro and it was decided 
to measure the concentration of 4-hydroxynonenal (4-HNE) in cardiac tissue of wild type 
and EcsitN209I/N209I animals instead. 4-HNE is the product of lipid peroxidation by ROS and 
unlike most ROS it is long lived, meaning measurements in ex vivo tissues are possible. 
Samples analysed are from male (n=3) and female (n=3) wild type and EcsitN209I/N209I 
hearts at 16 weeks of age.   
Results from this assay (Figure 6.8) show a reduction in cardiac levels of 4-HNE and by 
proxy a corresponding reduction in ROS produced by the mitochondria. This result is 
perhaps unsurprising given the large reduction in the levels of intact complex I seen in 
cardiac tissue without a corresponding elevation of complex III. As complex I and III are 
the main sites of ROS production in the mitochondria an overall reduction in the ROS 
producing sites would logically result in reduced ROS despite mitochondrial dysfunction.  
 
Figure 6.8. Cardiac 4-hydroxynonenal levels in cardiac tissue from wild type and EcsitN20I/N209I animals. 
Results indicate a reduction in 4-HNE levels and correspondingly it can be assumed that ROS production 
is decreased too. Mean ± SEM, **p<0.01. 
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6.5. Energy Insufficiency of Tissue with Complex I Dysfunction 
The idea of the failing heart being an energy starved organ is well established with 
reduction in ATP and PCr levels being reported in patients as well as animal models [101, 
106, 108]. To determine if this was the case in EcsitN209I/N209I animals both ADP:ATP ratio 
and AMPK activation were assessed. Samples analysed are from male (n=3) and female 
(n=3) wild type and EcsitN209I/N209I hearts at 16 weeks of age. 
6.5.1. ADP:ATP Ratio 
The ADP:ATP ratio was assessed in freeze clamped hearts collected from both wild type 
and EcsitN209I/N209I animals by enzylight™ ADP/ATP ratio assay kit. This kit allows for first 
the measurement of ATP as it reacts with the D-luciferin substrate and then, following 
the conversion of ADP to ATP, for the indirect measurement of ADP concentration.  
Results (Figure 6.9) show no significant changes in the concentration of ATP or ADP 
between wild type and EcsitN209I/N209I animals. However, the ratio of ADP to ATP shows 
a small but significant elevation in EcsitN209I/N209I animals. This increase in [ADP] relative 
to [ATP] suggests increased turnover of ATP in the myocardium which is temporarily 
elevating ADP levels whilst they await conversion back to ATP. This result alone does not 
provide a clear picture of what is going on in the cardiac tissue regarding energy 
insufficiency as there are no changes in ATP levels and without PCr readings it is 
impossible to draw a meaningful conclusion. 
 
Figure 6.9. Luminescence readings of [ATP] and [ADP] as well as ADP/ATP ratio in wild type and 
EcsitN209I/N209I animals.  Results show no significant differences in [ATP] or [ADP] but do demonstrate a 
small elevation in ADP/ATP which in itself is difficult to interpret. Mean ± SEM, *p<0.05. 
W T H O M W T H O M W T H O M
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
3
4
5
6
7
C a rd ia c  A T P  a n d   A D P  le v e ls
A s s a y / G e n o t y p e
L
u
m
in
e
s
c
e
n
c
e
R
a
tio
 (A
D
P
/
A
T
P
)
A T P A D P R a t io
(A D P / A T P )
*
219 
 
Further limitations with this result come from the fact that ATP may be readily converted 
to ADP once the sample has been taken or indeed following lysis in solution, therefore 
artificially increasing [ADP] whilst diminishing the [ATP]. This fact may explain the 
unexpected ratio of ADP:ATP in these samples. Typically [ATP] would be expected to be 
maintained at around 10mmolL-1 whilst [ADP] would be around 50µmolL-1, 3 orders of 
magnitude lower than [ATP] and the opposite of what is observed in this assay. With this 
in mind, the results from this assay will not be taken into consideration when drawing 
conclusions.  
6.5.2. AMPK Phosphorylation 
As a less direct but potentially more readily measurable metric of energy insufficiency 
of the heart, the phosphorylation levels of AMPK can be measured. AMPK is 
phosphorylated by an upstream kinase (AMPK kinase) in response to high AMP levels 
which occur when [ADP] is elevated and [ATP] reduced. Activated AMPK is then 
responsible for remodelling the energy supply systems of the cell to focus them towards 
ATP production.  
AMPK activation levels (Figure 6.10) in EcsitN209I/N209I animals show a surprising decrease 
in comparison to wild type in heart tissue. This result is opposed to that of the ADP/ATP 
ratio which, whilst difficult to interpret and inconclusive, suggested that there may be a 
slight elevation of [ADP] in the hearts of EcsitN209I/N209I animals.  
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Figure 6.10. Quantification and representative blots of total and phosphorylated AMPK in wild type and 
EcsitN209I/N209I cardiac tissue collected by clamp freezing. Contrary to expectations results show a marked 
decrease in AMPK phosphorylation levels in EcsitN209I/N209I samples when compared to wild types, 
suggesting that [AMP] concentration is high and by association so too is [ATP]. Mean ± SEM, *p<0.05. 
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6.6. Discussion 
The aim of this chapter was to determine which downstream pathways may be activated 
in response to the mutation of Ecsit and may be responsible for the development of the 
cardiac phenotype as the previous chapter had demonstrated that the OXPHOS 
deficiency preceded the development of cardiomyopathy.  
Results from this chapter are mixed and provide an incomplete picture of the 
downstream effects of the N209I mutation in ECSIT that warrants further investigation. 
Firstly, the balance of mitochondrial fusion and fission seems to be shifted slightly in 
favour of fusion, with an elevation of MFN2 which is responsible for outer membrane 
fusion. However, this is not consistent as the inner membrane fusion protein shows a 
reduction in the level of isoforms typically associated with inner membrane fusion. 
There are also no changes in the activation of fission proteins.  
Mitophagy appears to be moderately upregulated which may be a response to 
dysfunctional mitochondrial subunits or may be the indirect result or unfolded protein 
response activation which was also seen. UPRmt activation is apparent due to the 
increased protein levels of the proteases CLPP and LONP1 and the chaperone HSP60 in 
heart tissue. This same activation pattern was not seen in brain tissue suggesting that it 
is the result of the complex I assembly defect that was only seen in heart in the previous 
chapter. However, it is of note that surgical models of ischemia/reperfusion injury in rats 
also demonstrate an activation of the UPRer which shares some components with the 
UPRmt. This may suggest that the activation seen here is not a direct result of misfolded 
mitochondrial protein, but is part of the normal response to cardiomyopathy [296].  
The first in a series of unexpected results was the reduction in the production of reactive 
oxygen species as measured indirectly by 4-HNE levels. Further reflection on this would 
suggest the initial expectation was misguided, as complex I is a key site of ROS 
production and with a reduction in functional complex I, logic would dictate that ROS 
should display a similar reduction.  
Finally, energy insufficiency was assessed as it is well associated with heart failure. This 
result however provided the second surprise as ADP/ATP ratio appeared only slightly 
elevated and it was difficult to draw meaningful conclusions as [ATP] was unchanged. It 
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is noteworthy that this result is suspect simply due to limitations of the assay. This assay 
is primarily designed for assessing viability of cell populations in culture and reliably 
measuring [ATP] in tissue samples presents a great number of challenges, not least 
maintaining ATP throughout the sample collection and measurement process as it may 
be quickly converted to ADP once the lysis of tissue is performed.      
In addition AMPK activation levels were significantly reduced, suggesting that [AMP] and 
by association [ATP] was high in these hearts, indicating no presence of energy 
insufficiency although as a single measurement further evidence would be beneficial. 
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Chapter 7: Discussion of Results 
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7.1. Summary of Results 
Throughout the experiments performed to this point, a unifying goal has been to 
determine how the mutation of Ecsit ultimately leads to cardiomyopathy through a 
complex I dysfunction without the presence of other obvious phenotypes.  
Initial phenotyping took place in a mixed background of C57BL/6J and C3H.Pde6b+ with 
the mutation lying in a C57BL6/J region of the genome. Through whole genome 
sequencing a mutation in Ecsit was identified and confirmed by Sanger and pyro 
sequencing. The mutation is an asparagine to isoleucine change at residue 209 of the 
ECSIT protein with protein prediction software indicating that the mutation would have 
a deleterious or disease causing effect on the protein structure or function.  Sequence 
homology to human ECSIT protein suggested that this mutation would lie in a putative 
pentatricopeptide (PPR) with a potential role in processing RNA, although no evidence 
exists for this function in ECSIT. With a putative function in RNA processing, as well as 
the assembly of complex I, it is possible to envisage a role for ECSIT in the regulation of 
expression of complex I subunits. This may take the form of negative regulation wherein 
ECSIT, or a fragment of it, is re-tasked as a signalling protein following successful 
complex I assembly. This new signalling peptide could then act directly on the expression 
of complex I proteins or indirectly, perhaps via PGC1α. 
Further phenotyping on incipient congenic animals obtained by 5 back-crosses to the 
C3H.de6b+ strain confirmed a cardiomyopathy in homozygous mutant animals. The 
phenotype was assessed by histology and echocardiography and was observed from 
roughly 4 weeks of age in EcsitN209I/N209I animals.  This cardiomyopathy had 
characteristics of both hypertrophic (increased wall thickness, hypertrophy of 
cardiomyocytes) and dilated cardiomyopathy (increased left ventricular volume). This 
cross-over between the two main cardiomyopathy types may represent an attempt to 
remodel the heart tissue in response to an initial development of one of these 
conditions. Further histological analysis with more consistent tissue collection 
techniques may allow for this question to be answered. However, it is my opinion that 
this is most likely a hypertrophic cardiomyopathy given the prevalence of this condition 
in association with mitochondrial disease and the overwhelming size and weight of the 
heart muscle seems unlikely to be a tissue response to dilated cardiomyopathy. 
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EcsitN209I/N209I animals also displayed some changes in body fat deposition, with 
homozygous animals displaying a reduced body weight from as early as 6 weeks of age 
and a reduced adiposity that was apparent from 14 weeks of age. This result may be 
directly related to the increase in triglyceride metabolism indicated by the clinical 
chemistry results. Decreased triglyceride as well as elevated glycerol and ketone bodies, 
in addition to changes in glucose and fructosamine concentrations, hint at a change in 
metabolism in EcsitN209I/N209I animals. Both of these results are suggestive of an increase 
in metabolism of their respective substrates, free fatty acids and glucose, without 
indicating a shift in the primary substrate being used, as might be expected with a failing 
heart shifting towards glucose metabolism. Clinical chemistry also revealed an increase 
in plasma concentrations of urea, creatinine and potassium, highly suggestive of kidney 
dysfunction. Whilst the presence of a kidney phenotype is not in question, whether it is 
a primary or secondary phenotype remains to be determined. Kidney disease has a well-
established link with hypertension [297] whilst HCM is more typically associated with 
hypotension [298]. However, some evidence exists to suggest that hypotension is a risk 
factor for chronic kidney disease [299] but it would seem more likely that the kidney 
failure is a direct result of the mitochondrial dysfunction and requires further 
investigation. It is interesting to note that the EcsitN209I/N209I samples seem to segregate 
into two groups, those with creatinine that is slightly elevated (18-25µmol/l) and those 
with a higher elevation of creatinine (30-40µmol/l). This stratification of the creatinine 
concentration in plasma may be a symptom of the mixed genetic background that these 
animals exhibit, despite being incipient congenic animals on the C3H.Pde6b+ 
background. We know from prior experience with kidney disease mutants that have 
arisen from the Harwell Ageing Screen that the C3H.Pde6b+ background exhibits an 
increased susceptibility to the development of kidney disease whilst the C57BL/6J seems 
to confer some protection (data unpublished). It is therefore conceivable that this 
stratification is influenced by a region of the genome that maintains a C57BL/6J nature 
in a proportion of these animals. It would be possible to further characterise this in the 
congenic EcsitN209I/N209I animals on both a C57BL/6J and C3H.Pde6b+ background.  
Results in chapter 2 focused on the potential roles of both the toll like receptor response 
and the morphogenetic protein pathway in the development of cardiomyopathy seen in 
the EcsitN209I/N209I animals. Results pertaining to the activity of ECSIT in the TLR pathway 
226 
 
indicate that it’s interaction with the binding partner TRAF6 is unaffected by the N209I 
mutation and that the inflammatory response may actually demonstrate a mild 
impairment in EcsitN209I/N209I animals, suggesting that this pathway is unlikely to lead to 
increased inflammation and subsequent cardiomyopathy. The data to support this 
decrease in activation is limited as the activation of JNK showed a trend but did not reach 
significance, it is possible that further repeats would achieve significance. 
As for the BMP pathway no signs of impairment were demonstrated at all. The fact that 
knockouts are embryonic lethal due to a significant impairment of this pathway is 
suggestive that this pathway is unhindered by the N209I mutation. Furthermore, 
impairment of this pathway could be expected to cause reduced viability of 
EcsitN209I/N209I embryos, as is the case for Ecsit-/-. However, a reduction in the number of 
EcsitN209I/N209I animals at weaning was not seen, suggesting that the BMP pathway is not 
significantly impaired. The key metric in this section is the expression of embryonic Tlx2 
which is lost in its entirety when Ecsit is knocked out but only shows a 50% reduction in 
EcsitN209I/N209I animals in comparison to wild types, although this result is not statistically 
significant. This reduction seems to be insufficient to significantly affect the viability of 
EcsitN209I/N209I embryos through the BMP pathway.  
The focus of this work was the role of ECSIT in complex I assembly, as this appeared as 
the most likely candidate to be affected by the N209I mutation. Initial work showed that 
mitochondria from EcsitN209I/N209I hearts showed some level of structural abnormalities, 
with the presence of hyper condensed, disorganised cristae as well as a small reduction 
in mitochondrial cross sectional area of both interfibrillar and perinuclear mitochondria. 
Protein and mtDNA levels did not demonstrate a change in the overall abundance of 
mitochondria in heart tissue although the level of PGC1α, the master regulator of 
mitochondrial biogenesis, was slightly elevated in heart tissue. This result may indicate 
that whilst there is an upregulation of the pathway that drives mitochondrial biogenesis, 
the mutation of ECSIT either inhibits the actual process or results in the production of 
defective mitochondria or mitochondrial subunits that are quickly eliminated by either 
mitophagy or the mitochondrial unfolded protein response.  
Analysis of complex I protein levels confirmed that there was a significant reduction in 
complex I levels in heart as well as in other tissues: brain, kidney, liver. The extent of 
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reduction varies considerably between tissues with the brain showing only a small 
reduction of around 25% whilst the heart shows a >95% reduction in NDUFB8 protein 
levels. This reduction in complex I protein level is not reflected across all proteins of 
complex I, with a more robust reduction in membrane arm proteins than in matrix arm 
proteins. Some proteins (NDUFS3 and MT-ND1) showed no significant reduction at all in 
heart tissue, potentially indicating that the control of expression of these proteins exists 
outside of that of the majority of complex I proteins. This would make sense for the 
mitochondrially encoded MT-ND1 as it is controlled and expressed entirely within the 
mitochondria, however the nuclear encoded NDUFS3 is nuclear encoded would logically 
follow the same regulatory controls as other nuclear encoded mitochondrial OXPHOS 
proteins. In the brain a greater number of proteins showed no significant changes in 
levels (NDUFV2, NDUFS3, NDUFA8) and of those that do, there is an overall smaller 
reduction in their levels. This may indicate that there is some sort of hierarchy to the 
regulation of these proteins, with the reduction in levels of lower levelled proteins 
(NDUFV2, NDUFS3 etc.) only occurring when higher level proteins are reduced below a 
certain threshold. However, this may also reflect the fact that some of these proteins 
are essential to the assembly of complex I (MT-ND1), or are required early in the 
assembly process, and others are at least partially disposable, or required later in the 
assembly process. This would mean that when stressed cellular processes focus on the 
essential building blocks first, maintaining them at close to normal levels where possible.   
Results also demonstrated that, whilst protein levels are reduced in a number of tissues, 
the activity of complex I does not necessarily follow suit in these tissues. Comparing 
heart and brain using in-gel activity and seahorse analysis of isolated mitochondria 
revealed that complex I activity and mitochondrial respiration were severely impacted 
by the presence of the N209I mutation in heart tissue. However, this was not true for 
complex I or mitochondria isolated from brain tissue, which showed comparable levels 
in wild type and EcsitN209I/N209I mitochondria in both assays. Whilst further investigation 
of other tissues is desirable, these data alone support the hypothesis that there are 
tissue specific differences in the complex I assembly process, and in particular the 
stage(s) controlled by ECSIT.  
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Protein levels of ECSIT tell a slightly different, and unexpected, story. ECSIT exists as a 
cytosolic (50kDa) and mitochondrial (45kDa) form in mouse tissues and the levels of 
these two protein products was upregulated in the cardiac tissue of EcsitN209I/N209I 
animals compared to wild types. Interestingly this pattern of regulation was not 
repeated in any other tissue tested, in fact, no differences could be seen at all in other 
tissues, suggesting why the main outcome of the mutation was cardiomyopathy with 
little effect observed in other tissues. Of most interest was the identification of a 
previously undescribed ~16kDa fragment in wild type heart tissue, which was absent 
from EcsitN209I/N209I hearts as well as all other wild type and EcsitN209I/N209I tissues. It is 
conceivable that this fragment is a portion of ECSIT produced by the cleavage of the 
45kDa ECSIT as part of the normal assembly process for complex I. If this is the case then 
it may be that the N209I mutation inhibits the cleavage, leading to an accumulation of 
the larger 45 and 50kDa ECSIT isoforms. Without identifying a specific protease 
responsible for this hypothetical cleavage it is difficult to determine how the N209I 
mutation might affect the cleavage of 45kDa ECSIT. However, if cleavage was to occur 
at this residue it would result in two products roughly 19 and 46 kDa in size. Although 
neither of these is the exact 16kDa size seen on the western blots it is possible that 
further cleavage of one of these two products occurs or that the size on the western blot 
is not does not reflect an accurate size of the protein product.  
Investigation of ETC and ECSIT protein levels in two week old hearts confirmed that the 
changes in the levels of these proteins precede the cardiomyopathy phenotype and are 
not an artefact of the phenotype. Interestingly, the levels of 45 and 50kDa ECSIT did not 
show increased levels in these 2 week old hearts whilst there was a reduction in the 
16kDa fragment. This probably indicates that these larger ECSIT proteins have not had 
time to accumulate in the mitochondria or cytosol yet and that this accumulation is a 
gradual process. The accumulation of these larger fragments may be a contributing 
factor to the development of cardiomyopathy, further investigation across more time 
points may reveal if this is the case.  
In addition to the alterations in ECSIT protein levels, data in this section also 
demonstrated that the mutation of ECSIT protein had no impact on the interaction 
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between ECSIT and other proteins of the MCIA complex such as NDUFAF1 and ACAD9, 
which also showed no changes in protein levels in any tissues tested.  
To assess complex I assembly, first and second dimensional blue-native PAGE was 
performed on mitochondria extracts from heart and brain of wild type and EcsitN209I/N209I 
animals. This revealed that EcsitN209I/N209I animals had some defects in some aspects of 
complex I assembly in heart tissue, but not in brain tissue. These defects are mainly 
related to the assembly of the membrane arm of complex I although some loss of other 
subunits was also seen. Interestingly, none of the same defects were seen in 
mitochondria isolated from brain tissue of the same animals. This further supports the 
hypothesis that complex I assembly is not a universal process but has tissue specific 
intricacies that result in an altered process and differential levels of complex I in tissues 
where an assembly factor mutation is present.  
Taken together, these data suggest that the N209I mutation of ECSIT has no impact on 
the formation of the protein’s previously described larger fragments (50 and 45kDa) or 
on the interaction between ECSIT and the MCIA proteins NDUFAF1 and ACAD9. There 
are two salient facts to remember when arguing a case for the importance of the 16kDa 
ECSIT protein. Firstly, that complex I assembly and activity in brain tissue are unaltered 
and those tissues tested that did show complex I protein level differences are less 
severely affected than heart tissue. The second is that the formation of the MCIA 
complex appears to be unaffected by the presence of the N209I mutation in ECSIT, 
reflected by the normal interaction of ECSIT with both NDUFAF1 and ACAD9, and by the 
normal protein expression of ACAD9 in the tissues tested. Taken together this suggests 
that the MCIA complex functions as expected in ECSITN209I/N209I animals and if we accept 
this as true then the mechanism for the defect seen in cardiac tissue must lie elsewhere, 
potentially in the presence of the 16kDa fragment identified in wild type heart tissue.  
From this work, I have developed the following working hypothesis based on existing 
knowledge and experimental results described to this point. In wild type animals ECSIT 
is expressed as full length 50kDa protein in all tissues and according to demand is poly-
ubiquitinated and targeted to mitochondria where it is imported and the mitochondrial 
targeting sequence cleaved, leaving a 45kDa ECSIT protein. Once localised to the 
mitochondria ECSIT forms part of the MCIA complex along with NDUFAF1 and ACAD9. 
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To this point, the N209I mutation of ECSIT has little to no impact on the activity of the 
protein. The MCIA complex is then involved in the assembly of the membrane arm of 
complex I through an, as yet unknown, mechanism. Following this, the mutation of ECSIT 
must impact complex I assembly as there are small differences seen in liver, kidney and 
brain. However, this role is different to that seen in the heart, as the defect in heart is 
considerably greater than in these other tissues. It is conceivable that whilst the MCIA 
complex forms correctly and functions in complex I assembly, that its efficacy is reduced 
by a small degree due to a reduced binding affinity or structural change that leads to a 
reduction in complex I activity.  
However, in the heart the role for ECSIT in complex I assembly differs, with a role for the 
16kDa fragment identified in wild type heart. It is possible that this only exists in heart 
tissue due to a modification of this process that is not required in less energy demanding 
tissues. It would seem likely that this product is produced by cleavage of the 45kDa 
fragment, which may create multiple fragments, although this cannot currently be 
confirmed. Data suggests that this 16kDa fragment forms a constitutive part of complex 
I and it may be assumed that in this manner ECSIT-16kDa behaves as an accessory 
subunit of complex I in a tissue specific manner. Whilst it is unclear why ECSIT-16kDa is 
only an accessory subunit in heart, or why loss of it would lead to reduced complex I 
levels in heart when it is not required in other tissues, there is a relationship between 
complex I activity levels and ECSIT-16kDa presence in heart tissue. Further work should 
focus on confirming the identity of the ECSIT-16kDa fragment and determining its 
sequence and role in complex I assembly. 
Following on from the identified defect of complex I assembly in heart tissue, work 
focused on identifying the downstream effects of complex I deficiency in an attempt to 
understand how the complex I deficiency results in cardiomyopathy. Mitochondrial 
fusion and fission exist in a delicate balance able to respond to alterations in 
mitochondrial function and eliminate defective subunits. In EcsitN209I/N209I animals, the 
fusion/fission mechanism appears to be slightly disturbed, with an elevation of the outer 
membrane fusion protein MFN2 but a reduction in long isoforms of OPA1 and no change 
in DRP1 activation. Ultimately, this process warrants further investigation, potentially 
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through the quantification of mitochondrial network dynamics rather than controlling 
proteins.  
Elevation of PINK1 protein levels suggest that mitophagy is elevated in EcsitN209I/N209I 
hearts which may be a result of a change in mitochondrial fusion/fission dynamics or a 
result of the inability of the UPRmt to cope with an accumulation of misfolded 
mitochondrial proteins. The UPRmt is seemingly robustly activated, indicating that it 
recognises the accumulation of misfolded complex I proteins and that the mutation of 
ECSIT does not impair the UPRmt response, which may have been a possibility given that 
ECSIT activates JNK2, a key activator of the UPRmt. As such it may be possible that the 
disruption of mitochondrial network dynamics feed directly in to the increase in 
mitophagy or that the accumulation of misfolded proteins simply accumulate too fast 
for the UPRmt to cope.  
Finally, there was an expectation that reactive oxygen species would be elevated and 
that there would be a substantial energy insufficiency in the heart of EcsitN209I/N209I 
animals. However, neither of these mechanisms were observed, with 4-HNE (as a 
measure of ROS) significantly reduced and AMPK activation also reduced. In hindsight, 
the reduction of ROS is not an unexpected result due to complex I being a significant site 
of ROS production. If the mechanism of complex I was impaired via a mutation of a key 
protein then it might make sense that ROS would accumulate due to defective electron 
transport. The actual mechanism is a reduction in total complex I abundance, which 
reduces the sites for ROS production and accordingly, reduces ROS levels. When taken 
into consideration, this result is in line with what would be expected given what is known 
about ECSIT’s role in complex I assembly. However, the reduction of AMPK is unexpected 
and more difficult to explain. AMPK is typically activated in response to an elevation of 
[AMP], which would be expected with the loss of [ATP] that typically accompanies 
mitochondrial deficiency. The most likely explanation is that the measurements were 
taken at a point preceding a measureable change in [ATP], as this is maintained at or 
close to normal levels by the buffering capacity of phosphocreatine until late stage 
disease. The confounding issue for this explanation is that AMPK activation is not 
maintained at or close to normal levels but are in fact reduced in EcsitN209I/N209I hearts, 
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suggesting that [AMP] is lower than in wild type controls, and therefore [ATP] is higher 
than controls.  
In summary, the N209I mutation in ECSIT results in a severe cardiomyopathy with some 
changes in glucose and fatty acid metabolism as well as mild kidney impairment and a 
reduction in weight, lean mass and fat mass of EcsitN209I/N209I animals. The TLR and BMP 
pathways appear mostly unaffected by the mutation, indicating that this region of ECSIT 
is either not key to the function of these pathways, or the change of this amino acid is 
tolerated. The mutation of ECSIT results in a defect in complex I assembly in multiple 
tissues with varying degrees of severity in various tissues. The effect on complex I 
assembly is most severe in heart tissue and this may be a result of an altered function 
or processing of ECSIT protein in this tissue. It is possible that, instead of functioning only 
as an assembly factor, a portion of ECSIT also acts as an accessory subunit of complex I 
in heart tissue and that the N209I mutation impairs this role, leading to a greater loss of 
complex I function and a severe cardiomyopathy.  
7.2. Implications for the Field of Mitochondrial Dysfunction Research 
Diagnosis of mitochondrial disease is typically performed on a muscle or skin biopsy to 
determine the mitochondrial function and biochemical basis of the disease [300]. The 
research I have undertaken as part of this thesis suggests that this method may obscure 
the diagnosis of a proportion of mitochondrial diseases due to tissue specific differences 
in mitochondrial function and behaviour. Whilst whole genome screening is becoming 
more prevalent [301] this relies on a complete understanding of the proteins, and 
therefore genes, involved in mitochondrial function to determine appropriate 
candidates.  
Furthermore, much work on the structure and function of complex I and assembly 
factors involved takes place in cardiac tissue from various species due to the relative 
abundance of mitochondria. The work I have completed so far suggests that this 
research should be diversified to determine how mitochondrial assembly processes are 
undertaken in other tissues and cell types. The possibility exists that there are many 
differences in mitochondrial complexes and/or their assembly, even from one cell type 
to another within the same tissue. Through a better understanding of these differences, 
it may be possible to develop better tailored therapies which are capable of targeting 
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specific cell or tissue types in order to restore function to defective mitochondria where 
it is most needed.  
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7.3. Future Work 
The work completed so far has raised many questions, which I have been unable to 
answer given the limitations of time and a suitable in vitro experimental system. First 
amongst these is the question of whether or not the 16kDa fragment is a portion of the 
ECSIT protein or whether it is an off target binding event of the antibody that only occurs 
in heart tissue. Given that ECSIT has limited sequence homology to any other known 
proteins it would be unexpected for this to be an off target binding event, however the 
possibility cannot be eliminated by this fact alone.  
If this were an off target binding of the antibody then there are two possible 
explanations for the results seen so far. Firstly, this may represent a cardiac specific 
protein that is reduced in expression in EcsitN209I/N209I hearts due to the development of 
the cardiomyopathy phenotype. An argument against this is that it is also reduced in 2-
week old heart tissue, before the onset of cardiomyopathy, and hence is not lost due to 
cardiomyopathy but precedes it. Secondly, this may be a mitochondrial protein that is 
reduced due to a loss of ECSIT function in mitochondria, similar to the way a number of 
complex I proteins that were tested were reduced. However, if this were the case it 
would represent an interesting discovery in itself as this protein was not detected in 
other tissues, suggesting that this may be a tissue specific mitochondrial protein.  
Future work could also focus on the tissue specificity of the complex I assembly defect 
and on identifying the metabolic cause of the alterations to glucose and fatty acid levels 
seen in plasma.  
It would also be desirable to look at the 2D BN-PAGE results in more detail, either 
through further 2D BN-PAGE experiments in a variety of tissues or by using complexome 
analysis to analyse multiple tissues or complexes at once and reduce the associated time 
and labour costs.  
It would also be potentially interesting to use an inducible or conditional Ecsit knockout 
mouse to investigate the development of the cardiomyopathy phenotype in more detail. 
Ultimately, this work could be validated by screening HCM patient populations for 
mutations in ECSIT, thereby confirming that loss of ECSIT function results in a tissue 
specific mitochondrial disease.  
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7.3.1. Identification of 16kDa Fragment 
To identify the 16kDa protein fragment seen in wild type and absent from EcsitN209I/N209I 
cardiac tissue a number of approaches were attempted, these include co-
immunoprecipitation using the original antibody as well as two antibodies raised against 
slightly different epitopes. The original antibody proved to be unsuitable for use in co-
immunoprecipitation experiments in any of the conditions tested despite previous 
publications suggesting it was. Other antibodies used were able to pull down the larger 
45 and 50kDa fragments of ECSIT through CO-IP but did not recognise the 16kDa 
fragment seen with the original Abcam antibody, making identification by co-IP and 
mass-spec impossible. Another possibility is to use the HIS tagged ECSIT protein cloned 
for other co-immunoprecipitation experiments and pull down using the anti-his 
antibody which is already known to be suitable for CO-IP. However, the 16kDa protein 
was not seen as part of these other CO-IP experiments suggesting that either the HIS tag 
is cleaved from the protein and is therefore undetectable, the 16kDa fragment is not 
produced in HEK293T cells that were used in these experiments, or that the 16kDa 
protein is definitely not a fragment of ECSIT.  
To determine which of these explanations is correct, it would be necessary to culture a 
cardiomyocyte cell line such as HL-1 [302], silence the native ECSIT protein expression 
by a method such as siRNA and transfect with the tagged HIS-ECSIT construct. This would 
potentially allow for the expression of all three (50, 45 and 16 kDa) fragments of ECSIT 
and would by-pass the need for a reliable antibody as the anti-HIS antibody used 
previously would be suitable. HL-1 cells have transfection efficiencies up to roughly 80% 
with cationic lipid based transfection systems such as lipofectamine or jetPRIME, 
although they are notoriously difficult to optimise by this method. Higher efficiencies 
can be obtained with adenovirus methods.  
Using a cardiac specific inducible knockout of Ecsit is unlikely to provide any useful 
information about the 16kDa fragment as loss of ECSIT protein could still lead to a loss 
of the 16kDa fragment, even if it is not an ECSIT protein fragment, just as is seen in 
EcsitN209I/N209I animals. 
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7.3.2. Reliable measurements of ROS and energy insufficiency 
Work so far measured ROS production indirectly by assessing the product of lipid 
peroxidation by ROS, 4-HNE. This method appears to be robust and gives reliable, 
repeatable measures. However, this is not a direct measurement of ROS production and 
there may be differences that are not detected as a result. A more direct measurement 
could be the use of amplex red to measure H2O2 production or mitoSOX™ Red to 
measure mitochondrial superoxide production. The limitation with both of these 
techniques is they are unsuitable for use with tissue lysates and given the difficulties 
with the culture of primary neonatal cardiomyocytes from EcsitN209I/N209I mice these 
techniques were considered inviable and hence the 4-HNE method was used. If 
cardiomyocyte culture could be optimised to allow for the measurement of ROS levels 
on EcsitN209I/N209I samples then either of these could be a viable option to support the 
results seen from the 4-HNE assay.  
In addition to ROS production measurements, energy sufficiency measurements were 
also measured via a proxy (AMPK phosphorylation) as ADP and ATP measurements 
proved difficult in tissue lysate. A more reliable method for the assessment of energy 
sufficiency would be the measurement of PCr:ATP ratio in live animals. This is possible 
using phosphorous-31 magnetic resonance spectroscopy (31P-MRS) on the in vivo mouse 
heart. This technique allows for assessment of both phosphocreatine and ATP levels in 
the contracting heart in order to determine the myocardial energy status [303]. This 
technique was not attempted due to a lack of access to the appropriate facilities and 
expertise, but could be done through an appropriate collaboration.   
7.3.3. Further investigation of tissue differences 
Significant differences can be seen in the complex I protein levels and activity between 
various tissues. Work to this point has shown that complex I protein levels are reduced 
to various levels in heart, kidney, liver, brain and muscle. However, comparison of 
tissues in more detail has been limited to heart and brain which represented the two 
extremes of this spectrum. Interestingly the level of complex I protein reduction does 
not represent the level of mitochondrial deficiency seen in these tissues suggesting that 
there may be a threshold level of complex I total protein that must be reached before 
any defect in mitochondrial dysfunction is seen. Investigating the mitochondrial function 
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of each of the tissues in this spectrum may reveal important information about the 
possibility of this ‘threshold’. 
Many of the Seahorse results presented so far have used isolated mitochondria to 
determine ETC function. The isolation of mitochondria by differential centrifugation is 
imperfect and only isolates a proportion of the total mitochondrial pool. This results in 
an incomplete representation of the total mitochondrial pool as the isolation 
preferentially selects certain mitochondrial populations over others and results in 
increased fragmentation of those that are isolated successfully [304]. Repeating 
experiments on permeabilised primary cells from wild type and EcsitN209I/N209I animals 
would provide a more complete and reliable picture of the mitochondrial function in 
those tissues in question. The issue with this approach is selecting which cell type to 
assess, as many of those tissues measured thus far contain multiple cell types, each with 
their own metabolic demands and intricacies. Furthermore, this approach was 
attempted with cardiomyocytes with limited success. Successfully culturing 
cardiomyocytes would also allow for a XF mito fuel flex test to be performed to 
determine if wild type and EcsitN209I/N209I cardiomyocytes have differing preferences for 
metabolic fuels. The XF mito fuel flex test is a form of Seahorse assay that provide 
cultured cells with various metabolic fuels (glucose, glutamine and fatty acid oxidation). 
Further Seahorse analysis in the form of sequential impairment of each complex of the 
electron transport chain could also reveal if the mitochondrial dysfunction is entirely a 
result of complex I deficiency or if other complexes are also under (or over) performing, 
despite no changes in protein levels. Furthermore, if this experiment could be 
performed in primary cells from wild type and EcsitN209I/N209I animals then the 
mitochondrial function as well as metabolism of a variety of different substrates 
(glutamine, fatty acids) can be assessed to determine if EcsitN209I/N209I animals 
preferentially metabolise certain substrates due to the complex I assembly defect in 
certain tissues. 
7.3.4. Changes in Cardiac Metabolism 
The clinical chemistry results shown in section 3.8.1 hint at a change in the metabolism 
of certain substrates, with an increase in metabolism of both glucose and fatty acids. 
Assessing the levels of a variety of metabolites to give an overall picture of the so-called 
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‘metabolome’ could reveal which metabolic pathways are differentially regulated and 
provide further avenues of investigation regarding the link between cardiomyopathy 
and mitochondrial dysfunction.  
This assessment may be performed using a variety of NMR spectroscopy and mass-spec 
techniques that can identify a great number of metabolites from tissue extracts and 
determine the levels of these metabolites. By comparing wild type and EcsitN209I/N209I 
results we could determine which metabolic pathways are activated and which are 
suppressed in the hearts (or other tissues) of EcsitN209I/N209I animals.  
This work is already underway through a collaboration with Dr. Jules Griffin at the 
University of Cambridge and will form part of a future publication. 
7.3.5. Complexome Analysis 
Complexome analysis is the assessment of constituent proteins of complexes by mass 
spectrometry. For mitochondria, and in particular complex I analysis, this first involves 
isolating mitochondria and isolating mitochondrial complexes, sub-assemblies and 
proteins by blue native PAGE. Following blue native PAGE, gels are cut into 60 evenly 
sized slices and each slice is de-stained, trypsinised and analysed to determine the 
constituent proteins in each complex or subassembly. This provides results similar to the 
2D BN-PAGE performed in chapter 5.5.2 but with a more complete overview that do not 
rely on the affinity of antibodies. This technique has been employed to determine the 
assembly pathway of complex I and could be used to determine in greater detail the 
effect on complex I assembly of the ECSIT N209I mutation.  
This method might also be useful to determine if the 16kDa protein fragment identified 
is ECSIT by looking for ECSIT peptides as a constituent portion of fully assembled 
complex I. As my data already shows that the only fragment associated with complete 
complex I is the 16kDa fragment tryptic peptides in complex I must come from this 
fragment. 
7.3.6. Knockout Mice 
As constitutive knockouts of Ecsit are embryonically lethal it is not possible to study a 
total loss of ECSIT function in a mouse model. However, using an inducible tissue specific 
conditional model it may be possible to investigate the development of cardiomyopathy 
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by looking at the development of complex I dysfunction following knockout of the gene. 
This method would also allow for the investigation of ECSIT protein half-life and to 
determine the requirement for ECSIT in adult hearts that are already fully grown. With 
ECSIT known to be involved in development through the BMP pathway it remains a 
possibility that the requirement for ECSIT in the heart is a developmental one. It is well 
documented that foetal cardiac metabolism is focused on glucose metabolism, shifting 
to fatty acid metabolism sometime after birth and that heart failure is typically 
associated with a return to this foetal metabolic profile [305, 306]. We can speculate 
that ECSIT, through its link with both embryonic development and mitochondrial 
function, has a role in this metabolic switch and that the mutation of ECSIT impairs this 
role, leading to a continued preference of the heart for glucose metabolism. Whilst this 
is purely speculation without any supporting evidence, it would be an interesting avenue 
of investigation given what is known about ECSIT. 
7.3.7. Rescue of Phenotype 
EcsitN209I/N209I mice develop a cardiomyopathy phenotype that develops gradually from 
around 4 weeks of age and is ultimately fatal between 16 and 18 weeks of age. It may 
be possible to replace the defective gene using a bacterial artificial chromosome (BAC) 
which expresses the ECSIT gene, replacing the defective protein in EcsitN209I/N209I animals. 
As transgenic BAC mice would express the functional protein from birth this experiment 
would determine if rescue was possible before the development of the phenotype. Of 
more interest would be to return functional ECSIT to the cardiac tissue, or whole body 
after the cardiomyopathy development has already begun. This could be achieved by 
administering AAV9 virus expressing the wild type gene allowing for the replacement of 
the protein at any point during an animals life span [307]. This could be attempted as a 
time course, with proof of principal potentially taking place in new born animals and 
further experiments taking place at 4, 8, 12 and 16 weeks to determine if the 
replacement of ECSIT can rescue not only complex I activity but also the cardiomyopathy 
phenotype after the cellular and tissue changes have already occurred. 
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7.4. Concluding Remarks 
The use of ENU mutagenesis has led to the identified a novel mouse model of 
hypertrophic cardiomyopathy resulting from a point mutation (N209I) in the gene Ecsit, 
a complex I assembly factor.  The mutation leads to a significant reduction in complex I 
assembly in cardiac tissue whilst only minimally affecting tissues such as brain, kidney 
and liver.  ECSIT protein is also known to be involved in both the toll-like receptor 
response and the bone morphogenetic protein pathway, however, data I have 
generated suggest that these pathways are either unaffected or only minimally affected 
by this mutation and are not involved in disease pathogenesis.  
The working hypothesis I have established based on the data described in this thesis 
suggests that ECSIT protein is involved in complex I assembly in a tissue specific manner 
and whilst it is required in all tissues, its role in cardiac tissue differs significantly and it 
is only this role that is significantly affected by the N209I mutation.  
In conclusion, the EcsitN209I mutation represents a novel model of cardiomyopathy as 
well as a useful tool for investigating the currently poorly understood role of complex I 
assembly factors in the process of complex I assembly and how this process may differ 
on a tissue by tissue basis. 
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9.1. Appendix 1 
Mass spec results from the 4 gel slices isolated in 2D BN-PAGE showing the proteins 
identified in each gel slice.  
Slice A Slice B Slice C Slice D 
ALDH6A1  ABAT  ACAA2  ABCB8  
ATP5A1  ABCB8  ACAD10  ACADVL  
ATP5B  ACAA2  ACADL  ACOT13  
DBT  ACAD10  ACADM  ACTB  
DLST  ACAD11  ACADS  AIFM1  
DSP  ACAD9  ACADVL  APOO  
HELZ2  ACADL  ACAT1  ATP2A2  
HSPA9  ACADM  ACO2  ATP5A1  
IMMT  ACADVL  ACOT2  ATP5B  
KRT1  ACAT1  ACOT9  ATP5C1  
KRT10  ACO2  ACOX3  ATP5D  
KRT13  ACOT9  ACSL1  ATP5E  
KRT2  ACOX1  ACSS1  ATP5F1  
KRT42  ACSL1  ACTB  ATP5H  
KRT5  ACTB  ACTC1  ATP5J  
KRT6B  ACTR3  ADHFE1  ATP5J2  
KRT73  ADSSL1  AFG1L  ATP5L  
KRT76  AFG3L2  AFG3L2  ATP5O  
KRT77  AGK  AGK  BDH1  
KRT79  AHSG  AIFM1  CASQ2  
KRT82  AIFM1  ANXA2  CCSMST1  
SAMM50  ALB  APMAP  CHCHD3  
  ALDH2  ATP2A2  CHCHD4  
  ALDH5A1  ATP5A1  CKMT2  
  ALDH6A1  ATP5B  COL10A1  
  ANXA2  BCAT2  COX4I1  
  APOH  BCKDHA  COX5A  
  ART3  BCL2L13  COX5B  
  ATP1A1  BDH1  COX7A1  
  ATP1B1  BSG  COX7A2L  
  ATP2A2  BZW2  CPT1B  
  ATP5A1  CASQ2  CPT2  
  ATP5B  CKM  CRAT  
  ATP5C1  CKMT2  CS  
  ATP5H  COQ6  CSPG4  
  ATP5O  COQ8A  CYB5B  
  BCKDHA  CPT2  CYC1  
  BCL2L13  CRAT  DIAPH3  
  BDH1  CS  DSP  
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  CASQ2  D2HGDH  EPB42  
  CKMT2  DECR1  FABP5  
  COQ8A  DLD  FAM162A  
  COX4I1  DNAJA2  FECH  
  COX7A1  DNAJA4  GNB4  
  CPT1B  DSP  GOT2  
  CPT2  ECI1  GPX4  
  CRAT  EEF1A1  HADH  
  CS  EHD1  HADHA  
  CYC1  EHD2  HADHB  
  DECR1  EHD4  HBA  
  DES  ENO1  HBB-B1  
  DLST  ENO3  HSPA5  
  DSG1B  ETFA  HSPA9  
  DSP  ETFB  HSPD1  
  ECHS1  ETFDH  IDH2  
  EEF1A1  FABP5  IMMT  
  EEF1A2  FARS2  KIF24  
  EHD2  FH  KRT1  
  ENO3  FLAD1  KRT10  
  EPHX1  FLOT2  KRT14  
  FH  GC  KRT2  
  GK  GCDH  KRT42  
  GLUD1  GNAS  KRT5  
  GOT2  GOT2  KRT6A  
  HADHA  GRSF1  KRT73  
  HADHB  HADH  KRT76  
  HBB-B1  HADHA  KRT79  
  HK1  HADHB  MB  
  HK2  HBB-B1  MDH2  
  HSD17B4  HIBADH  MGST3  
  HSPA14  HK1  MPC2  
  HSPA5  HK2  MPV17  
  HSPA8  HNRNPM  MRPL12  
  HSPA9  HSD17B4  MRPL17  
  HSPD1  HSPA5  MRPL20  
  IDH2  HSPA9  MRPL23  
  IDH3A  HSPD1  MRPL43  
  IDH3G  HTRA1  MRPL49  
  IMMT  IARS2  MRPS10  
  JUP  IDH1  MRPS23  
  KIF27  IDH2  MRPS28  
  KRT1  IDH3G  MTCO2  
  KRT10  IFT20  MTND3  
  KRT14  JUP  NDUFA1  
  KRT16  KRT1  NDUFA10  
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  KRT17  KRT10  NDUFA11  
  KRT2  KRT14  NDUFA12  
  KRT31  KRT2  NDUFA13  
  KRT34  KRT42  NDUFA2  
  KRT35  KRT5  NDUFA3  
  KRT42  KRT6A  NDUFA4  
  KRT5  KRT71  NDUFA5  
  KRT6A  KRT79  NDUFA6  
  KRT75  KYAT3  NDUFA7  
  KRT76  L2HGDH  NDUFA8  
  KRT77  LEG1  NDUFAF3  
  KRT79  LRIG3  NDUFB11  
  KRT81  LRP6  NDUFB3  
  KRT85  MDH2  NDUFB4  
  LONP1  MGST3  NDUFB5  
  LRPPRC  MRM3  NDUFB6  
  MCCC2  MRPL37  NDUFB7  
  MDH2  MRPS30  NDUFB8  
  MFGE8  MTOR  NDUFC2  
  MGST3  NADK2  NDUFS1  
  MLYCD  NAGA  NDUFS2  
  MRC1  NCEH1  NDUFS4  
  MRPS30  NDRG2  NDUFS5  
  MTCH2  NDUFS2  NDUFS6  
  MTCO1  NFS1  NDUFS7  
  MTCO2  NNT  NDUFS8  
  MT-CO3  OAT  NDUFV1  
  NCEH1  OXCT1  NDUFV2  
  NDUFS2  OXSM  NES  
  NDUFV1  PA2G4  NME2  
  NNT  PAFAH1B1  NME3  
  OGDH  PDHA1  NPPA  
  OPA1  PDHB  OPA1  
  PDHX  PDIA6  PCCA  
  PLEC  PDK1  PDHA1  
  PMPCB  PDK2  PDHB  
  PRDX1  PDK4  PHB  
  PRX  PGK1  PHB2  
  RPS27A  PMPCB  PRDX2  
  SAMM50  PRDX2  PRDX5  
  SDHA  RPS27A  RICTOR  
  SERPINH1  SAMM50  RPS27A  
  SFN  SCCPDH  RTN2  
  SLC25A12  SDHA  SAMM50  
  SLC25A3  SDHB  SCCPDH  
  SLC25A4  SEMA4D  SDHA  
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  SLC25A5  SEPSECS  SDHC  
  SLC30A9  SERINC3  SLC25A11  
  SLC4A1  SERPINH1  SLC25A12  
  SPRR2B  SLC25A12  SLC25A3  
  STEAP3  SLC25A13  SLC25A4  
  SUCLA2  SLC25A3  SLC25A5  
  TGM3  SLC25A4  SLC4A1  
  TKTL1  SLC25A46  SUCLA2  
  TRIM72  SLC25A5  TMEM11  
  TUFM  SLC2A4  TMEM160  
  UQCRC1  SQOR  TMEM186  
  UQCRC2  SUCLA2  TMEM242  
  UQCRFS1  SUCLG2  TOMM22  
  VAT1  TIMM44  TUFM  
  VDAC2  TM9SF2  UQCR10  
  VDAC3  TM9SF3  UQCRB  
    TMEM143  UQCRC1  
    TMX4  UQCRC2  
    TNPO2  UQCRFS1  
    TOMM70  UQCRQ  
    TPP1  USMG5  
    TRMU  VDAC2  
    TUBA1B    
    TUFM    
    TXNDC5    
    UQCRC1    
    UQCRC2    
    VDAC2    
    YARS2    
 
